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Astract
A number of cellular responses mediated by protein kinase C (PKC)
in the anterior pituitary gland involve a form of PKC that is unusually resistant
to the PKC inhibitor H7. In this study, inhibition by staurosporine, H7 and Ro
31-8220 of phorbol 12,13-dibutyrate-induced PKC activity in cytosol
partially-purified from rat midbrain, anterior pituitary and a number of other
tissues, as well as COS 7 cells, was studied. An in vitro mixed micelle
histone IMS phosphorylation assay was used to allow comparison of Ca2+-
dependent and Ca2+-independent PKC activity. In anterior pituitary but not
midbrain or COS 7 cells, Ca2+-independent activity was notably resistant to
H7 but sensitive to staurosporine and Ro 31-8220. All Ca2+-dependent
activity was sensitive to these three inhibitors. Comparison of PKC activity
from a variety of different tissue sources showed H7-resistant, Ca2+-
independent activity also occurred in lung but not in spleen, thalamus or
cerebellum. Mezerein and 1,2-dioctanoyl-sn -glycerol also activated this H7-
insensitive PKC from anterior pituitary. Phosphorylation of a number of
substrates by anterior pituitary PKCs were also compared. When [Ala9-10,
Lys11 >12] glycogen synthasei-12 (GS peptide) but not [Ser]25 PKC a-19-31
was the phosphate acceptor, a clear component of the activity, which was
Ca2+-independent, was resistant to H7. The tissue distribution of this activity
and its characteristic resistance to H7 but not other inhibitors, does not
obviously correlate with that of any of the well-characterised PKCs, and may
reflect either a novel or a modified isoform.
To further characterise this H7-resistant PKC, it was necessary to
separate it from other pituitary PKCs. Initial fractionation studies showed that
DEAE-celiulose chromatography can separate Ca2+-independent PKC
activity from anterior pituitary tissue into fractions with different sensitivities to
H7. Furthermore fractionation by hydroxyapatite (HAP) chromatography of
both anterior pituitary and midbrain extracts resulted in three main peaks of
PKC activity but only anterior pituitary contained significant PDBu-induced
PKC activity which eluted after the third peak. This activity was not seen in
other tissues such as spleen and COS 7 cells but was present in lung and
aT3-1 cell extracts. Ca2+-independent activity in this fraction from pituitary
was sensitive to the PKC inhibitor Ro 31-8220 but relatively resistant to H7.
H7-resistant activity was also detected in fractions of HAP eluate from lung
and aT3-1 cells. Immunoblotting with antisera specific for PKC a, (31, 5, e, £
and 0, isoforms present in pituitary, showed that this fraction did not contain
the major immunoreactivity for any of these PKCs. Phosphatidylserine-
dependent autophosphorylation of HAP fractions from anterior pituitary
revealed the presence of a 140 kDa protein which was not seen in midbrain
and whose distribution between the fractions correlated with the H7-resistant
PKC activity. Similarly, immunoblotting with an antiserum raised to a PKC
consensus sequence (in the catalytic domain) showed a prominent
immuno reactive species at approximately 130 kDa which was present
selectively in those HAP fractions from anterior pituitary and lung that
displayed H7-resistant activity. Thus the 130 kDa protein may well represent
the H7-resistant kinase, and may be related to one of the known PKCs or a
novel isoform of PKC.
The possibility that a novel PKC isoform may be expressed in anterior
pituitary was examined by polymerase chain reaction (PCR) amplification of
reverse transcribed RNA from anterior pituitary and DNA from a rat pituitary
cDNA library. This employed degenerate oligonucleotide primers
corresponding to peptide sequences conserved between PKC isoforms but
not other protein kinases to amplify partial core sequences of putative PKC
genes. Analysis of clones using selected restriction endonucleases and
subsequent DNA sequencing analysis identified sequences encoding PKC
a, e and £ but no novel PKC-related sequences. The possible reasons for
this as well as alternative strategies yet to be employed are discussed in the
light of PKC sequences published since the design of this study.
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Protein phosphorylation by protein kinases is a regulatory event
essential to many ceil signalling pathways. Protein kinase C (PKC) is a
serine/threonine kinase that is involved in a wide variety of cellular
responses, including neurotransmitter release, hormone secretion, cell
growth and differentiation, and regulation of gene expression (Nishizuka,
1992). It was initially identified as a proteolytically-activated protein kinase
(Inoue et al., 1977; Takai et al., 1977) that was later discovered to be Ca2+-
activated and dependent on phospholipids for its activity (Takai et al.,
1979b). It was soon linked to signal transduction pathways following
inositol phospholipid hydrolysis, a process that results in the production of
diacylglycerol (DAG), which was found to activate PKC (Takai et al., 1979a).
It is now known that DAG generated by other reactions is also able to
activate PKC (Exton, 1990; Pelech and Vance, 1989), and this enzyme is
the major cellular receptor for the tumour-promoting phorbol esters
(Nishizuka, 1988). These compounds activate PKC in a manner similar to
DAG (Castagna et al., 1982) and are widely used to mimic agonist-induced
responses that are thought to involve PKC. Protein kinase C is now known
to represent a family of related kinases which are structurally similar but vary
in their Ca2+-dependence and other biochemical properties (Nishizuka,
1988), and this may contribute to enabling PKC to play a role in such a wide
variety of cellular responses (Hug and Sarre, 1993).
1.1 PKC ISOFORMS
Initially three different Ca2+-dependent isoforms of PKC, PKC I, II and
III, were identified by hydroxyapatite (HAP) purification of rat brain tissue
(Huang et al., 1986b), although more isoforms were soon identified by
molecular cloning studies (Ono et al., 1988). Eleven different isoforms have
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been cloned to date (Johannes et al., 1994; Nishizuka, 1992) although it is
possible that further PKCs may exist. These isoforms may be divided into
three groups on the basis of their activation characteristics (Nishizuka,
1992). The classical PKCs (cPKCs), the first group to be identified, consist
of PKC a, |3I, (3II and y and are all dependent upon Ca2+ for activation. The
novel or nPKCs (8, e, r| and 9) are active in the absence of Ca2+ although
these isoforms, like the cPKCs, require phorbol esters or DAG for activation.
The third group, the atypical or aPKCs, currently has three members (PKC £,
i (A,) and p) and these isoforms are not thought to be activated by either
phorbol esters or Ca2+ (Johannes et al., 1994; McGlynn et al., 1992;
Nakanishi and Exton, 1992; Selbie et al., 1993). These eleven isoforms are
the product of ten different genes and are all structurally related, although
the most recently identified isoform, PKC p , is more distantly related to the
other isoforms (Johannes et al., 1994).
1.2 PKC STRUCTURE
The PKC molecule has two domains, an N-terminal regulatory
domain and a C-terminal catalytic domain, as is common to most single
subunit protein kinases (Hanks et al., 1988), the two domains being linked
by a flexible hinge region (Pears and Parker, 1991). From the sequence of
the cDNAs it is clear that the cPKCs have four conserved domains (C1-4)
and five variable regions (V1-5) (Coussens et al., 1986) as shown in Figure
1.1. The nPKCs and aPKCs lack the C2 domain. This domain is thought to
be responsible for Ca2+ dependency of the cPKCs, although there is no
evidence in this domain of a typical EF hand Ca2+ binding sequence as
seen in other Ca2+ binding proteins (Huang, 1989). Deletion of this region
in PKC y results in a kinase that is capable of being activated by phorbol
esters but is independent of Ca2+ (Ono et al., 1989a). There is now
3
evidence, from deletion mutants of PKC (31, to suggest that Ca2+ is bound
mainly to the C1 region but the C2 domain confers specificity for Ca2+
binding in the cPKCs (Luo and Weinstein, 1993). Other divalent cations, eg
Mg2+ which is present in cells at millimolar concentrations, are proposed to
substitute for Ca2+ in activation of the nPKCs (Luo and Weinstein, 1993).
The C1 domain contains an autoinhibitory domain, as is seen in a
number of other kinases (Soderling, 1990), and cysteine-rich regions similar
to those seen in DNA binding proteins (Parker et al., 1989). The
autoinhibitory or pseudosubstrate domain is fairly well conserved between
the cPKCs but different in the nPKCs and cPKCs (Parker et al., 1989). All
the PKC isoforms have a conserved distance of 15 amino acids between the
end of the pseudosubstrate domain and the beginning of the first cysteine-
rich region but the significance of this is unclear (Hug and Sarre, 1993).
The cPKCs and nPKCs contain two cysteine rich regions while there is only
one in the aPKCs C, and i (Ono et al., 1989b, Selbie et al., 1993). Protein
kinase C ji also contains two cysteine rich regions although, unlike in the
other PKC isoforms, they are separated by a long intervening sequence
(Johannes et al., 1994). These cysteine rich regions are thought to be
involved in phorbol ester binding (Burns and Bell, 1991) and the aPKCs C,
and i contain only one such sequence and these isoforms are unable to
binding phorbol esters (Liyanage et al., 1992; Selbie et al., 1993). However
it has been shown that one of the cysteine regions alone is capable of
binding these activators (Burns and Bell, 1991) and site-directed
mutagenesis experiments have been conducted to determine the minimum
requirements for phorbol binding (Quest et al., 1994). These regions are
known to bind two zinc molecules and it has been suggested that this is
essential for stabilising the structure involved in lipid interactions and
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phorbol ester binding (Quest et al., 1992), although the precise relationship
between zinc and phorbol ester binding at present remains unclear.
The C3 domain contains the consensus amino acid sequence G X G
X X G, (X representing any amino acid), which is conserved in many protein
kinases (Hanks et al., 1988) as well as nucleotide binding proteins
(Wierenga and Hoi, 1983) and from molecular modelling studies, this has
been suggested to represent the ATP binding site (Sternberg and Taylor,
1984). This consensus sequence is altered in PKC £ and i, where the third
glycine residue is replaced by an alanine (Hug and Sarre, 1993). However
as these isoforms do show kinase activity (Liyanage et al., 1992; McGlynn et
al., 1992; Selbie et al., 1993), the significance of this is unclear. A second
consensus ATP binding motif is also present in the C4 domain of PKC a and
(3 but not y, though all the cPKCs have similar Kms for ATP (Huang et al.,
1988).
The C4 domain contains the phosphate transfer region and the
putative substrate recognition site. The phosphate transfer region contains
a triplet of amino acids (DFG) which represent the most highly conserved
sequence in the catalytic domain of protein kinases (Kemp and Pearson,
1990), although PKC £ varies by one amino acid in this sequence (Hug and
Sarre, 1993). The aspartic acid residue of this triplet is thought to be
involved in the base-catalysed transfer of the phosphate to the protein
substrate (Taylor, 1989). The distance of 105-108 amino acids (113 in PKC
y) between the ATP site and the phosphate transfer region is also conserved
(Hug and Sarre, 1993). The exact location of the substrate binding site has
not been established but it has been proposed to contain a stretch of 29
amino acids in the C4 domain, and synthetic peptide analogues of this
region are thought to activate PKC by competing with the pseudosubstrate
domain (House et al., 1989).
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The variable regions differ distinctly between isoforms but are highly
conserved between species, suggesting that they may play a role in
determining the properties and function of the individual isoforms (Huang,
1989). The V1 domain is elongated in the nPKCs relative to the cPKCs and
it has been suggested that this region may have a modulatory effect on the
conserved domains that are common to both classes of PKCs (Hug and
Sarre, 1993). The V3 region forms the hinge between the regulatory and
catalytic domains and contains the sites for cleavage by both calpain and
trypsin (Huang and Huang, 1986; Schaap et al., 1990). This region in PKC
a also contains a potential Ca2+ binding domain, as suggested by its
homology to Ca2+/calmodulin dependent protein kinases, but this is not
present in either the p or y isoforms so its role in determining the sensitivity
of this isoform to Ca2+ is unclear (Huang, 1989).
Protein kinase C |x varies extensively in the regulatory domain when
compared to the other PKC isoforms (Johannes et al., 1994). It contains two
cysteine-rich regions but these are separated by 79 amino acids, in contrast
to the 15 or 22 amino acids in the cPKC and n PKCs respectively, and this
isoform is unable to bind phorbol esters. It also contains a putative signal
peptide and transmembrane domain, suggesting a permanent membrane
location, in contrast to the transient membrane association of the other
PKCs. Thus it is likely that PKC p. has a distinctly different cellular role to the
other members of the PKC family.
1.3 Properties of PKC isoforms
The individual PKC isoforms vary greatly in both their patterns of
expression and their biochemical properties, which differ particularly




Individual isoforms have distinct phospholipid preferences, though all
may be activated in the presence of phosphatidylserine (PS)(Nishizuka,
1992). For example, cardiolipin (CL) is able to replace PS as a cofactor for
PKC a, (3 and y, in the presence of DAG or PDBu, resulting in near maximal
activity for all three isoforms (Huang et al., 1988). However the subtle
differences in the affinity of DAG or PDBu binding between these isoforms,
when determined in the presence of PS, were accentuated when this lipid
was replaced by presence of CL (Huang et al., 1988). Phosphatidylinositol
(PI) can substitute for PS as a cofactor in activation of PKC a, pi (Kochs et
al., 1993a) and e (Koide et al., 1992), while for PKC 8, maximum
tetradecanoylphorbolacetate (TPA) -stimulated activity was over 2 fold
greater with PI than PS as a cofactor (Mizuno et al., 1991). Interestingly,
phosphatidylinositol 4,5 bisphosphate (PIP2) is able to substitute for DAG as
an activator for PKC a, pi (Kochs et al., 1993a) and y (Lee and Bell, 1991)
but not for PKC pil (Lee and Bell, 1991). It has however been suggested
that this activation occurs by a different mechanism (Azzi et al., 1992) and at
a distinct site from that to which DAG binds (Lee and Bell, 1991). Protein
kinase C r\, but not PKC a or 8, is specifically activated by cholesterol
sulphate alone and the level of stimulation is greater than that occurring with
PS and phorbol ester as activators (Ikuta et al., 1994).
Some PKC isoforms can also be activated by fatty acids, although the
mechanism by which this occurs is poorly understood and there have been
some conflicting results. Activation of PKC by fatty acids has been shown to
be both dependent on (Sekiguchi et al., 1987) and independent of Ca2+
(Murakami et al., 1986) and DAG has been shown to have no effect on this
activation (Sekiguchi et al., 1987). However another later study suggested
that PKC a, p and y are all activated synergistically by DAG and unsaturated
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fatty acids, with a further increase in activity in the presence of PS
(Shinomura et al., 1991). In this case, unsaturated fatty acids including
arachidonic, oleic, linoleic and linolenic were found to be active while
saturated fatty acids, such as palmitic and stearic acids, were inactive and,
in the presence of fatty acid and PS, these isoforms were active at basal
levels of Ca2+. Protein kinase C e has also been shown to be activated by
arachidonic acid in both the presence and absence of PS (Koide et al.,
1992) while PKC 5 in the presence of diglyceride and PS was strongly
inhibited by this fatty acid (Ogita, 1992). Lysophospholipids, in particular
lysophosphatidylcholine (LysoPC), are also able to potentiate DAG
activation of PKC in vitro (Shinomura et al., 1991) although the
concentration is critical as, at higher concentrations, lysoPC inhibits the
activity of PKC a, 0 and y (Sasaki et ai., 1993). LysoPC shows no effect in
the absence of PS and DAG, and it has been suggested that lysoPC acts by
increasing the affinity of PKC for PS (Sasaki et al., 1993). The activity of the
nPKCs 5 and e, however, is not enhanced by lysoPC.
Protein kinase C £ shows distinctly different activation characteristics
from the other PKC isoforms, as it exhibits a low level of constitutive,
activator-independent activity (Liyanage et al., 1992; McGlynn et al., 1992)
and is not responsive to phorbol esters (McGlynn et al., 1992; Nakanishi
and Exton, 1992). The activity of this isoform, when purified from kidney,
has been shown to be stimulated by PS and cis-unsaturated fatty acids,
although the signals that activate this isoform in vivo are unknown
(Nakanishi and Exton, 1992). There is evidence that PKC but not cPKC,
is strongly activated by phosphatidylinositol 3,4,5-triphosphate (PIP3), which
is produced by phosphatidylinositol 3-kinase (PI-3 kinase)(Nakanishi et al.,
1993). This suggests that this isoform may be activated downstream of
tyrosine kinases (Nakanishi et al., 1993), although in another study the
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nPKCs e and rj were shown to be activated by PIP3 (Toker et al., 1994) On
the basis of sequence homology, particularly in the C1 domain, it has been
suggested that PKC 1 (and PKC X, the mouse homologue (Akimoto et al.,
1994)) may share similar properties with PKC (Selbie et al., 1993) and
phorbol ester binding studies detected no specific binding to PKC X
(Akimoto et al., 1994). Expression of PKC p has shown that, in vitro, this
isoform does not efficiently bind nor is it activated by phorbol esters
(Pfizenmaier et al., 1993). The phospholipid requirements of PKC p have
not yet been investigated.
Substrate specificity
The PKC isoforms have been shown to vary greatly in their substrate
specificity when their activity is assayed in vitro (Hug and Sarre, 1993). In
particular, it is clear that the Ca2+-independent PKC isoforms are unable to
efficiently phosphorylate histone (Liyanage et al., 1992; Schaap and Parker,
1990). This is thought to be due to interactions of the regulatory domain
with the substrate binding region of the catalytic domain, as proteolytic
cleavage of PKC e resulted in a constitutively-active catalytic subunit that
was readily able to phosphorylate this substrate (Schaap et al., 1990).
Furthermore, a chimeric protein containing the regulatory subunit of PKC y
fused to the catalytic subunit of PKC e also showed histone phosphorylation
activity (Pears et al., 1991). More recent studies have shown that the
pseudosubstrate region alone is capable of influencing the substrate
specificity and co-factor dependence of PKC t\, as deletion of this region
generated a cofactor-independent enzyme with high histone kinase activity
(Dekker et al., 1993).
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Tissue and cellular distribution
Each isoform shows a distinct tissue distribution (Nishizuka, 1988;
Wetsel et al., 1992). Within each class of PKCs, there is at least one isoform
that is virtually ubiquitous, while the other class members show a more
specific tissue distribution (Nishizuka, 1992). PKC a , [3, 8, e and £ are all
found in many tissues throughout the body, including brain, skin, lung,
spleen and thymus (Nishizuka, 1988; Wetsel et al., 1992), while PKC y is
exclusively found in the nervous system (Shearman et al., 1987) and PKC 0
is predominantly located in skeletal muscle (Osada et al., 1992). It has been
suggested that the ubiquitously-distributed isoforms may perform functions
that are essential for cell survival, while the isoforms with a tissue specific
distribution may have distinct functions in specialised differentiated cells
(Hug and Sarre, 1993). There are however notable deviations in the
distribution of the generally ubiquitous isoforms, for example PKC a has not
been detected in liver where PKC (3 is the major isoform (Rogue et al.,
1990), and it has been suggested that these isoforms may substitute for
each other in different tissues with respect to identical or similar function
(Hug and Sarre, 1993).
The intracellular distribution of different isoforms within unstimulated
cells also varies considerably. PKC a is predominantly cytosolic in
unstimulated cells (Borner et al., 1992b) while PKC (3 and y are
predominantly membrane associated (Nishizuka, 1988; Strulovici et al.,
1991). The cellular distribution of both PKC 5 and e seems to depend on the
cell type. Both are found predominantly in the particulate fraction in rat 6
fibroblasts (Borner et al., 1992b) and renal mesangial cells (Huwiler et al.,
1991; Huwiler et al., 1992) while PKC 8 is cytosolic in human platelets
(Grabarek et al., 1992) as is PKC e in GH4C1 pituitary gland cells (Kiley et
al., 1990). In most cell lines PKC £ seems to be cytosolic (Borner et al.,
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1992b, Huwiler et al., 1992), although in Hela cells it has been reported to
occur predominantly in the particulate fraction (Ways et al., 1992). PKC q in
several human cell lines has been detected exclusively in the nucleus (Grief
et al., 1992), although another report found that this isoform in mouse and
human keratinocytes was predominantly located in the cytoplasm around
the nucleus but not in the nucleus itself (Chida et al., 1994). Expression of
PKC 0 in COS cells results in the majority of this isoform appearing in the
particulate fraction in unstimulated cells (Osada et al., 1992). Thus it would
appear that, for most isoforms, the cellular location is not only determined by
the primary sequence of the protein but also the cell type in which it is
expressed. The exception to this may be PKC p, as this isoform has a
potential transmembrane domain in the V1 region which may result in the
mature protein being permanently membrane-bound (Johannes et al.,
1994).
It may be only limited regions of the protein that are responsible for
dictating the properties and distribution of particular isoforms, as suggested
by the pi and pil isoforms. These proteins are both products of the p gene
produced by alternative splicing of the mRNA at the 3' end (Coussens et al.,
1986). The resulting proteins share identical conserved domains and only
differ in the V5 region, at the carboxy terminus of the catalytic domain, the
amino acids of this region showing 50% identity (Parker et al., 1989).
However these two isoforms have been shown to vary in their activation
characteristics, for example pll but not pi may be activated by PIP2 in place
of DAG (Lee and Bell, 1991). The ratios in which these isoforms are present
in many tissues varies (Farago and Nishizuka, 1990) as does their cellular
location, as shown in neuronal cells where pi is sometimes associated with
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the plasma membrane while (311 is often localized in the Golgi complex
(Nishizuka, 1988).
The individual nature of the activation characteristics of each isoform
as determined in vitro may reflect the ability of different isoforms to be
activated in response to specific agonists.
1.4 Mechanism of PKC activation
Activation of most of the PKC isoforms is dependent on PS and either
DAG or phorbol esters, along with Ca2+forthe cPKCs (Huang, 1989).
Diglycerides competitively inhibit phorbol ester binding so it is thought that
both these types of activators interact with the same site (Kazanietz et ai.,
1993; Sharkey and Blumberg, 1985). The binding of PS is strongly co¬
operative when measured in a mixed micelle assay (Hannun et al., 1985).
Binding of phospholipid cofactors and phorbol esters or DAG is thought to
induce a conformational change that results in unmasking of the catalytic
domain (Huang, 1989). Autoinhibitory domains have been identified for a
number of protein kinases that act by interacting with elements of the
catalytic domain (Soderling, 1990). A pseudosubstrate domain has been
identified in the C1 region of PKC (House and Kemp, 1987) which
resembles the natural substrate recognition sequence for PKC but lacks the
serine or threonine residue for phosphorylation. It is suggested that this
domain in the absence of cofactors binds to the active site maintaining the
enzyme in an inactive state by preventing access to potential substrates (Fig
1.2). The interaction with cofactors is thought to cause a conformational
change (Huang, 1989) resulting in the removal of the pseudosubstrate
domain from the substrate binding site so allowing access to the substrate.
This is supported by experiments which have shown that the
pseudosubstrate domain is exposed to proteases when the enzyme binds
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PS and DAG, but is masked when the enzyme is inactive (Orr et al., 1992).
The substrate does however play a role in determining the cofactor
requirement, at least in vitro, as there are some substrates, such as
protamine sulphate, which are phosphorylated independently of
phospholipid and DAG (Bazzi and Nelsestuen, 1987; Liyanage et al., 1992).
It has however been suggested that a similar structural alteration occurs in
the case of protamine suphate binding resulting in the exposure of the
pseudosubstrate to proteolysis (Orr and Newton, 1994).
Translocation
Translocation of PKC from the cytosol to the membrane has been
associated with PKC activation and also subsequent down-regulation. In
the unstimulated cell, PKC is found in both the soluble and membrane
fractions, the distribution between the two varying with PKC isoform content.
However cytosolic PKC is recruited to the membrane in response to DAG
and, in the cases of the cPKCs, increased levels of intracellular Ca2+, and it
has been suggested that the interaction of PKC with the membrane is
stabilised when phospholipid and DAG or phorbol ester is bound (Bell,
1986). It has been proposed that there are two forms of membrane
associated PKC, one that is reversibly bound and the other which is
membrane inserted (Bazzi and Nelsestuen, 1988a). The latter form is
constitutively active and shows no further increase in activity with either
phorbol esters or Ca2+ (Bazzi and Nelsestuen, 1988b). Proteins that are
thought to bind to PKC in its active form following translocation to the
membrane have been identified in some cell types, for example hepatocytes
(Mochly-Rosen et al., 1991a). These receptors for activated C kinase
(RACKS) are suggested to play a role in anchoring PKC at the membrane,
by direct protein-protein interaction (Mochly-Rosen et al., 1991b). They are
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thought to bind PKC at a site distinct from the substrate binding site and they
have been shown to increase PKC phosphorylation of other substrates. It
has been suggested that they may prolong PKC activation by holding the
enzyme molecule in the active conformation. A peptide that prevented PKC
from binding to RACK 1 in vitro has been used to investigate the
involvement of PKC interaction with RACKS in PKC-mediated function in
vivo . Microinjection of this peptide into Xenopus oocytes was found to
block insulin-induced oocyte maturation and PKC p translocation in
response to insulin (Ron and Mochly-Rosen, 1994). The sequence of this
peptide resembles that of an endogenous kinase C inhibitor protein
(KCIP)(Toker et al., 1990), so modulation of PKC binding to RACKS may
play a role in regulation of PKC activation in vivo (see Section 1.6). Other
PKC binding proteins have also been identified that are also PS-binding
proteins (Kiley and Jaken, 1994). These proteins are different from the
previously mentioned RACKS as they are also PKC substrates, and while
PKC binding to RACK 1 is irreversible in vitro, PKC binding to these proteins
is decreased by phosphorylation.
Proteolysis and Downregulation
Proteolytic cleavage by calpain, a Ca2+-dependent cysteine
protease, occurs following activation and translocation of PKC, and the
conformational change associated membrane binding causes the V3, hinge
region of the enzyme to be more susceptible to proteolysis (Newton, 1993).
This results in generation of the constitutively-active catalytic domain, called
PKM, which is not regulated by DAG or phospholipid (Kishimoto et al.,
1989). It is unclear, however, whether this is followed by further proteolysis
and degradation, so terminating the kinase activity, or if the catalytic
fragment, released from the membrane to the cytosol, persists as a
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constitutively active kinase (Hug and Sarre, 1993). It has been suggested
that PKM may play a role in long term PKC-mediated responses, for
example long term potentiation (LTP)(Sacktor et al., 1993). Different
isoforms vary in their susceptibility to such limited proteolysis (Huang et al.,
1989) and a role for the V3 domain in determining the rate of cleavage has
been suggested (Kishimoto et al., 1989).
Persistent stimulation of cells with either phorbol esters or agonists
that activate PKC results in PKC down-regulation (Hug and Sarre, 1993),
which is due to an increase rate of proteolysis (Young et al., 1987) and can
occur without any change in the rate of synthesis. PKC isoforms are
differentially downregulated in vivo (Hug and Sarre, 1993) and it has been
suggested that this may be due to their different susceptibilities to
proteolysis (Kiley et al., 1991). However, experiments where the V3 hinge
domain of PKC a was exchanged for sequences from other membrane
proteins that do not undergo proteolysis, showed that, while mutants varied
in their rate of proteolysis by calpain, including one which was totally
resistant to cleavage, all were sensitive to TPA-induced down-regulation
(Junco et al., 1994). Selective down-regulation of certain PKC isoforms
following agonist stimulation may be due to activation of these isoforms and
not others by the stimulus, although the precise relationship between
activation and down-regulation is unclear. The use of kinase-negative
mutants to try and clarify this relationship has provided contradictory results.
While there are some reports that kinase-negative mutants of PKC a and y,
when expressed in COS cells, could be downregulated by phorbol esters
(Freisewinkel et al., 1991; Pears and Parker, 1991), an alternative report
found that, in comparison to the wild type, there was severe impairment of
phorbol ester-induced down-regulation of a kinase-negative mutant of PKC
a, expressed in either COS cells or rat fibroblasts (Ohno et al., 1990). It has
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been suggested that selective down-regulation of particular PKC isoforms
may be at least partly due to the cellular compartment in which they are
located (Kiley et al., 1991).
1.5 PKC ACTIVATION IN VIVO
Activation of protein kinase C in vivo occurs following hydrolysis of
membrane phospholipids, as summarised in Figure 1.3. It was first detected
in response to receptor-mediated inositol phospholipid breakdown, the
resulting DAG increasing the affinity of PKC for Ca2+ and so activating it
(Takai et al., 1979a). It has since been shown that DAG produced from
phosphatidyl choline (PC) hydrolysis, by either a PC-specific phospholipase
C (PLC) or by action of a phosphatase on the phosphatidic acid (PA)
generated by phospholipase D (PLD), is also capable of activating PKC
(Azzi et al., 1992), though different isoforms may be involved. This form of
PLC may require tyrosine phosphorylation for its activation (Choudhury et
al., 1991), which provides a potential route for cross-talk between cascades
involving activation of tyrosine kinases and those involving PKC activation.
Receptor stimulation results in an initial peak of DAG production from
breakdown of PI by PLC, with a simultaneous increase in intracellular levels
of Ca2+ (Asaoka et al., 1992). This DAG is rapidly metabolised by DAG
kinase but there is frequently a second peak of DAG production resulting
from signal-induced PC hydrolysis (Exton, 1990). This second phase of
DAG production can persist for several hours and may be essential for the
prolonged activation of PKC necessary for long term cellular events, such as
cell proliferation and differentiation (Azzi et al., 1992). It is possible that
activation of PKC itself may be responsible for the sustained elevation of
DAG (Nishizuka, 1992), as there is evidence to suggest that PKC may be
involved in PLD activation (Billah and Anthes, 1990; Pelech and Vance,
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1989). Phorbol esters or a membrane-permeant DAG activate PLD,
although there is conflicting evidence concerning the requirement for ATP
(Conricode et al., 1992; Olson et al., 1991; Tettenborn and Mueller, 1988)
and the effect of kinase inhibitors on this process (Cao et al., 1990;
Liscovitch and Amsterdam, 1989; Sandmann and Wurtmann, 1991;
Yamada et al., 1991). It has been suggested that PKC stimulation of PLD
may be independent of protein phosphorylation, although the mechanism
by which this could occur remains unknown (Conricode et al., 1992).
Protein kinase C is also involved in the activation of phospholipase
A2 (PLA2)(Godson et al., 1990; Hartung and Toyka, 1987), which occurs in
response to most agonists that induce PI hydrolysis (Nishizuka, 1992). PLA2
is responsible for breakdown of membrane phospholipids, in particular PC,
to give free fatty acids, such as arachidonic acid, and lysophospholipid, both
of which can either induce or enhance PKC activation (Shinomura et al.,
1991), so providing a further mechanism for prolonged PKC activity
(Nishizuka, 1992). As unsaturated fatty acids have been shown to lower the
requirement of the cPKC for Ca2+ (Shinomura et al., 1991), this could
enable these isoforms, activated by the initial DAG formation, which occurs
concurrently with elevated levels of intracellular Ca2+, to remain active once
the Ca2+ levels have returned to basal. It is also possible that this
production of unsaturated fatty adds as a later response may result in
activation of isoforms that were not involved in the initial early response, for
example PKC £ which may be activated by free fatty acids but not by DAG
(Nakanishi and Exton, 1992). As well as a role in potentiation of PKC
stimulation by promoting further DAG production, PKC is also involved in the
negative feedback control of this system, as PKC activation also causes
down-regulation of agonist-induced PI hydrolysis (Pachter et al., 1992).
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As previously mentioned PKC is also activated in response to growth
factors, such as epidermal growth factor (EGF) and lysoPA (Ohno et al.,
1994). Binding of these agonists to their receptors results not only in
activation of PLC but also PI-3 kinase (Bjorge et al., 1990; Kumagai et al.,
1993). This kinase is responsible for the phosphorylation of PI-4.5-P2 to
give PI-3,4,5-P3 (PIP3)(Whitman et al., 1988) The physiological roles of
PIP3 are not yet fully understood but it has been shown in vitro that this
inositol phospholipid is capable of activating both the aPKCs and nPKCs
(Nakanishi et al., 1993; Toker et al., 1994). It has also been suggested that
activation of PKC by PI-3-kinase may be partly a direct phosphorylation
event, as the catalytic subunit of this enzyme is thought to have protein
kinase activity (S. Ohno; unpublished data).
1.6 Regulation of PKC activity
As previously mentioned, activation of PKC is associated with
translocation to the membrane and subsequent limited proteolysis. It has
been proposed that this may represent a physiological regulatory
mechanism (Pontremoli et al., 1990) resulting in the termination of PKC
activity. There are also a number of other mechanisms by which PKC
activity may be regulated.
Phosphorylation
It has been suggested that phosphorylation may be important in the
regulation of PKC. Many PKC isoforms, for example PKC 5 and e, are seen
as doublets on western blots when obtained from native tissues, consistent
the presence of different phosphorylation states (Koide et al., 1992; Ogita,
1992). Expression of PKC a in COS1 cells produced phosphorylated
protein that was found to be inactivated by dephosphorylation and the initial
phosphorylation event was shown to be independent of PKC activity (Pears
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et al., 1992). The importance of phosphorylation in the regulation of PKC
activity means that caution is necessary when expressing isoforms in non-
mammalian expression systems as the correct phosphorylations may not
occur. Problems have been encountered, for example, when using the
baculovirus system to express PKC 5 as initially only 1% of the protein
produced was catalytically active, and inefficient phosphorylation was
proposed as the reason for this problem (Rankl et al., 1994). The kinases
responsible for PKC phosphorylation are not at present clearly defined.
Protein kinase C 5, but not cPKCs, has been shown to be phosphorylated in
vitro by the tyrosine kinases src and to a lesser extent fyn (Gschwendt et al.,
1994), and overexpression of PKC 8, in both 32D hematopoietic cells and
NIH-3T3 fibroblasts, resulted in tyrosine phosphorylation of this isoform in
response to TPA (Li et al., 1994). In both these cases, tyrosine
phosphorylation enhanced PKC 8 activity, although tyrosine phosphorylated
PKC 8, immunoprecipitated from keratinocytes expressing oncogenic ras,
showed reduced activity when compared to nonphosphorylated PKC 8
(Denning et al., 1993). Thus while it appears that PKC 8, but not some of
the other PKC isoforms, is regulated by tyrosine phosphorylation, the effect
on PKC 8 activity seems to vary with cell type or the tyrosine kinase
responsible.
Autophosphorylation
Autophosphorylation has been described for most protein kinases,
although this is not necessarily linked to modulation of kinase activity (Miller
and Kennedy, 1986). All isoforms of PKC have been shown to undergo
autophosphorylation (Hug and Sarre, 1993) in an activator-dependent
manner, though the Km for ATP for this reaction is 10-fold lower that for
substrate phosphorylation (Huang et al., 1986; Newton and Koshland,
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1989). Both the regulatory and catalytic domain are autophosphorylated,
modified residues being found in the amino-terminal region, the carboxy-
terminal tail and the hinge section between the regulatory and catalytic
domains, and this reaction is thought to follow an intramolecular mechanism
(Flint et al., 1990; Huang et al., 1986). The sites of autophosphorylation are
poorly conserved between PKC isoforms (Azzi et al., 1992), but some motif
selectivity must exist because phosphorylated residues are often located
next to other serine or threonine residues which show no
autophosphorylation (Hug and Sarre, 1993). Different isoforms not only
select different sites but they also vary in which type of amino acid is
preferred. PKC a and C, were found to autophosphorylate almost exclusively
on serine residues, while PKC pi autophosphorylated primarily threonine
residues and PKC pll showed no clear preference (S. Gaubatz and T Sarre,
unpublished data from (Hug and Sarre, 1993)). Autophosphorylation of
PKC results in increased affinity for phorbol esters, increased sensitivity to
Ca2+ and increased rate of histone phosphorylation (Huang et al., 1986). It
has also been suggested that autophosphorylation in the V3 region close to
the site of calpain cleavage may change the susceptibility to proteolysis
(Azzi et al., 1992).
Endogenous PKC inhibitors
The presence of endogenous inhibitors has been suggested as one
mechanism by which PKC activity may be regulated in vivo. One group
reported isolation of 3 closely related potent PKC inhibitor proteins from
sheep brain, which were called kinase C inhibitor proteins (KCIP-1)(Toker et
al., 1990). These acidic proteins of 29-33 kDa showed amino acid
sequence homology with the carboxy-terminal region of the annexin family
of Ca2+/lipid binding proteins. They were subsequently identified as
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members of the 14-3-3 family of proteins (Toker et al., 1992), which are
found in most mammalian tissues and are thought to function as regulators
in a variety of signal transduction pathways (Aitken et al., 1992). Inhibition
of PKC by KCIP-1 does not appear to be due to competition with ATP, DAG,
Ca2+ or substrate, and it has no effect on [3H]PDBu binding (Toker et al.,
1990). Part of the sequence of KCIP-1 resembles the carboxyl terminus of
the annexins, a family of Ca2+ and lipid binding proteins, one of which
(annexin V) has been shown to inhibit PKC (Schlaepfer et al., 1992). It has
been suggested that the region in KCIP-1 that resembles the annexins may
bind the regulatory domain of PKC, and a synthetic peptide based on this
sequence, from annexin-l, has been shown to prevent PKC binding to
RACKS (Mochly-Rosen et al., 1991b). It has therefore been suggested that
these proteins may act as regulators of PKC translocation (Aitken et al.,
1992).
Other endogenous PKC inhibitors have also been detected. A 17
kDa protein called protein kinase C inhibitor I (PKCI) was isolated from
bovine brain and its amino acid composition was found to members of the
resemble that of the calmodulin family of Ca2+-binding proteins (McDonald
et al., 1987). Its inhibitory effect on PKC, however, was reported not to
involve competition with Ca2+ or phospholipid cofactors. The sequence
published, however, was later found to correspond to an FK 506 binding
protein that had co-purified with the PKC inhibitor (Mozier et al., 1991).
Recently a 70 kDa protein from maize has been cloned and found to have
high similarity to bovine PKCI (Simpson et al., 1994). While this 70 kDa
protein has little effect on PKC activity alone, it has been shown that to
synergise with KCIP (Robinson and Aitken, 1994). A peptide inhibitor
(designated IN) has been detected, in phytohaemogglutinin-activated
peripheral-blood mononuclear cells, which is thought to act on the
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regulatory domain of PKC as it was ineffective at inhibiting the catalytic
domain generated by trypsin cleavage of PKC (Gandini et al., 1993).
Therefore it appears that PKC activity may be regulated in vivo by a variety
of endogenous inhibitors in different cell types.
Regulation of PKC gene expression
At present little is known about the factors responsible for the
regulation of the PKC genes or their promoter sequences of the PKC genes
(Hug and Sarre, 1993). Comments can only be made concerning the rat
PKC y and human PKC p promoters, as these are currently the only ones
that have been cloned (Chen et al., 1990; Niino et al., 1992; Obeid et al.,
1992). Both these promoters contain an AP1 site and at least one AP2 site.
As these sites are responsible for conferring inducibility by phorbol esters
on promoters containing them, it is possible that PKC p and y are positively
regulated by themselves or other PKC isoforms (Hug and Sarre, 1993).
This could represent a means by which PKC mRNAs are replenished
following PKC activation and subsequent degradation (Hug and Sarre,
1993). The PKC y promoter contains a cAMP response element (Locker
and Buzard, 1990), potentially allowing activation of the cAMP second
messenger system to upregulate PKC-mediated responses. Deletion
analysis of the PKC p promoter identified both positive and negative
regulatory regions, and control of transcription by these regions is cell type
specific (Niino et al., 1992). In order to identify the elements responsible for
the different expression patterns shown by PKC isoforms, it will be
necessary to compare the promoter sequences of these isoforms with those
not yet isolated.
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1.7 Cellular Roles of PKC
A wide variety of possible roles for PKC in cellular responses have
been proposed, as shown in Table 1, as well as in crosstalk between
different second messenger pathways (Houslay, 1991). In the nervous
system, PKC has been shown to be involved in the enhancement of
neurotransmitter release (Pozzan et al., 1984; Tanaka et al., 1984),
regulation of Na+ (West et al., 1991) and Ca2+ ion channels (Campbell et
al., 1988) and modulation of neuronal plasticity (Malenka et al., 1986; Wang
and Feng, 1992). Protein kinase C participates in inflammatory processes
and immune responses, as signaling through PKC has been implicated in
the activation of neutrophils (Tauber, 1987), lymphocytes (Berry et al., 1990;
Cambier and Ransom, 1987) and differentiation of myeloid cells to
macrophages (Aihara et al., 1991). There is also good evidence that PKC
plays an important role in the activation of platelets (Rink et al., 1983; Wang
et al., 1993).
Protein kinase C is involved in nuclear events, such as control of the
cell cycle and regulation of gene expression (Nishizuka, 1992). The Ca2+-
independent PKCs may be activated as part of the cascade initiated by
growth factors such as EGF, leading to regulation of the cell cycle (Hattori et
al., 1992; Rossomando et al., 1992). Protein kinase C has been shown to
phosphorylate DNA topoisomerase (Pommier et al., 1990) and lamin B
(Fields et al., 1988); nuclear proteins both involved in the control of DNA
synthesis. PKC is involved in regulation of gene expression, as treatment of
cells with phorbol esters results in the increased transcription of a number of
genes, due to activation of transcription factors. Activation of PKC results in
phosphorylation of the inactive I-kB/NFkB complex on the inhibitory protein
(licB)(Ghosh and Baltimore, 1990), releasing the NFkB transcription factor
which then moves to the nucleus and binds specifically to DNA. PKC also
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activates the AP1 transcription factor, a complex of the c-fos and c-jun
proteins, which confers inducibility by phorbol esters to genes containing
the TPA-response element in their promoter (Karin, 1992). The activation of
this complex by PKC seems to involve pathways leading to the both the
phosphorylation of c-fos and the dephosphorylation of c-jun (Karin, 1992).
Modulation of gene expression by PKC is thought to occur not only at the
transcriptional level but also by regulation of the rate of translation (Hug and
Sarre, 1993). The ribosomal S6 protein, as well as the initiation factor
complex, have been shown to be phosphorylated in response to phorbol
esters (Morley and Traugh, 1990). This protein is thought to be
phosphorylated predominantly by ribosomal S6 kinases and PKC has been
implicated in one of the two phases of EGF-induced activation of S6 kinase
in Swiss 3T3 cells (Susa et al., 1989). Components of the translation
initiation complex have also been found to be phosphorylated both in vitro
and in cultured cells by PKC (Morley et al., 1991; Smith et al., 1991). It has
been suggested that translational control mechanisms may be involved in
PKC-mediated proliferation and differentiation events (Hug and Sarre,
1993), as these events are accompanied by significant alterations in the rate
of protein biosynthesis (Hershey, 1991). Indeed, loss of the PKC-dependent
phase of S6 kinase activation resulted in a diminished mitogenic response
to EGF in Swiss 3T3 cells (Susa et al., 1989).
In addition to these stimulatory events, PKC also plays a role in the
negative feedback regulation of a variety of cell signalling processes,
involved in both the short term and prolonged responses of the cell. In the
short term, PKC appears to be involved in decreasing intracellular Ca2+
levels elevated by IP3 (Nishizuka, 1988). It has already been mentioned
that PKC is involved in inhibiting Ca2+ mobilisation by blocking receptor-
mediated hydrolysis of PI, but it is also thought to stimulate IP3 hydrolysis by
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activating an IP3 phosphatase (Persons et al., 1988). It is proposed that
PKC may stimulate the removal of intracellular Ca2+ by activation of the
Ca2+-transport ATPase and the Na+/Ca2+ exchange protein (Nishizuka,
1986).
Protein kinase C also negatively regulates long-term responses such
as cell proliferation (Nishizuka, 1988). The EGF receptor has been shown
to be phosphorylated by PKC both in vitro and in vivo, resulting in down-
regulation by decreasing high-affinity binding of EGF and inhibiting ligand-
induced tyrosine phosphorylation (Schlessinger, 1986). A similar response
occurs in T-lymphocytes; treatment of these cells with TPA and a Ca2+
ionophore resulting in phosphorylation of the T-cell receptor and preventing
any further proliferative response to antigen (Cantrell et al., 1985).
Many of the effects seen following PKC activation are not a result of
direct phosphorylation of the effector proteins but due to PKC initiating
cascades of phosphorylation by activation of other kinases. Activation of
mitogen activated protein kinase (MAP kinase) has been shown following
PKC activation (Adams and Parker, 1992) although the classical cascade of
MAP kinase activation is through ras, raf and MAP kinase kinase
(MEK)(Marx, 1993). It has been shown that Raf-1 may by activated by
serine phosphorylation and PKC has been suggested as a likely candidate
(Carroll and Stratford-May, 1994). Recent studies have shown that PKC can
phosphorylate and stimulate Raf-1 in vitro (Kolch et al., 1993), and there is
evidence that direct phosphorylation and activation of Raf-1 by PKC occurs
in vivo in hematopoietic cells (Carroll and Stratford-May, 1994). Activation
of MAP kinase provides an alternative, indirect means by which PKC can
modulate gene transcription, as MAP kinase is also able to phosphorylate
transcription factors resulting in enhancement of gene expression (Edwards,
1994).
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Protein kinase C also plays a role in cross talk between a number of
second messenger systems. As well as the previously mentioned effects on
the MAP kinase cascade, PKC may also be involved in the regulation of
cAMP-mediated intracellular signalling pathways. Phorbol esters have
been shown to both stimulate and inhibit cAMP levels in a number of cell
types, tissues and cell lines (Houslay, 1991). These diverse responses may
be due to the actions of different PKC isoforms as well components of the
cAMP cascade, such as heterotrimeric G-proteins, adenylyl cyclase, and
phosphodiesterase. In the HT4 neural cell line, phorbol ester stimulation of
cAMP levels was found to synergise with adrenaline receptor-mediated
effects, although some activation of the cAMP cascade was found to be
essential for phorbol-induced stimulation. It was therefore proposed that
PKC was only able to phosphorylate a component of the adenylate cyclase
activation mechanism when in an activated not resting state (Morimoto and
Koshland, 1994).
There is also evidence that PKC can influence the cGMP/guanylate
cyclase system. Protein kinase C is able to phosphorylate guanylate
cyclase in vitro, leading to its activation, (Zwiller et al., 1985) and treatment
of pinealocytes with phorbol esters results in increased cGMP levels (Ho et
al., 1987). Recent studies on rat colonic particulate guanylate cyclase have
shown that activation of this enzyme by both raised intracellular Ca2+ levels
and the vitamin D3 metabolite, 1,25-dihydroxycholecalciferol, occur via a
PKC-dependent pathway (Khare et al., 1993; Khare et al., 1994). In PC12
cells, PKC has been shown to phosphorylate and activate soluble guanylate
cyclase (Louis et al., 1993), so providing one mechanism whereby agonist-
stimulation of PI hydrolysis can result in raised levels of cGMP.
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1.8 ROLES of specific PKC isoforms
The number of PKC isoforms, their variations in biochemical
properties and expression in different cell types has led to the suggestion
that different isoforms may activate different cellular pathways and
phosphorylate different proteins (Azzi et al., 1992). This is supported by
studies showing that the expression of PKC isoforms in haemopoietic cells
is cell type and B cell differentiation stage-specific (Mischak et al., 1991),
while the expression of PKC isoforms is modulated during granulocyte
differentiation (Hashimoto et al., 1990). Furthermore the exclusive
localisation of PKC yin the central nervous system (Shearman et al., 1987)
suggests that this isoform has a specialised function (Nishizuka, 1988).
Roles have been proposed for different PKC isoforms on the basis of which
isoforms are activated, as reflected by translocation, on stimulation of cells
with different agonists (Wilkinson and Hallam, 1994), as well as the
selective down-regulation of isoforms on prolonged agonist stimulation.
The possible roles of isoforms in fibroblast transformation by the ras
oncogene has been studied by measuring the levels of isoform expression,
which showed PKC a and 5 to be increased but PKC e decreased, as
detected both at the mRNA and protein level (Borner et al., 1992a).
Studies of the effects of overexpression of individual isoforms have
been widely used to evaluate the roles of different PKC isoforms. PKC 5 has
been implicated in control of the cell cycle, as when this isoform, but not
PKC a, pil or is overexpressed in CHO cells, treatment with phorbol esters
prevents progression of the cell cycle through M phase (Watanabe et al.,
1992). PKC 8 has also been suggested to play a role in MAP kinase
activation as cells overexpressing this isoform showed prolonged phorbol
ester-induced stimulation of MAP kinase activity (Yamaguchi, Ogita and
Nishizuka, unpublished data from Nakamura and Nishizuka, 1994). Other
27
isoforms are also likely to play a role in MAP kinase activation through Raf-
1, however, as PKC a has been shown to be able to phosphorylate and
activate Raf-1 in vitro (Kolch et al., 1993). Overexpression of PKC isoforms,
along with a reporter construct under the control of a TPA response element,
has provided evidence for the involvement of PKC 8, e and £ but not a in
serum, EGF and lysoPA-induced stimulation of gene expression (Ohno et
al., 1994). This is consistent with the observation that EGF and lyso PA
cause an increase in phosphorylation levels of PKC 5 and e but not a (Ohno
et al., 1994). There has been considerable interest in elucidating the
isoforms involved in cell proliferation, due to the implications for cancer
therapy. Overexpression of PKC a does not appear to result in cell
transformation (Borner et al., 1991; Eldar et al., 1990) while PKC 5 slowed
the growth rate of NIH 3T3 cells, PKC e having the opposite effect on these
cells (Hug and Sarre, 1993). Contradictory results have been obtained for
PKC pi and PKC y, PKC pi causing transformation of rat 6 fibroblasts
(Housey et al., 1988) but not of rat liver epithelial cells (Hsieh et al., 1989),
while PKC y may (Persons et al., 1988) or may not (Cuadrado et al., 1990)
cause transformation of NIH 3T3 cells. It therefore appears that the effects of
overexpression may depend on the cell line in which it is expressed, as well
as on the levels of expression that result (Hug and Sarre, 1993). It has also
been suggested that overexpression may result in incorrect signalling,
through the phosphorylation of non-physiological substrates, as the
overexpressed protein may undergo inappropriate compartmentalisation
(Wilkinson and Hallam, 1994).
Dominant kinase-negative mutants have also been used to evaluate
the roles of different isoforms. By this method, PKC £ has been implicated in
mitogenic signal transduction and placed downstream of ras activation
(Berra et al., 1993). This isoform has also been linked to activation of the
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transcription factor NFkB (Diaz-Meco et al., 1993). A further role proposed
for this isoform is in the maintenance of LTP, as PKC £ may show persistent
activation by conversion to the constitutively-active PKM following induction
of LTP (Sacktor et al., 1993).
The number of roles that have been proposed for different PKC
isoforms, along with the sometimes contradictory results obtained when
trying to ascribe roles to particular isoforms, suggests that the selection of
isoforms activated in response to a particular stimulus may be determined
not only by the biochemical properties of each isoform, but also by the type
of cell, the isoforms that it expresses and the subcellular distribution of those
isoforms.
1.9 PKC PHARMACOLOGY
Protein kinase C has been implicated in many cell responses by the
use of PKC activators to mimic agonist-induced responses or by using PKC
inhibitors to block the pathway (Wilkinson and Hallam, 1994). The most
commonly used PKC activators, in addition to diglycerides, are the phorbol
esters and related compounds, including phorbol 12,13-dibutyrate (PDBu)
and TPA. However while the diacylglycerol, 1-oleoyl-2-acetylglycerol has
similar affinities for all the PKC isoforms (Kazanietz et al., 1993), some of the
phorbol esters show selectivity between isoforms (Kazanietz et al., 1993;
Ryves et al., 1991). Phorbol esters like PDBu and 12-deoxyphorbol esters
show a slight preference for the Ca2+-dependent isoforms (Kazanietz et al.,
1993), while sapintoxin A will activate PKC a, pi, y and e but not PKC 5. The
mezerein-like compounds are also more potent at activating the cPKCs, the
most striking of which, thymeleatoxin, shows almost 20-fold less affinity for
PKC e and r\ over PKC pi (Kazanietz et al., 1993). Another commonly used
phorbol ester is TPA, which is effective at activating the Ca2+-dependent
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PKC isoforms, particularly PKC (31, in the absence of Ca2+ (Ryves et al.,
1991). Phorbol esters and other diterpenes are not the only
pharmacological agents that may be used as PKC activators. The
macrocyclic lactone, bryostatin, is also a potent PKC activator which is
active at picomolar concentrations rather than the nanomolar concentrations
required for the phorbol esters, although it also acts by binding to the
regulatory domain (Blumberg and Pettit, 1992).
Protein kinase C activators have been shown to vary in their tumour-
promoting capabilities. The phorbol esters, such as TPA, act as full tumour
promoters, producing inflammation and induce ornithine decarboxylase
activity, as well as decreasing epidermal differentiation (Slaga et al., 1980).
Diterpenes, such as mezerein, induce some of the biological effects of the
phorbol esters, for example induction of cell proliferation and stimulation of
DNA synthesis, but are up to 50 times less active than TPA as complete
tumour promoters, although they are potent second stage tumour promoters
(Slaga et al., 1980). As these differences in biological activity may reflect
the involvement of different PKC isoforms, the development of isoform-
specific activators would prove useful for evaluating the roles of particular
PKC isoforms in vivo.
The use of phorbol esters to mimic agonist-induced responses
thought to involve PKC must, however, be treated with some caution.
Phorbol esters, unlike DAG, are metabolically stable and the use of high
concentrations may result in a decrease in the substrate specificity of PKC
phosphorylation in vivo (Wilkinson and Hallam, 1994). Many phorbol
esters, unlike DAG, are also able to activate Ca2+-dependent PKC isoforms
in the absence of Ca2+ (Ryves et al., 1991), so the responses initiated by
these compounds may not entirely resemble those occurring physiologically
following agonist stimulation. Furthermore PKC is not the only cellular
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receptor for phorbol esters. N-chimaerin is a p21 rac-GTPase-activating
protein (rac-GAP) as well as a high affinity phorbol ester receptor and the
rac-GAP activity of n-chimaerin has been found to be stimulated by PS
alone or synergistically with phorbol esters (Ahmed et al., 1993). Another
high affinity phorbol ester receptor is unc-13, a protein identified in
Caenorhabditis elgans that plays a role in synaptic transmission (Maruyama
and Brenner, 1991). This protein shows sequence identity to the C1/C2
domains of PKC and also binds phorbol esters in a phospholipid dependent
manner (Ahmed et al., 1992).
Protein kinase C inhibitors may be divided into two categories,
depending on whether they bind to the regulatory or catalytic domain.
Some regulatory domain inhibitors interfere with Ca2+ and phospholipid
binding, for example dibucaine, (Mori et al., 1980) but these are not specific
for PKC as they also inhibit Ca2+/calmodulin dependent kinases (Hidaka
and Hagiwara, 1987). More specific inhibitors act by inhibiting phorbol
binding, for example gossypol and the fungally-derived calphostins. The
most potent calphostin is calphostin C, which shows a similar potency for
PKC a, (3 and y. It requires photoactivation in order to inhibit phorbol
binding, although the mechanism of this light-dependent inhibition is not
fully understood (Azzi et al., 1992). Tamoxifen and adriamycin are also
regulatory domain inhibitors that are thought to interfere with the interaction
between PKC and phospholipids (Su et al., 1985; Wise and Kuo, 1983),
although both of these compounds and also gossypol are also able to
inhibit the catalytic fragment of PKC, with only a 2-3 fold difference in
potency. It has been suggested that many PKC inhibitors may have multiple
sites of action (Nakadate et al., 1988). The problem with the regulatory
domain inhibitors is that they tend to be hydrophobic and so may exert non¬
specific effects on kinases and at the cell membrane. Sphingosine is a
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physiological inhibitor of PKC and it has also been used to inhibit PKC in
vitro, although it is not specific for PKC as it also inhibits calmodulin-
dependent protein kinases (Jefferson and Schulman, 1988). It is another
inhibitor which is thought to have multiple sites of action, as it is reported to
inhibit [3H] PDBu binding at concentrations similar to those at which it
inhibits kinase activity, but it is also capable, at low concentrations of
phospholipid, to inhibit the activity of the catalytic fragment (Nakadate et al.,
1988). Sphingosine has, however, been shown to have mitogenic effects
that are independent of PKC (Zhang et al., 1990) and it is readily converted
to sphingosine 1-phosphate (Zhang et al., 1991), which also has a variety of
cellular effects including activation of PLD (Spiegel, 1993) and release of
Ca2+ independent of IP3, (Ghosh et al., 1990). Thus sphingosine is not a
useful tool for evaluation of PKC activation in vivo.
There is also a variety of PKC inhibitors that act on the catalytic
domain. These include the isoquinolines, such as H7, and the microbially-
derived indole carbazoles, including staurosporine and K252a. These are
ail thought to interact with the ATP binding site (Hidaka et al., 1984; Tamaoki
et al., 1986), although their precise sites of action seem to vary. H7
competes kinetically with ATP (Hidaka et al., 1984) but only partially protects
the ATP binding site from covalent chemical reagents (Ohta et al., 1988) and
it displaces [3H]N,A/-dimethyl staurosporine binding only at very high
concentrations (Thomson et al., 1991). Staurosporine has a high potency in
cells that appears to be incompatible with a solely ATP-competitive
mechanism (Ruegg and Burgess, 1989) and it has been reported that the
inhibitory effect of this compound is not influenced by the presence of
excess ATP (Tamaoki et al., 1986). Thus the exact mechanism of inhibition
by staurosporine is unclear. The problem with these three inhibitors is that
they all show poor selectivity for PKC over other kinases, as the ATP binding
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region of PKC is highly homologous with that of other serine/threonine
kinases as well as tyrosine kinases (Hanks et ai., 1988). Recently the
bisindolylmaleimide inhibitors, including Ro31-8220 and GF109203X, have
been developed, based on the structure of staurosporine. These
compounds have also been shown to be competitive inhibitors with respect
to ATP, but display high selectivity for PKC over other kinases (Davis et al.,
1989; Toullec et al., 1991) and are reported to vary in their potency on
different PKC isoforms (Wilkinson et al., 1993). Another related compound,
Go 6976, is also a potent, selective PKC inhibitor which has been shown to
distinguish between the Ca2+-dependent and Ca2+-independent PKC
isoforms, as it inhibited PKC a and (31 at nanomolar concentrations but even
micromolar concentrations had no effect on PKC 8, e or £ (Martiny-Baron et
al., 1993). Recently another ATP competitive inhibitor, rottlerin, has been
identified with specificity for PKC 5 over other PKC isoforms, which are at
least one order of magnitude less sensitive to this inhibitor (Gschwendt et
al., 1994). While rottlerin showed some specificity for PKC 8 over other
protein kinases, it inhibited Ca2+/calmodulin-dependent protein kinase III
with similar potency to PKC 8. It is possible that further development of
rotterlin- or staurosporine-related compounds may result in inhibitors with
improved isoform-selectivity which would be invaluable tools for dissecting
the physiological roles of individual isoforms.
The substrate binding site provides an alternative target for catalytic
domain inhibitors, the most effective of which are based on the PKC
pseudosubstrate region. As previously mentioned, this region is an
autoinhibitory domain that is thought to interact with the substrate binding
site, in the absence of activators, so preventing PKC activity. It has been
shown that synthetic peptides consisting of this sequence are PKC substrate
antagonists, due to the presence of the basic residue determinants
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necessary for substrate recognition. These peptides were found to be able
to inhibit both substrate phosphorylation and autophosphorylation, and
were specific for PKC over other kinases that require arginine in their
sustrate recogniton motif, such as cAMP-dependent protein kinase (House
and Kemp, 1987). In view of the variation between PKC isoforms in their
pseudosubstrate domain, it is possible that these peptides may show some
selectivity between-PKC isoforms. This is supported by evidence that in
Xenopus oocytes, which contain PKC a, p, y and TPA-evoked PKC activity
was inhibited by the a but not the C, pseudosubstrate inhibitor, while
immunoprecipitated PKC C, was inhibited by the £ but not a pseudosubstrate
inhibitor (Dominguez et al., 1992).
1.10 PKC IN THE ANTERIOR PITUITARY GLAND
As previously mentioned, even within one tissue type, different
activators and inhibitors vary in their ability to affect individual PKC-
mediated responses. This may be due to these pharmacological agents
affecting only some of the PKC isoforms present in that tissue. In the
anterior pituitary gland, there is increasing evidence for the existence of
pharmacologically distinct forms of PKC and their involvement in a number
of anterior pituitary cell responses. The PKC activators mezerein and PDBu
have been shown to induce release of both growth hormone (GH) and
luteinising hormone (LH) from rat anterior pituitary tissue, but these
responses vary in their sensitivity to PKC inhibitors (Thomson et al., 1993b).
Both responses are blocked by staurosporine and the more selective PKC
inhibitor Ro31-8220. However inhibition of LH release by H7 shows two
components, one H7-sensitive and one relatively H7 resistant, while GH
release is totally resistant to this inhibitor. Agonist-induced hormone
release can also show this unusual pharmacological profile. Luteinising
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hormone-releasing hormone (LHRH) is able to increase the responsiveness
of gonadotrophs, the LH-secreting cells in the anterior pituitary, to LHRH.
This process, known as self-priming, is also mediated by PKC, as it is
blocked by Ro31-8220 and other PKC inhibitors, but the PKC involved is
relatively resistant to inhibition by H7 (Johnson et al., 1992b).
Protein kinase C is also involved in the modulation of L-type Ca2+
channels in anterior pituitary tissue, and it has been shown that this is
involved in PDBu-induced release of GH but not LH (Johnson et al., 1993).
PDBu has been shown to have dual effects on these channels depending
on cell type, as, in pituitary tissue, K+-induced Ca2+ influx is facilitated by
PDBu, while in the clonal pituitary GHacell line, PDBu inhibits this response
(MacEwan and Mitchell, 1991). There is evidence to suggest that the
facilitation in pituitary tissue is mediated by the H7-resistant form of PKC
mentioned above, while the inhibition seen in GH3 cells is the result of a
different, H7-sensitive form of PKC (MacEwan et al., 1991; MacEwan et al.,
1992).
Studies have been conducted to identify the downstream targets of
this H7-resistant PKC-like kinase. It has been shown to be involved in the
activation of mitogen-activated protein kinase (MAP kinase) by LHRH, in
both pro-oestrous anterior pituitary tissue and the aT3-1 gonadotroph cell
line (Mitchell et al., 1994; Sim and Mitchell, 1994). This H7-resistant PKC-
like kinase has also been implicated in the activation of PLA2 induced by
both PDBu and LHRH; LHRH-induced arachidonate production is sensitive
to Ro31-8220 but relatively resistant to H7, while the PDBu-induced
response shows two components of varying sensitivities to H7 (Thomson
and Mitchell, 1993). It is possible that this PLA2 response may be
downstream of MAP kinase, as the high molecular weight form of PLA2 has
a potential phosphorylation site for MAP kinase (Lin et al., 1993). This is
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supported by evidence that the TPA-evoked activation of PLA2 in
macrophages is a result of PKC activation of MAP kinase (Qui and Leslie,
1994) and a mechanism for agonist-induced activation of CPLA2 involving
PKC activation of MAP kinase has been proposed from overexpression
studies of CPLA2 in COS and CHO cells (Lin et al., 1993).
1.11 The aim of this study
PKC activity showing a similar pharmacological profile to that
described above in these anterior pituitary cell events (that is induced by
phorbol esters and inhibited by staurosporine but not H7) has been
detected in the cytosolic fraction from anterior pituitary but not that obtained
from midbrain, in an in vitro kinase assay. The aim of this study has been to
further characterise this H7-insensitive PKC-like kinase, both in terms of its
pharmacology, biochemical properties and tissue distribution, and by further
purification and molecular biological approaches, to explore the possibility
that this may represent a novel isoform of PKC or an unknown PKC-like
kinase.
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Table 1 Possible roles of PKC In cellular responses
Roles that have been proposed for PKC in vivo in a variety of tissues and
cell types are indicated. Adapted from (Nishizuka, 1986).
Table 1.1
Tissues and cells Responses
Endocrine systems
Adrenal medulla Catecholamine secretion
Adrenal cortex Aldosterone secretion
Pancreatic islets Insulin release
Pituitary cells Pituitary hormone release
Exocrine systems
Pancreas Amylase secretion
Gastric gland Pepsinogen secretion
Gastric acid secretion
Alveolar gland Surfactant secretion
Nervous system
Neuromuscular junction Transmitter release
Caudate nucleus Acetylcholine release
PC12 cells Dopamine release
Neurones Dopamine release
Muscular systems

















Figure 1.1 Structure of the PKC isoforms.
A schematic representation of the cDNA sequences of the known PKC
isoforms. The cPKCs are Ca2+-dependent while the nPKCs and aPKCs
are Ca2+-independent. The aPKCs unlike the other isoforms are not
dependent on phorbol esters. The boxed regions represent the conserved
domains (C1-4) whilst V1-5 are the variable domains. Cys, cysteine-rich






























Figure 1.2 Proposed mechanism of PKC activation.
In the absence of DAG and phospholipid (and Ca2+ for the cPKCs), the
pseudosubstrate region of the regulatory domain interacts with the
substrate binding site so preventing access to potential substrates. Binding
of DAG and phospholipid results in a conformational change which
removes the pseudosubstrate domain allowing the substrate binding
domain to interact with substrate proteins. Cleavage of the hinge region by
proteases removes the regulatory domains resulting in a constitutively
active catalytic domain. R regulatory domain, C catalytic domain, S




Figure 1.3 PKC activation following signal-induced membrane
phospholipid degradation.
Pathways by which PKC may be activated following stimulus-induced
phosphatidyl inositol and phosphatidylcholine hydrolysis. R, receptor;
PI(4,5)P2, phosphatidylinositol 4,5-bisphosphate; PC, phosphatidylcholine;
1(1,4,5)P3, inositol 1,4,5-trisphosphate; DAG, diacylglycerol; FFA, cis-
unsaturated fatty acid; LysoPC, lysophosphatidylcholine; PKC, protein
kinase C. Dashed lines indicate positive and negative feedback of PKC on












2.1 PKC activators and inhibitors
PDBu, mezerein (LC Services Corporation), 1,2 dioctanoyl glycerol
(DOG)(Sigma), staurosporine (Calbiochem) and Ro31-8220 (Roche
Products Ltd, Welwyn Garden City, UK) were made up as 1-10 mM stock
solutions in dimethylformamide (DMF). With the exception of DOG (freshly
prepared), all of these reagents were used from stocks maintained at -20°C.
H7 was dissolved in distilled water (10 mM stock) and used from aliquots
maintained at -20°C.
2.2 Commonly used solutions
5 x agarose gel loading buffer: 0.25% (w/v) bromophenol blue,
0.25% (w/v) xylene cyanol, 1 mM
EDTA, 30% glycerol.
10 x TBE: pH 8.3; 108.9 g/l Tris base, 55.7 g/I
boric acid, 4.7 g/l EDTA.
TE: 10 mM Tris/HCI (pH 8), 1 mM
EDTA
Tris-saturated phenol: frozen phenol was thawed by bringing to room
temperature then heated to 68°C in a water bath. Hydroxyquinoline (0.1%)
was added as a preservative and phenol was equilibrated with an equal
volume of 0.5 M Tris/HCI (pH 8.0) followed by an equal volume of 0.1 M
Tris/HCI (pH 8.0) until buffer pH was > 7.0. Phenol was finally equilibrated
with 0.1 volumes of 0.1 M Tris/HCI (pH 8.0) and stored at 4°C under a layer
of 0.1 M Tris/HCI (pH 8.0).
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2.3 Bacterial culture medium
L-agar:
AIX plates:
L-broth: 10 g/l tryptone, 5 g/l yeast extract, 5 g/l NaCI.
L-broth to which 1 % bactoagar was added.
L-agar was melted over a bunsen burner and left
to cool to room temperature. Ampicillin (50 mg/ml),
isopropylthio-p-D-galactoside (IPTG)(50 mg/ml)
and X-gal (5-bromo-4-chloro-3-indolyl-B-D-
galactopyranoside)(4%) were added (1:1000
dilution of each) before plates were poured and
allowed to cool at room temperature. Once set,
plates were stored for up to 2 weeks at 4°C. Stock
solutions of ampicillin, IPTG and X-gal were stored
at -20°C.
Methods
2.4 Cytosolic PKC activity assay
Partially-purified cytosolic PKC activity was determined as the PDBu-
induced histone lll-S thiophosphorylation in the presence of
phosphatidylserine (PS). Partial purification was necessary to remove
endogenous inhibitors and phosphatases. A mixed micelle assay was used
to enable the Ca2+-dependent and -independent activity to be analysed
separately, as PKC activation is obligatorily dependent on
phorbol/diglyceride activators under these conditions (Hannun and Bell,
1986). All of the activity measured was PS-dependent as it was absent
when PS was replaced by PC, which is unable to act as a cofactor in PKC
activation (Nishizuka, 1984b). Thiophosphorylation was measured as ATP-
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y-35S is an acceptable phosphate donor for many protein kinases (Eckstein,
1985) and the products of the reaction are more resistant to subsequent
phosphatase activity (Coyne et al., 1987; Wagner and Vu, 1989). However
thiophosphorylation occurs at a slower rate than phosphorylation (Wise et
al., 1982) and the kinetics of thiophosphorylation, using the method
described below, have been shown to be linear up to 30 min (D J MacEwan
and R Mitchell; unpublished results).
This method is modified from those in references (Huang et al., 1988;
Wise et al., 1982). Tissue from male Wistar rats (230-350 g) was
homogenised in 2 volumes of 20 mM Tris/HCI (pH 7.5) containing 50 mM 2-
mercaptoethanol, 2 mM EDTA, 1 mM phenylmethylsulphonyl fluoride
(PMSF)(Sigma), 0.01% (w/v) leupeptin (Sigma) and 20 |iM trans-
epoxysuccinyl-l-leucylamido (4-guanidino) butane (E64)(Sigma).
Alternatively, COS 7 cells (cultured at 37°C in DMEM with 10% normal calf
serum under 5% CO2) were washed in Ca2+/Mg2+-free Hank's salt solution
and then harvested from tissue culture flasks by scraping into ice-cold
homogenisation buffer. The suspension was then homogenised using a
Ystral polytron homogeniser (Scientific International Industries Ltd,
Loughborough, Leics, UK). The homogenate was centrifuged (16,000 g, 20
min, 4°C) and the supernatant was collected and recentrifuged (16,000 g, 5
min, 4°C). The supernatant from the second spin was taken to represent
cytosol and was partially purified by loading onto 0.5 ml (cells and
pituitaries) or 1.5 ml (other tissues) diethylaminoethyl (DEAE) cellulose
(DE52; Whatman International Ltd, Maidstone, Kent, UK) in a Bio-Rad Poly-
Prep chromatography column (Bio-Rad Laboratories, Richmond, California,
USA) at 4°C. The matrix was then washed with 6 column volumes of
homogenisation buffer before the partially-purified PKC was eluted with 3
column volumes of buffer containing 150 mM NaCI. Cytosolic PKC activity
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was then measured in an assay mixture (total volume 100 pi) containing,
unless otherwise stated, (final concentrations): 10 mM MgCl2, 200 pg/ml PS
(sodium salt) (Lipid Products, Nutfield, Surrey, UK), 0.04% Nonidet P-40
(Calbiochem, Novabiochem, Nottingham, UK), 1.25 mg/ml histone lll-S
(Sigma), 50 pM ATP-y-[35S](NEN)(0.18 pCi/tube), 1pM PDBu (LC Services
Corporation, Scientific Marketing Associates, Barnet, UK) and 25 pi cytosol.
Phosphatidylserine vesicles were prepared by drying the lipid from
chloroform/methanol under a stream of N2. The subsequent film of PS was
scraped into 20 mM Tris/HCI (pH 7.5) with 0.5 mM EGTA, sonicated, then
0.16% Nonidet P-40 was added. The mixture was vortexed before use.
Assay tubes also contained either 600 pM CaCl2 (100 pM free Ca2+) or 5
mM EGTA (less than 3 nM free Ca2+) and inhibitors at various
concentrations. All assay components and drugs were dissolved in 20 mM
Tris HCI (pH 7.5) with 0.5 mM EGTA except the substrate, histone IMS, which
was dissolved in the MgCl2 solution. Reactions were started by the addition
of enzyme, incubated at 30°C for 15 min and stopped by quenching with 20
pi 0.1 M ATP in 0.1 M EDTA (pH 7.0). 50 pi of the quenched reaction
mixture was spotted onto a 4 cm2 piece of P-81 cellulose phosphate ion-
exchange chromatography paper (Whatman International Ltd) then washed
(3 x 10 ml, 2 min, room temperature) in 75 mM H3PO4, dried and counted by
liquid scintillation.
2.5 Hydroxyapatite chromatography
PKC isoforms were resolved by hydroxyapatite (HAP)
chromatography (Biogel HT, Bio-Rad Laboratories, Watford, Herts, UK),
using a procedure based on that published in (Huang et al., 1986a, Kuo et
al., 1980) and similar to that described in (Connor and Clegg, 1993).
Midbrain or anterior pituitary tissue from male Wistar rats was homogenised
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in 6 volumes of ice-cold buffer (25 mM Tris/HCI, 250 mM sucrose, 2 mM
EDTA, 10 mM EGTA, 50 mM 2-mercaptoethanol) containing 1 mM PMSF, 1
mM benzamidine, 2 (ig/ml soya bean trypsin inhibitor and 25 |ig/ml
leupeptin and centrifuged (10 min, 6000 g, 4°C). The resulting supernatant
was strained through glass wool and Triton X-100 was added (final
concentration 1% (v/v)) before further centrifugation (60 min, 105 000 g,
4°C). The PKCs in the supernatant were partially purified on DEAE
cellulose columns as described in Section 2.4 but the elution buffer
contained 300 mM NaCI. This fraction was dialysed into 5 mM potassium
phosphate buffer (pH 7.5) containing 10% (v/v) glycerol, 0.5 mM EDTA, 0.5
mM EGTA, 1 mM DTT and loaded onto a HAP column equilibrated in the
same buffer, which was also used to wash the column (4 volumes).
Proteins were eluted in a linear potassium phosphate gradient (5-300 mM;
total volume 150 ml, fraction volume 2.5 ml) and the PKC activity was
assayed. Fractions were pooled as appropriate, and dialysed against 50%
glycerol, 10 mM Tris HCI, 0.5 mM EDTA, 0.5 mM EGTA, 25 mM 2-
mercaptoethanol (pH 7.5) for storage at -20 °C.
2.6 Data Analysis
Basal activity with PS alone (at appropriate inhibitor concentrations)
was subtracted from the inhibitor curves in the absence/presence of Ca2+. A
normalised asymmetric sigmoid Hill curve was fitted to the Ca2+
independent evoked activity and subtracted from the evoked activity values
obtained in the presence of Ca2+. A normalised curve was then similarly
fitted to the resulting values for Ca2+-dependent activity. Curve fitting was
carried out using the iterative error-weighted curve fitting program, P.fit
(Biosoft, Cambridge, UK).
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2.7 Immunoblotting with antibodies to PKC isoforms
Pituitary HAP fractions were diluted 1:1 (v/v) with 50 mM Tris/HCI (pH
7.2), or, for immunostaining of PKC a, (3i, £ and 0, concentrated 5 fold and
resuspended in the same buffer using a Centricon-30 ultrafiltration device
(Amicon, Stonehouse, Gloucs, UK) then heated at 100°C for 5 min in the
presence of 2% (w/v) SDS and 5% (v/v) 2-mercaptoethanol. Four |il or, for
immunostaining of PKC 8, 1 |il aliquots were applied to 7.5% homogenous
microgels and then SDS-PAGE and electroblotting were performed using a
PhastSystem apparatus (Pharmacia Biotech, Milton Keynes, Bucks, UK).
PKC isoforms were identified with rabbit polyclonal antisera raised to
isoform-specific peptide sequences in a, 8, e and £ (2 |ig/ml)(Gibco BRL,
Paisley, Renfrew, UK) and pi (2.5 fold dilution)(Marais and Parker, 1989).
The specificity of staining with these antisera was confirmed in each case
using antibody blocked by preincubation with the relevant antigenic peptide
(1 (ig/ml). Protein kinase C 0 was detected using a mouse monoclonal
antibody (1 |ig/ml; Transduction Labs, Lexington, KY, USA). Both the
midbrain and pituitary HAP fractions were also immunoblotted with a rabbit
polyclonal consensus antibody raised to a sequence in the C4 domain
conserved between all the PKC isoforms (PKC a:[Ac 543-550-
Cys])(Calbiochem). In each case the antibody reaction was visualised with
horseradish peroxidase-labelled anti-IgG (Scottish Antibody Production
Unit, Carluke, Lanarks, UK) followed by an enhanced chemiluminescence
detection system (ECL; Amersham, Aylesbury, Bucks, UK).
2.8 Autophosphorylation
Midbrain and pituitary HAP fractions were incubated at 30°C in a
mixture containing 13.3 mM MOPS/KOH, 10.7 mM magnesium acetate, 67
pM [y-32P] ATP (approximately 106 cpm), 6.7 mM DTT, 4.2 mM 2-
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mercaptoethanol, 83 |iM EDTA, 1 mM EGTA, 1 mM CaCl2, 50 |ig/ml PS, 3.3
mM Tris/HCI, 2 (ig of BSA and 1 |ig/ml protein kinase A peptide inhibitor
(Connor and Clegg, 1993). After 30 min, reaction mixtures were heated to
100°C for 5 min in the presence of 2% (w/v) SDS and 5% (v/v) 2-
mercaptoethanol and then SDS/PAGE was performed on 15 cm
homogenous 8% gels. Phosphoproteins were located by autoradiography
after gels had been fixed, stained with Coomassie Blue and destained.
2.9 Preparation of total RNA
RNA was prepared using Nucleon total RNA kit (Version 1.1)(Scotlab,
Coatbridge, Strathclyde, UK) according to the manufacturer's instructions.
Fresh or frozen tissue was homogenised in lysis solution (2 ml/100 mg
tissue), using a polytron homogeniser. 600 |il of deproteinisation solution
was added per 1 ml of lysis solution, tubes were vortexed and incubated on
ice for 5 min. 24:1 chloroform:isoamyl alcohol (1.4 ml/ml of lysis solution)
was added and after vortexing, tubes were incubated on ice for a further 10
min. After centrifugation (10 000 g, 5 min, 4°C), the upper aqueous phase
was transferred to a fresh RNAse-free tube and the chloroform extraction
procedure was repeated, nucleon silica suspension (700 |il/15 ml tube)
being added following centrifugation. Further centrifugation (1400 g, 3 min,
4°C) was then required to compact the silica at the interface before the
aqueous phase was again transferred to a fresh tube. One volume of 100%
ethanol (-20°C) was added and after incubation for 30 min at -20°C, nucleic
acids were pelleted (12 000 g, 10 min, 4°C) and washed with 70% ethanol,
centrifuged (12 000 g, 10 min, 4°C) and dried at room temperature for 10
min. After resuspending in 180 |il RNAse free water, 20 |il DNase restriction
buffer and 2 |il DNAse was added. Tubes were incubated at 37°C for 15
min before the RNA was precipitated using 0.5 volumes ammonium acetate
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(7.5 M) and 2.5 volumes 100% ethanol (-20°C). The RNA was then stored
at -70°C until required. Immediately prior to use, RNA was pelleted (10 000
g, 10 min, 4°C), washed with -20°C 70% ethanol (500 pi), repelleted (10
000 g, 5 min, 4°C) and dried at room temperature for 10 min. It was then
resuspended in the appropriate volume of RNAse free water.
2.10 PCR techniques
2.10.1 Reverse transcriptase PCR
Fragments were amplified from total RNA by reverse transcriptase
PCR (RT-PCR), using the Perkin-Elmer Cetus GeneAmp RNA PCR kit
according to the manufacturer's instructions. In all cases, random hexamers
were used to reverse transcribe all the RNA. A master mix was prepared
containing (final concentrations): 5 mM MgCl2, 1 x PCR buffer II (Mg2+ free
buffer), dNTPs (each 1 mM), 1 U/pil RNase inhibitor, 2.5 pM random
hexamers, and sterile distilled water (dH20) to a final volume of 18 pi per
sample. This was then added to 2 pi total RNA (containing 1pg) and the mix
was overlaid with mineral oil to prevent evaporation. Tubes were incubated
at room temperature for 10 min to allow the extension of the hexameric
primers by reverse transcriptase, before being heated to 42°C for 15 min,
99°C for 5 min and then cooled 5°C for 5 min. A PCR master mix containing
(final concentrations): 2 mM MgCl2,1 x PCR II buffer, 2.5 U/100 pi AmpliTaq
DNA polymerase and sterile dH20 to a final volume of 78 pi was added to
each tube by pipetting under the oil. One pi of each primer (final
concentration 0.15 pM) was then added to give a total volume of 100 pi.
The PCR cycling was conducted according to conditions determined for
each pair of primers. In general, the melting temperature (Tm) for each
oligonucleotide primer was calculated using the equation:
Tm= 81.5 + 16.6 (log [Na+]) + 0.41 (fraction G +C) - (600/N)
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N=length of oligonucleotide
Initial PCR amplification was usually conducted annealing at a
temperature approximately 5°C below the Tm for the two primers. The
annealing temperature for subsequent reactions was altered according to
the products initially contained. To increase the stringency of the PCR, the
annealing temperature was raised by 3-10°C.
2.10.2 PCR from cDNA libraries
5-10 pi cDNA library (1010 bacteriophage/ml) was heated to 95°C for
10 min then cooled to 4°C over a period of 15 min, to denature the DNA.
DNA was amplified in a mix containing (final concentrations): denatured
cDNA library, sense and antisense primers (each 140-350 nM), 1 x PCR
buffer, 100 pM dNTPs and double dH20 to a final volume of 99.5 pi The mix
was overlaid with mineral oil (Sigma) and the PCR cycling was commenced,
according to conditions determined for each pair of primers, as described in
Section 2.10.1. When the temperature reached 94°C at the beginning of the
first cycle, 2.5 U Taq polymerase was pipetted under the mineral oil. This
'hot start' procedure, adding Taq polymerase only once the temperature
reached 94°C, was used to ensure that polymerisation could not occur
before the primers had annealed to their specific target sequence. After
amplification was complete, 5-20 pi of the PCR mix was analysed by
agarose gel electrophoresis (Section 2.18.2) to determine the products.
2.11 Purification of DNA fragments
2.11.1 Wizard purification
The Wizard DNA clean-up system (Promega) was used for the
separation of DNA fragments from small nucleotides, proteins and salts,
according to the manufacturer's instructions. Samples (volume 50-500 pi)
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were added to 1 ml of Wizard DNA clean-up resin and mixed by inverting.
The resin containing the bound DNA was pipetted in the barrel of a 3 ml
disposable syringe with a Wizard minicolumn attached. The slurry was
pushed into the minicolumn using the plunger then the column was washed
by pushing through 2 ml isopropanol (80%). The syringe was removed and
the minicolumn centrifuged (20 sec, 12 000 g) to dry the resin. After leaving
at room temperature for 5-15 min to allow the isopropanol to evaporate, the
DNA was eluted by applying 50 pi prewarmed water or TE (65-70°C),
leaving for 1 min, then centrifuging (12 000 g). The purified DNA was stored
at -20°C.
2.11.2 Gel Purification
To separate the required PCR product from other DNA fragments, the
Geneclean II kit was used according to the manufacturer's instructions.
Fragments were excised from a 1% TBE agarose gel and the gel slice
weighed to determine the volume. 4.5 volumes of sodium iodide and 0.5
volumes of TBE modifier (as provided in the kit) were added and the
agarose was melted by incubation at 45-55°C for 5 min. 5-10 pi glassmilk
(silica matrix suspension) was added, depending on the mass of DNA
present, and the solution was incubated on ice for 5 min to allow the DNA to
bind to the silica. The glassmilk/DNA complex was pelleted by
centrifugation for approximately 5 sec and the supernatant discarded before
the pellet was washed 3 times by resuspending in approximately 10
volumes of ice cold NEW wash solution (NaCI/ethanol/water, in Tris/EDTA
pH7-8.5, as provided in the kit). The tube was then respun and the
remaining supernatant removed to ensure that the eluate was not diluted
with residue wash solution. DNA was eluted by resuspending the pellet in
an equal volume of TE or water and incubation at 45-55°C for 2-3 min
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before centrifuging for 30 seconds to pellet the resin. The supernatant
containing the eluted DNA was removed and retained, and the elution
procedure repeated to maximise the recovery.
2.12 Ethanol precipitation
Before the purified DNA fragments could be ligated into a cloning
vector, ethanol precipitation was necessary to concentrate the DNA. 0.1
volumes 3 M sodium acetate were added, samples were vortexed and 2.5
volumes ethanol were added. Samples were then incubated in a dry
ice/ethanol bath for 15-20 min or overnight at -20°C. DNA was pelleted by
spinning for 10 min in an Eppendorf bench top centrifuge at room
temperature and washed to remove the salts in 500 pi 70 % ethanol. Pellets
were dried at 37°C for 10 min and resuspended in an appropriate volume of
TE or water.
2.13 Ligation of DNA fragments into plasmid vector
Ligation reactions were performed in a total volume of 10 pi,
containing 1 pi 10 x ligation buffer (0.5 M Tris/HCI pH 7.6, 100 mM MgCl2,
10 mM DTT), 1 mM ATP, 1 U T4 DNA ligase (BCL) and a 1:1-1:5 molar ratio
of vector DNA:insert DNA. Typically, approximately 50-100 ng of vector
DNA was used. Ligation reactions were incubated at 10-25°C overnight
before being transformed into E.coli as described below.
2.14 Preparation and transformation of competent E. coli
A single colony of Escherichia coli of strains DH5a or JM109 was
grown overnight in 3 ml L-broth, diluted into 40 ml L-broth and grown in an
orbital shaker at 37°C until OD540 reached 0.3. Cells were pelleted by
centrifugation (7000 rpm, 5 min, 4°C), placed on ice, and resuspended in
0.25 volumes ice cold 0.1 M MgCl2. Cells were pelleted as before,
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resuspended in 0.05 volumes MgCl2 and left on ice for 45 min. After
pelleting as before, cells were resuspended in the same volume of sterile
storage buffer (0.1 M MOPS (pH 6.5), 50 mM CaCl2 , 20% glycerol) and left
on ice for a further 20 min to acquire full competence. Competent cells were
aliquoted into 1.5 ml eppendorf tubes, snap frozen in a dry ice bath and
stored at -70°C.
To transform cells, ligation products were diluted to a volume of 60 pi,
added to 100-200 pi competent cells and incubated on ice for 30 min. Cells
were then heated shocked at 42°C for 2 min in a water bath and incubated
on ice for 10 min. Cells were added to 2 ml L-broth and incubated at 37°C
for 2 hours. Cells were pelleted, resuspended in 100 pi L-broth and spread
on AIX plates, prepared as described in Section 2.3. Plates were incubated
overnight at 37°C. These plates contain X-gal, which may be degraded by (3
galactosidase. Colonies which contain the DNA fragment are unable to
produce (3 galactosidase so remain white, while colonies containing
plasmid vector but no DNA fragment turn blue, due to degradation of the X-
gal. White colonies were picked for mini-prep analysis as described below.
2.15 Small scale preparation of plasmid DNA
Plasmid DNA was prepared by the alkaline lysis method. Single,
white colonies of E coli were picked from AIX plates and grown overnight in
3 ml L-broth containing ampicillin (50 pg/ml) at 37°C in a rotator. 1.5 ml of
this culture was used to prepare plasmid DNA. Cells were pelleted by
centrifuging for 1 min and resuspended in 100 pi GTE solution (50 mM
glucose, 25 mM Tris, 10 mM EDTA). After 5 min at room temperature, 200 pi
of alkaline SDS solution (1% SDS, 0.2 N sodium hydroxide) was added.
Tubes were mixed, incubated on ice for 5 min, and 150 pi ice-cold 3 M
potassium acetate containing 11.5% (v/v) glacial acetic acid was added,
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followed by a further incubation on ice. Tubes were then spun in a bench
top centrifuge for 7 min and the supernatant was transferred to a fresh tube.
A phenol/chloroform extraction was then performed using 0.5 volumes Tris-
saturated phenol (prepared as described in Section 2.2) and 0.5 volumes
chloroform:isoamyl alcohol (24:1, v/v). Plasmid DNA was precipitated from
the upper aqueous with 0.7 volumes of isopropanol and washed in 70%
ethanol. After air drying (10 min, 37°C), the pellet was resuspended in
either 40 pi TE containing RNase (20 pg/ml) for subsequent restriction
analysis, or 20 pi sterile dh^O, for sequencing. Plasmid DNA was stored at
-20°C.
2.16 Restriction enzyme digestion of DNA
DNA was digested using 1 unit of restriction enzyme per 1 pg of DNA.
Reaction buffer, volume as appropriate to give the dilution specified by the
manufacturer, and dh^O were added to a final volume large enough to give
a final enzyme dilution of 1:10. This reduced the glycerol, in which the
enzyme is stored, to a level at which it would not inhibit digestion. Reactions
were incubated at 37°C, unless otherwise specified by the enzyme supplier,
for 2-4 hours before the resulting DNA fragments were separated by
agarose gel electrophoresis (Section 2.18.2).
2.17 DNA sequencing
Plasmid DNA was sequenced by the dideoxy method, using the
Sequenase version 2.0 kit (USB) according to the manufacturer's
instructions. DNA samples (2-5 ng) were made up to a volume of 60 pi with
sterile dh^O and denatured by the following method. 15 pi 2 M sodium
hydroxide was added and tubes were incubated for 10 min at 37°C. After
addition of 15 pi sodium acetate (3 M) and vortexing, DNA was precipitated
in 300 pi absolute ethanol, either in a dry ice/ethanol bath for 15 min or
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overnight at -20°C. The precipitate was then collected by centrifugation for
10 min and washed in 70% ethanol before being raised in 7 pi dP^O. The
appropriate primer was annealed to the denatured DNA in a final volume of
10 pi containing 2 pi sequenase reaction buffer (200 mM Tris HCI pH 7.5,
100 mM MgCl2, 250 mM NaCI) and 10 ng primer by heating to 85°C
followed by cooling to room temperature. Plasmid DNA was sequenced
using the SP6 promoter, T7 or M13 forward primers provided with the
Sequenase version 2.0 kit. The products of asymmetric PCR were
sequenced using the primer which was limiting in the PCR reaction.
Annealed DNA samples were then extended and labelled in an incubation
mix containing 1 pi 0.1 M DTT, 2 pi labelling mix (diluted 1:5 in dH20 from a
solution containing dCTP, dGTP and dTTP (7.5 pM each)), 5 pCi 35S
dATPaS (Amersham, 1000 Ci/mMol) and 2 pi Sequenase Version 2.0
(diluted 1:8 in a buffer containing 10 mM Tris/HCI (pH 7.5), 5 mM DTT, 0.5
mg/ml BSA) at room temperature for 2-5 min. 3.5 pi aliquots were then
added to 4 tubes each containing 2.5 pi of termination mix for one
nucleotide (containing 8 pM ddNTP) and incubating at 37°C for 5 min before
4 pi stop solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue,
0.05% xylene cyanol FF) was added. Products were then separated by
polyacrylamide/urea gel electrophoresis.
2.18 Electrophoretic techniques
2.18.1 Denaturing polyacrylamide/urea gel electrophoresis
6% denaturing polyacrylamide gels were prepared by dissolving 42 g
urea (Aristar, BDH), 20 ml of 30% (33:1) acrylamide:bisacrylamide (BDH,
premixed) and 10 ml TBE pH 8.8 (10x) in a final volume of 100 ml. The
solution was filtered through Whatman membrane filters (0.45 pM pore size)
under vacuum and degassed. 70 pi TEMED (N,N,N',N',-teramethylethylene
diamine) and 70 jil ammonium persulphate (APS)(25%) was added to 70 ml
gel mix immediately before the solution was poured between 300 mm x 400
mm x 0.4 mm glass plates previously sealed with 5% agarose. 20-tooth
combs (0.4 mm) were inserted and the gels left to polymerise. Gels were
then attached to vertical gel electrophoresis apparatus (Gibco BRL, Model
S2) containing 0.5 x TBE buffer and pre-electrophoresed at 1200 V for 30
min prior to loading. Samples were boiled for 2 min, 4 pi were loaded into
the wells and the gel electrophoresed at 1500 V for 3-4 hours. Gels were
fixed for 30 min (5% methanol, 15% acetic acid) before being transferred to
Whatman No. 1 paper, covered with Saran wrap and dried using a heated
vacuum gel drier (Biorad Model 583). The dried gel was then exposed to
autoradiographic film (Fuji RX X-ray film), typically for 16 hours at room
temperature. Films were developed for 2 min in Kodak LX-24 developer (4
fold dilution), fixed for 2 min in Kodak FX-40 fixer (4 fold dilution), rinsed in
water and dried.
2.18.2 Horizontal agarose gel electrophoresis
1% (w/v) agarose (Agarose MP, Boehringer) gels containing 0.5
mg/ml ethidium bromide were made up in 1 x TBE. 100 ml horizontal gel
slabs (140 mm x 110 mm x 30 mm) or 25 ml mini agarose gels (83 mm x 57
mm x 30 mm) were placed in gel electrophoresis apparatus (Gibco BRL,
Model HS or Gibco BRL, Model Horizon 58 respectively) containing
sufficient 1 x TBE buffer to cover the gel. Samples were loaded in 0.2
volumes of loading buffer and gels were usually electrophoresed at 100 V
for as long as required to see sufficient band separation. DNA fragments
were visualised using a long wave UV transilluminator. DNA was
photographed using Polaroid film type 667 in a Polaroid Cu-5 camera.
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Figure 2.1 Flow diagram of the basic procedure used to
measure partially purified PKC activity.
Unless otherwise stated, PKC was partially purified from tissues by this
method. In cases where peptide substrates replaced histone IMS, reactions
were stopped by the addition of TCA and the precipitated pelleted by
centrifugation (16 000 g, 5 min, 4°C) before spotting a sample of the
supernatant onto P81 paper.
Figure 2.1
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Figure 2.2 Flow diagram of the procedure used for
purification of PKC by HAP chromatography.
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Characterisation of native PKC
activity from different tissue sources
3.1 Introduction
There are currently known to be eleven different isoforms of PKC
(Nishizuka, 1992), which have been found to exhibit unique tissue
distributions (Wetsel et al., 1992), as well as varying in their biochemical
properties. The cPKCs a, (3 and y are classified as being dependent on
Ca2+ for activation (Nishizuka, 1992), although there is evidence to suggest
that these isoforms may be stimulated by some PKC activators, for example
TPA, in the absence of Ca2+(Ryves et al., 1991). Furthermore the presence
of unsaturated fatty acids has been shown to lower the Ca2+ dependence of
the cPKCs (Shinomura et al., 1991), and it has been reported that
autophosphorylation may produce Ca2+-independent forms of PKC (3
(Pelech et al., 1991).
Isoforms have also been found to vary in their phospholipid
dependence (Bazzi and Nelsestuen, 1987) and activation by diglycerides
and phorbol esters (Kazanietz et al., 1993; Ryves et al., 1991). Although all
isoforms are activated by PS, individual isoforms are potently stimulated by
other phospholipids. PKC 5, for example, was strongly activated by
phosphatidyl inositol (PI) in the presence of phorbol esters (Mizuno et al.,
1991), while there is evidence that PKC e shows a preference for cardiolipin
(Konno et al., 1989). It has been suggested that PKC r| may be strongly
activated by cholesterol sulphate in the absence of phorbol esters (Ikuta et
al., 1994), while PKC a and pi may be activated by PIP2 in place of phoTbol
esters, and PI can act as a cofactor for these isoforms in place of PS (Kochs
et al., 1993a). Furthermore cis-unsaturated fatty acids, such as arachidonic
acid, act synergistically with diglycerides and PS in the activation of the
cPKCs while arachidonic acid has an inhibitory effect on PKC 5. (Ogita,
1992). Most evidence suggests that the aPKCs 1 and p are not activated
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by diglycerides and phorbol esters (McGlynn et al., 1992; Nakanishi and
Exton, 1992; Pfizenmaier et al., 1993; Selbie et al., 1993) and expression of
PKC £ in baculovirus showed that this isoform is unable to bind PDBu and
the highly potent PKC ligand bryostatin even at high concentrations
(Kazanietz et al., 1993). These isoforms are instead constitutively active in
the presence of phospholipids (Liyanage et al., 1992; McGlynn et al., 1992).
There are also reports that the PKC isoforms vary extensively in their
specificity for different substrates, both synthetic and endogenous, as
detected in in vitro kinase activity assays. The nPKCs and cPKCs are
thought to be more restricted than the cPKCs in the substrates that they can
efficiently phosphorylate, and there are reports that these isoforms show
little activity on histone (Schaap and Parker, 1990; Schaap et al., 1989), a
commonly used substrate for in vitro activity assays.
In view of the variations in the properties of the PKC isoforms, and the
differences detected in different assay systems, it was decided to compare
the properties of PKC partially-purified from a variety of tissue sources with
those of the H7-resistant PKC from anterior pituitary, investigated under the
same conditions. This form of PKC has been detected previously in studies
of stimulus-secretion coupling in the anterior pituitary (Johnson et al., 1992b,
Johnson et al., 1993; Thomson et al., 1993b) as well as in vitro in cytosol
partially purified from this tissue. A mixed micelle assay system was
selected as this enables the Ca2+-dependent and -independent activity;to
be analysed separately and PKC activation is obligatorily dependent on
phorbol/diglyceride activators under these conditions (Hannun and Bell,
1986). A variety of tissue and cell lines, chosen for their isoform content,
were used as sources of PKC. Midbrain was investigated because it is
reported to contain all of the well-characterised PKC isoforms (Scott-Young,
1989), while the other tissues were studied because of their reported
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enrichment in particular isoforms. The COS 7 fibroblast cell line was used
as these cells are reported to contain only PKC a and £ (Kosaka et al., 1988;
Ways et al., 1992).
Protein kinase C activity was evoked by either of the diterpenes,
PDBu and mezerein, or by the synthetic diglyceride, 1,2-dioctanoyl-sn-
glycerol (DOG), as these activators have been shown to differ in their ability
to activate various PKC-mediated processed in vivo (Johnson et al., 1992;
MacEwan and Mitchell, 1991; MacEwan et al., 1991). For example, PDBu
elicits inverse effects on depolarisation-induced Ca2+ influx through L-type
Ca2+ channels, causing facilitation in anterior pituitary pieces while having
an inhibitory effect in the GH3 clonal pituitary cell line (MacEwan and
Mitchell, 1991). Dioctanoyl-s/7-glycerol, however, was only able to elicit the
facilitatory response, whereas mezerein caused a facilitatory response in
both tissues. As, in each case, the facilitatory response was relatively
resistant to H7, it was suggested that mezerein may be a selective activator
of the H7-resistant form of PKC (Mitchell et al., 1992). There is also
evidence to support this from studies of LH release from anterior pituitary
tissue. Both PDBu and mezerein induce LH release that is inhibited by H7
in a biphasic manner, but the H7-resistant component represents a larger
proportion of the release induced by mezerein than by PDBu (Thomson et
al., 1993b).
Thus the biochemical properties of the H7-resistant kinase were
characterised and compared with those of PKCs from a variety of tissues of
known isoform content to determine whether the H7-resistant kinase could
be identified as any of the eleven PKC isoforms already characterised.
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3.2 Specific Methodology
Tissue from male Wistar rats was homogenised, centrifuged and
partially purified by DEAE cellulose chromatography, as described in
Section 2.4. Tissue from one organ was used, except in the case of
anterior pituitary tissue, when 10 rat or 3 sheep pituitaries were taken.
Alternatively, COS 7 cells (cultured at 37°C in DMEM with 10% normal
calf serum under 5% CO2) were washed in Ca2+/Mg2+-free Hank's salt
solution and then harvested from tissue culture flasks by scraping into
ice-cold buffer before homogenization. Protein kinase C activity was
measured as described in Section 2.4. Unless otherwise stated the
substrate for thiophosphorylation was histone IMS. The assay procedure
was identical when myelin basic protein (MBP) was used as the
substrate. When peptide substrates were used, the method in Section
2.4 was modified slightly. The reaction was terminated by addition of 20
pi trichloroacetic acid (TCA)(6.8% w/v final). After incubation on ice for 15
min, TCA-precipitable material was removed by centrifugation and the
supernatant was spotted onto 2x2 cm pieces of P-81 cellulose phosphate
ion-exchange chromatography paper (Whatman International Ltd,
Maidstone, Kent, UK), which were washed extensively in 75 mM H3PO4,
dried and counted by liquid scintillation. The sequences of the peptide
substrates used are as follows:
PKC a pseudosubstrate peptide (RFARKGSLRQKNV)
PKC £ pseudosubstrate peptide (ERMRPRKRQGSVRRRV)
PKC £ pseudosubstrate peptide (EDKSIYRRGSRRWRKL)
glycogen synthase-(1-12) peptide (PLSRTLSVAAKK)
AcMBP(4-i4) peptide (AcQKRPSQRSKYL)
histone H1 phosphorylation site peptide (RRKASGP)
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3.3 Results
Activation of PKC by phorbol 12, 13-dibutyrate
Protein kinase C activity in anterior pituitary cytosol, measured as
histone IMS thiophosphorylation, was evoked by PDBu in a concentration-
dependent manner (10 nM-3 |iM), in both the absence (<3 nM) and
presence (100 pM free) of Ca2+, as shown in Figure 3.1. This reaction was
specific as no activation was detected when 4 p-PDBu was replaced by the
essentially inactive stereoisomer, 4 a-PDBu (Figure 3.1). The EC50 values
(concentration at which the activator achieved 50% of the maximal
response) were 637 ±311 nM and 380 ± 117 nM in the absence and
presence of Ca2+ respectively. This was compared with the EC50 values for
a number of other tissues as shown in Table 3.1. While the potency of
PDBu varied between tissues, particularly in the absence of Ca2+(ECso
values in the range 620-2270 nM), in all cases PDBu was more potent in the
presence of Ca2+ (EC50 values 77-380 nM). There were also variations in
the proportion of the maximum activity occuring in the absence of Ca2+, with
only 48% in COS 7 cells, in which PKC a is the only phorbol ester
responsive isoform (Kosaka et al., 1988), while 80% of the activity in spleen,
which contains predominantly PKC a, p and 8 (Johnson et al., 1994), was
Ca2+-independent (Table 3.1). For subsequent inhibition studies, PKC
activity was elicited by 1|iM PDBu as at this concentration, in most tissues,
the response was almost maximal for both Ca2+-dependent and Ca2+-
independent activity, with typical values in midbrain of 5.6 ± 0.4 and 12.0 ±
0.3 x 103 dpm per mg tissue equivalent. The corresponding values for
anterior pituitary were 3.0 ± 1.3 and 3.6 ± 1.9 x 103 dpm per mg tissue
equivalent.
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Effects of different PKC inhibitors
The effects of different PKC inhibitors on PDBu-evoked PKC activity
from rat midbrain, anterior pituitary and COS 7 cells was studied. The Ca2+-
dependent and Ca2+-independent activity was compared in both tissues,
while in COS 7 cells the PKC activity evoked by 1 pM PDBu was entirely
Ca2+-dependent. Table 3.2 shows IC50 values (the concentration required
to inhibit 50% of the effect) for inhibition by H7, staurosporine and Ro 31-
8220. In midbrain, staurosporine, Ro 31-8220 and H7 all inhibited both
Ca2+-dependent and -independent activity with similar IC50 values (0.1-0.1.5
pM, 0.18-0.19 pM and 20-30 pM respectively, as shown in Table 3.2). The
potencies of all three inhibitors on activity from COS 7 cells were similar to
those obtained in midbrain. This is in contrast to anterior pituitary where,
although staurosporine and Ro31-8220 inhibited Ca2+-dependent and
-independent activity with similar potencies, H7 was considerably less potent
on Ca2+-independent activity (IC50 values of 148 ± 38 and 25 ± 4 pM for
Ca2+-independent and -dependent respectively).
Regional differences in H7 inhibition of PKC
In order to determine the tissue distribution of the H7-resistant PKC
activity, the effect of H7 on PDBu-evoked PKC activity from a variety of
tissues and cell lines was studied and the IC50 values are shown in Table
3.3. In the majority of the regions investigated, there was no difference in the
potency of H7 on the Ca2+-dependent and -independent activity evoked by
PDBu, the IC50 values ranging from 10 to 45 pM. However, in cytosol from
anterior pituitary and perhaps to a lesser extent lung, the Ca2+-independent
but not -dependent activity was relatively insensitive to H7 (IC50 values for
Ca2+-independent activity of 145 ± 38 pM and 87 ± 37 pM respectively, while
those for Ca2+-dependent activity were 25 ± 4 pM and 39 ± 6 pM
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respectively). Unless otherwise stated, the tissues studied were obtained
from male Wistar rats. However sheep anterior pituitaries were also
investigated, to determine whether the H7 resistant PKC activity was present
in other mammalian species and to evaluate their potential as a source of
this form of PKC for further studies. As shown in Table 3.3, PDBu-evoked
Ca2+-independent activity in sheep anterior pituitaries was indeed relatively
resistant to H7 (IC50 value 128 ± 13 pM) although no Ca2+-dependent
activity was detected in this tissue.
In view of the possibility that mezerein may represent a selective
activator of the H7 resistant PKC (Mitchell et al., 1992; Thomson et al.,
1993b), and therefore allow detection of H7-resistant activity in tissues
containing only small quantities of this kinase, the inhibition by H7 of
mezerein-evoked activity from a number of tissues was investigated.
However, as shown in Table 3.4, Ca2+-independent activity in midbrain,
thalamus and spleen was sensitive to H7 (IC50 values in the range 25-40
pM); the potency of H7 on mezerein-evoked activity being similar to that for
PDBu-evoked activity in these tissues. H7-resistant activity in pituitary and
lung was activated by mezerein (IC50 values 148 ±21 and 75 + 10
respectively), the potency of H7 being similar for both mezerein and PDBu-
evoked activity.
Protein kinase C activity evoked by mezerein and PDBu did, however,
vary in Ca2+-dependency. In anterior pituitary, maximal activity was evoked
by mezerein (1 pM) in the absence of Ca2+ and thus no separate
determination of the potency of H7 on Ca2+-dependent mezerein-evoked
activity could be made. The maximal amount of PKC activity was similar with
both PDBu and mezerein, the only difference being the Ca2+dependence.
This is consistent with previous reports that with some activators, cPKCs do
not display rigorous Ca2+dependence (Ryves et al., 1991), and we have
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evidence to suggest that mezerein is more potent than PDBu at activating at
least PKC a in the absence of Ca2+(Johnson et al., 1994).
As there is evidence to suggest that histone IIIS is a poor substrate for
the Ca2+-independent PKC isoforms (Schaap and Parker, 1990; Schaap et
al., 1989), the effect of H7 on PDBu-evoked activity was investigated using
an alternative protein substrate, myelin basic protein (MBP). This protein is a
better substrate for most of the Ca2+-independent PKCs and is a particularly
good substrate for PKC 6 (Kazanietz et al., 1993). The resulting IC50 values
are shown in Table 3.5. In most tissues the potency of H7 on PDBu-evoked
MBP thiophosphorylation was similar to that obtained for histone IIIS
thiophosphorylation, although the total amount of activity detected was much
higher. For example, in midbrain, detectable PDBu-evoked PKC activity was
approximately 3 fold greater for MBP than histone IIIS, with typical values of
53.5 and 17.6 x 103 dpm per mg tissue equivalent respectively. However in
anterior pituitary cytosol, Ca2+-independent activity was sensitive to H7 (IC50
value 34 ± 7 pM), suggesting that this substrate is more selective for the
other Ca2+-independent PKC isoforms in pituitary than for the H7-resistant
kinase. H7-resistant MBP phosphorylation was detectable, however, in
cytosol from skin taken from the ears (IC50 value 150 ± 30 pM), although all
the PDBu-evoked activity in this tissue was Ca2+-independent. The IC50
value for this tissue could not be determined using histone IIIS as the
substrate as there was no activity detectable.
Effect of substrate on PKC activity from rat midbrain
In view of the differences previously seen in the properties of PKC
activity from some tissues with different substrates, and reports that histone is
a poor substrate for some PKC isoforms (Schaap and Parker, 1990; Schaap
et al., 1989), the H7 inhibition of midbrain PKC activity was compared using
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a variety of protein and synthetic peptide substrates. Figure 3.2 shows the
relative kinase activity detected and the Ca2+-dependence with each
substrate. In some case accurate Km values for some of these substrates
cannot be consistently obtained (Kazanietz et al., 1993) so a fixed high
concentration of substrate was used, as has been done in previous studies
(Kazanietz et al., 1993; Koide et al., 1992). The total amount of midbrain
PKC activity detected varied greatly with the phosphate acceptor, the highest
activity occurring with the glycogen synthase (GS) peptide, which was six
times greater than the histone IMS thiophosphorylation activity. The peptides
based on PKC phosphorylation sites from histone and MBP (Yasuda et al.,
1990) were the poorest substrates tested, with the histone peptide showing
little detectable phosphorylation. This is consistent with a recent report that
all the cPKCs and PKC 5, e, r| and £, expressed in baculovirus show no
detectable activity with this substrate (Kazanietz et al., 1993). The relative
proportion of the midbrain PKC activity that was dependent on Ca2+ differed
considerably when using different substrates. In general the peptide
substrates showed the least Ca2+ dependence, with the majority of the
activity occuring in the absence of Ca2+. However with the AcMBP(4--|4)
peptide, the converse was true with only one fifth of the total activity occurring
in the absence of Ca2+, although with the MBP protein itself, the majority of
the activity was Ca2+-dependent. The IC50 values obtained for Ca2+-
dependent and -independent PKC activity, in a midbrain cytosolic
preparation, with each substrate are given in Table 3.6. The potency of H7
on Ca2+-independent activity showed little variation, phosphorylation of all
substrates being inhibited with IC50 values in the range 12-45 (iM. However
there was greater variation between different substrates for Ca2+-dependent
activity, H7 being highly potent on GS peptide phosphorylation (IC50 4 ± 1
^M).
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A Ca2+-dependent PKC is highly sensitive to H7
Figure 3.3 shows the inhibition of PKC activity from rat midbrain
evoked by PDBu ( a) and mezerein ( b). While Ca2+-dependent and
-independent PDBu-evoked activity were inhibited with similar potencies
(IC50 values 22 ± 1 and 28 ± 5 p.M respectively), when activity was evoked
by mezerein, the Ca2+-dependent activity was potently inhibited by H7 (IC50
value 6 ± 1pM) compared with the Ca2+-independent activity (IC50 value 28
± 4 pM)(Figure 3.3b). However the Ca2+-dependent activity represented a
smaller proportion of the total activity evoked by mezerein (19%) than with
PDBu (40%), even though the total amount of activity detectable was similar.
All activity evoked by both of these activators was sensitive to inhibition by
the more PKC selective inhibitor Ro 31-8220 (IC50 values 0.12-0.21 jiM).
Potent inhibition by H7 of Ca2+-dependent PKC activity was not only
detected in rat midbrain, as shown in Table 3.4, as Ca2+-dependent activity
evoked by mezerein in cytosol from thalamus, spleen and lung was also
highly sensitive to H7. As this potent inhibition was seen in all the tissues
analysed using mezerein, it is possible that it could be a result of a direct
interaction between mezerein and H7. However this seems unlikely as there
was little difference in the potency of H7 on mezerein and PDBu-evoked
Ca2+-independent activity (Tables 3.3 and 3.4). Furthermore activation of
this apparently highly H7-sensitive PKC was not specific to mezerein, as it
could also be detected in midbrain cytosol when activity was induced by
PDBu, using GS peptide as the substrate for the reaction (IC50 values for
Ca2+-dependent and Ca2+-independent activity 4 ± 0.5 and 13 ± 2 pM
respectively)(Figure 3.4, Table 3.6). There was also some evidence of highly
H7-sensitive activity with MBP as the substrate (IC50 value in thalamus 6 + 5
pM, Table 3.5), although this represented only a small proportion of the total
activity in this tissue (12%) and highly H7-sensitive activity was not detected
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in other tissues with this substrate. While both thalamus and midbrain
contain all of the cPKCs, spleen and lung contain only PKC a and (3, as PKC
y expression is restricted to the CNS. Thus this suggests that either PKC a or
(3 may be responsible for this highly H7-sensitive PKC activity. To further
investigate this possibility, both these isoforms were purified from rat brain by
hydroxyapatite (HAP) chromatography. The PDBu-induced phosphorylation
of GS peptide was measured, as there is more detectable activity with this
substrate than with histone IIIS. H7 inhibited the Ca2+-dependent activity in
the PKC a fraction with an IC50 value of 31 ±9 pM while the PKC (3 fraction
was potently inhibited (IC50 value of 3 ± 1 pM)(Figure 3.5).
Characterisation of an H7-resistant form of PKC in anterior
pituitary
The potency of H7 on PKC activity in anterior pituitary cytosol evoked
by either PDBu (1 pM), mezerein (1 pM) or DOG (1 mM) was compared,
using histone IIIS as the substrate, as these activators have shown
differences in their effects on Ca2+ channels in pituitary cells (Mitchell et al.,
1992). At these concentrations both Ca2+-dependent and -independent
PKC activity was almost maximal (M Johnson and R Mitchell; unpublished
data). For all three activators, the Ca2+-independent activity was relatively
insensitive to H7 (IC50 values 145 ± 38, 148 ± 21 and 118 ± 42 pM
respectively)(Figure 3.6). The Ca2+-dependent activity induced by PDBu
and DOG in anterior pituitary cytosol was H7 sensitive (IC50 values 25 ± 4,
21 ± 10 pM) and represented 43% and 53% respectively of the total PKC
activity detected with each activator. As previously mentioned, 1 pM
mezerein evoked maximal activity in the absence of Ca2+.
As histone IIIS is reported to be a poor substrate for the Ca2+-
independent PKC isoforms (Schaap and Parker, 1990; Schaap et al., 1989),
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and there is relatively little activity in anterior pituitary compared to other
tissues, the PDBu-evoked activity in anterior pituitary cytosol was compared
using a number of protein and synthetic peptide substrates. As shown in
Table 3.7, when histone was replaced with either MBP or the a, e or £
pseudosubstrate peptides, there was little difference between the potency of
H7 on the Ca2+-independent and -dependent activity, with IC50 values in the
range 20-40 pM. Thus H7-resistant activity was not detectable in anterior
pituitary cytosol with these substrates. However, when GS peptide was used
as the substrate, Ca2+-independent PDBu-evoked activity was inhibited in a
biphasic manner with the majority of the activity (55%) being relatively
insensitive to H7 (IC50 value 84 ± 18 pM), the other 45% being potently
inhibited by H7 (IC50 value 4 ±1). Therefore, as the activity detected using
this substrate was higher than with histone IMS, this substrate was used for
subsequent purification studies.
3.4 Discussion
In this chapter, PKC activity partially purified from several tissue and
cell line sources has been compared. The potency of PDBu on PKC from
pituitary, midbrain and spleen, as well as the COS 7 monkey fibroblast cell
line, differed considerably (Table 3.1), although in all cases PDBu was more
potent in the presence of Ca2+. This is consistent with previous evidence
that PDBu binds with higher affinity to the Ca2+-dependent PKCs than to the
Ca2+-independent isoforms (Kazanietz et al., 1993). Phorbol dibutyrate was
least potent on PKC from COS 7 cells in the absence of Ca2+, although in
the presence of Ca2+, the EC50 value was similar to those obtained for PKC
from the other tissues. As these cells contain only PKC a and £ (Kosaka et
al., 1988; Ways et al., 1992) and PKC £ is reported to be insensitive to
phorbol esters (McGlynn et al., 1992; Nakanishi and Exton, 1992), this is
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likely to reflect activation of PKC a in the presence and absence of Ca2+.
This difference in potency is in contrast to a previous report, which found that
this isoform, produced in a baculovirus expression system, bound PDBu with
similar affinity whether Ca2+ was present or not (Kazanietz et al., 1993).
While the binding affinity may not be the only factor influencing the potency
of activation by phorbol esters, it is also possible that recombinant PKC
isoform may lack post-translational modifications, such as phosphorylation,
that occur in mammalian cells (Borner et al., 1989; Pears et al., 1992).
Indeed PKC isoforms produced in baculovirus expression in some cases
have been found to display severely diminished activity (Rankl et al., 1994).
There were also differences between tissues in the proportion of the total
activity that was activated in the absence of Ca2+, which is likely to reflect
differences in the nPKC content of these tissues, as well as the extent to
which the cPKCs present may be activated independently of Ca2+. In COS 7
cells, which contain no nPKC isoforms, approximately 50% of the total
activity was activated in the absence of Ca2+. This is consistent with
previous evidence that PKC a may be activated by phorbol esters in the
absence of Ca2+ (Ryves et al., 1991).
Inhibition studies compared the effects of three catalytic domain
inhibitors, staurosporine, H7 and Ro31-8220, and have shown differences in
their inhibition properties. These compounds have all been reported to be
ATP-competitive inhibitors (Davis et al., 1989; Hidaka et al., 1984; Tamaoki
et al., 1986) but there is evidence to suggest that, although they all bind
close to the ATP site, the precise sites of action appear to be different. H7
has been shown to compete kinetically with ATP (Hidaka et al., 1984) but
only partially protects the ATP site against denaturation by covalent chemical
reagents (Ohta et al., 1988), and this inhibitor displaces the binding of Ro 31-
8220-sensitive [3H]N,N-dimethyl staurosporine only at high concentrations
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(Thomson et al., 1991). Furthermore it has been suggested that the potency
with which staurosporine is reported to act in cells is too high for an purely
ATP-competitive mechanism (Ruegg and Burgess, 1989).
In this study, staurosporine was equipotent on the Ca2+-dependent
and -independent activity from midbrain, pituitary and COS 7 cells. This
compound is a potent PKC inhibitor but lacks selectivity, also inhibiting other
serine/threonine kinases as well as some tyrosine kinases (Riiegg and
Burgess, 1989). The more selective PKC inhibitor, Ro 31-8220 (Davis et al.,
1989), has been reported to show a modest difference in potency between
PKC isoforms (Nixon, 1992) and in this study there were small differences in
potency of this inhibitor on PKC activity from the sources tested. The only
marked differences in potency, however, occurred with H7; the Ca2+-
independent activity from anterior pituitary being particularly insensitive to
this inhibitor (Table 3.2). This is consistent with previous reports from this
laboratory that a number of pituitary cell functions are mediated by an H7-
resistant form of PKC (Johnson et al., 1992b, MacEwan et al., 1992;
Thomson et al., 1993b), and from other laboratories describing phorbol
ester-evoked responses that are inhibited by staurosporine but not H7
(Nakadate et al., 1989; Watson et al., 1988). When the IC50 values for H7
were determined for a number of different tissues, there was little variation in
potency on the Ca2+-dependent activity from all the tissues tested including
COS 7 cells where PKC a is the only phorbol ester-responsive isoform
present)(Kosaka et al., 1988), spleen (containing some a but predominantly
(3 of the cPKCs)(Shearman et al., 1987) and cerebellum (particularly rich in
cPKC y)(Shearman et al., 1987). This is consistent with previous evidence
that the cPKCs are all sensitive to H7 (Pelosin et al., 1990). The IC50 values
for Ca2+-independent activity, however, showed wide differences, with
pituitary and perhaps lung (but not the other sources tested) containing H7-
67
resistant activity (Table 3.3). Pituitary cells have been shown by
immunoblotting to contain PKC a, (3, 5, 0, e and £ but not the yorri isoforms
((MacEwan, 1993) and D J MacEwan; unpublished data) while lung has
been reported to contain the nPKCs 5 and r\ but not e, as well as PKC £
(Bacher et al., 1991; Wetsel et al., 1992). However, Ca2+-independent
activity from thalamus and spleen, both containing large amounts of PKC 5
(Leibersperger et al., 1990; Scott-Young, 1989) showed no evidence of H7-
resistant activity (Table 3.3), and this isoform, purified from 3Y1 cells has
been reported to be sensitive to this inhibitor (Uchida et al., 1991). PKC e,
though present in pituitary, is absent from lung (Wetsel et al., 1992) and has
previously been shown to be H7-sensitive (Schaap and Parker, 1990).
Furthermore, there is evidence that PKC e is not able to efficiently
phosphorylate histone (Schaap and Parker, 1990; Schaap et al., 1989). The
other isoform common to both tissues, PKC C, is reported not to be activated
by phorbol esters (McGlynn et al., 1992; Nakanishi and Exton, 1992) and is
also present in COS 7 cells (Ways et al., 1992), which showed no PDBu-
evoked Ca2+-independent activity. Thus the tissue distribution of this H7-
resistant PDBu-evoked PKC activity clearly does not correspond to any of
these nPKC or aPKC isoforms.
The replacement of PDBu with mezerein as the agonist to evoke PKC
activity showed no evidence for any selectivity of this activator for the H7-
resistant kinase (Table 3.4). It had been suggested that mezerein may be a
good activator of the H7-resistant PKC in anterior pituitary as this activator
had facilitatory effects on 45Ca2+ influx through L-type Ca2+ channels in both
anterior pituitary and GH3 cells, a response that was resistant to H7 (Mitchell
et al., 1992). However the results shown in Table 3.4 suggest that it may
instead be a relatively poor activator of the PKC responsible for the inhibition
of influx through these channels that is predominant when PDBu is the
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activator. Thus, in a partially-purified cytosolic preparation containing
essentially all the isoforms of PKC present in each tissue, it may show no
clear selectivity for the H7-resistant PKC.
As histone is reported to be a poor substrate for the Ca2+-independent
PKC isoforms (Schaap and Parker, 1990; Schaap et al., 1989), MBP
thiophosphorylation was also compared in a number of tissues. While there
was little difference in the IC50 values for H7 inhibition of PKC activity for
most tissues with either of these substrates, there was a clear difference in
anterior pituitary (Table 3.5). In this tissue, the Ca2+-independent activity
was H7-resistant with histone IMS but not MBP as the substrate. This does
not necessarily mean that the H7-resistant kinase is unabie to phosphorylate
MBP, however, as if the activity of this form of PKC was similar with the two
substrates, it is possible that it is masked by the activity of the other Ca2+-
independent isoforms present in anterior pituitary cytosol, which prefer MBP
to histone IMS as the substrate. The anterior pituitary contains the nPKCs 5
and e, both of which are reported to show greater activity towards this
substrate that towards histone, with MBP being a particularly good substrate
for PKC 5 (Kazanietz et al., 1993).
In view of the differences evident when histone was replaced with
MBP, and reports that cofactor-dependence varies with substrate (Saido et
al., 1992), the properties of PKC from rat midbrain were compared with a
variety of substrates. Differences were seen in both potency of H7 and Ca2+
dependence of the activity with each substrate (Table 3.6, Figure 3.2).
Phosphorylation of the AcMBP(4_i4) peptide, for example, was almost totally
Ca2+-dependent. It is possible that Ca2+ may interact directly with this
peptide, to present it in a better conformation for phosphorylation, as it has
been previously reported that Ca2+ enhances the activity of both cPKCs and
nPKCs on this substrate (Saido et al., 1992). It is also possible that different
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substrates may shift the position of the PDBu activation curve so the ability of
1 pM PDBu to activate different PKC isoforms may vary, affecting the Ca2+
dependence of evoked activity. There is evidence to suggest that some
nPKCs may be inhibited by Ca2+ (Schaap and Parker, 1990) and that this
phenomenon is substrate dependent (Saido et al., 1992). It is clear therefore
that the proportions of Ca2+-dependent and -independent activity in midbrain
cytosol with each substrate is a result of a variety of different effects, each
isoform present making a variable contribution to activity in the presence and
absence of Ca2+. The rate of phosphorylation of different substrates by
individual isoforms varies considerably (Olivier and Parker, 1991), so the
range of potencies for H7 inhibition are likely to reflect the differing
contribution of each isoform to the total PKC activity, both Ca2+-dependent
and Ca2+-independent.
Comparisons of the effect of H7 on PDBu and mezerein-evoked
activity in a variety of tissues showed that, when mezerein was the activator,
a form of Ca2+-dependent PKC was highly sensitive to this inhibitor (Tables
3.3 and 3.4). While this could be due to some interaction of mezerein with
H7, there was no difference in the potency H7 on mezerein and PDBu-
evoked Ca2+-independent activity. Phorbol esters and diterpenes, such as
mezerein and PDBu interact with the C1 region of the regulatory domain
(Burns and Bell, 1991) while the site of H7 action is in the catalytic domain of
the enzyme (Hidaka et al., 1984). While there is one report that the potency
of PKC inhibitors varies with the activator, this was only the case for inhibitors
acting on the regulatory domain, while catalytic domain inhibitors such as H7
and staurosporine were equipotent regardless of the activator used
(Robinson, 1992). Furthermore PDBu was also able to activate this form of
PKC, as was evident when GS peptide was used as the substrate for
midbrain PKC, as H7 was highly potent on the Ca2+-dependent activity
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detected in these conditions (Table 3.6, Figure 3.4). The presence of this
potently H7-inhibited activity in both brain-derived cytosol and that from other
tissues suggests that either PKC a or p may be responsible as PKC y is
expressed exclusively in the CNS (Shearman et al., 1987). As PDBu-
evoked activity in partially-purified cytosol from COS 7 cells, which contain
only cPKC a (Kosaka et al., 1988), showed no evidence of this highly In¬
sensitive cPKC (Table 3.2), this suggested that PKC p may be responsible
for this activity. GS peptide is reported to be a particularly good substrate for
PKC p while it is not very efficiently phosphorylated by PKC a and y
(Kazanietz et al., 1993). Therefore PKC p is likely to make a larger
contribution to the Ca2+-dependent activity relative to the other cPKCs when
GS peptide is the substrate, which could be the reason why highly in¬
sensitive activity was detectable using this substrate. This highly in¬
sensitive PKC also appears to be able to make a contribution towards the
Ca2+-independent activity, as a component of Ca2+-independent GS peptide
thiophosphorylation in anterior pituitary was potently inhibited by H7 (Table
3.7). Subsequent analysis of PKC a and p purified from rat brain by HAP
chromatography, which showed that Ca2+-dependent activity in the PKC p
but not the PKC a fraction was highly sensitive to H7 (Figure 3.5).
Differences in sensitivity to inhibition by H7 have previously been detected in
physiological models of PKC mediated processes. Phorbol dibutyrate
inhibits depolarisation-induced Ca2+ influx through L-type Ca2+ channels in
the anterior pituitary-derived GH3 cell line and this is highly sensitive to
inhibition by H7 (IC50 value 7 ± 4 pM)(Mitchell et al., 1992). PDBu-evoked
LH secretion from the anterior pituitary has a component that is highly H7-
sensitive (Thomson et al., 1993b). These in vitro studies suggest that this
may be due to the involvement of PKC p, which is consistent with evidence
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that the addition of either PKC a or (3 to permeabilised pituitary cells in
primary cultures causes LH secretion (Naor et al., 1989).
As previously mentioned, PKC activators have been shown to elicit
quite different effects on 45Ca2+ influx through L-type Ca2+ channels in the
anterior pituitary compared to the GH3 cell line (MacEwan and Mitchell,
1991; MacEwan et al., 1991), and to differ in their ability to activate individual
PKC isoforms in vitro (Ryves et al., 1991). This study has shown that both
mezerein and DOG, in addition to PDBu, were able to evoke H7-insensitive
Ca2+-independent PKC activity in pituitary cytosol (Figure 3.6), consistent
with the ability of these compounds to activate an H7-resistant form of PKC
which facilitates Ca2+entry through L-type channels (Johnson et al., 1993;
Mitchell et al., 1992). It has been reported that certain diterpenes are
capable of activating cPKCs in the absence of Ca2+ (Ryves et al., 1991) but
there is evidence that DOG is only able to activate PKC a and possibly p in
the presence of Ca2+ (Johnson et al., 1992a, Johnson et al., 1994). Thus the
ability of DOG to evoke the H7-resistant kinase activity suggests that this is
not due to Ca2+-independent cPKC activity.
Thus the evidence presented in this chapter suggests that the H7-
insensitive kinase, found in pituitary and apparently to a lesser extent in lung,
does not correspond to any of the well-characterised Ca2+-independent
isoforms, and it is not a cPKC activated in the absence of Ca2+. This activity
may represent one of the incompletely characterised isoforms, such as PKC
0 or A; alternatively it may be a modified form of one of the known PKCs or
perhaps a novel PKC isoform.
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Table 3.1 Activation by PDBu of PKC activity partially purified
cytosoi from the cytosoiic fraction of various tissues and cell
lines.
Tissue Activity in the
absence of Ca2+
(% of total activity)
EC50 value (fiM)
- Ca2 + +CM(0O+
pituitary 75 ±6 0.73 ± 0.33 0.43 ± 0.24
midbrain 62 ±4 0.88 ±0.13 0.10 ±0.03
spleen 80 ±7 0.62 ±0.12 0.08 ±0.01
COS 7 48* 2.3 ± 1.3 0.15 ±0.07
Phosphatidylserine-dependent histone MIS thiophosphorylation was elicted
by seven concentrations of PDBu (0-3 pM) in the absence (<3 nM) or
presence (100 pM free) of Ca2+. The EC50 values were determined by non¬
linear curve fitting (P. Fit) as descibed in Section 3.2. Values are means ±
S.E.M. (4<n<6).
* With COS 7 cells, the PKC activity curve did not reach a clear plateau,
therefore a mean maximum % activity figure was assigned, on the basis of
the response at the highest concentration tested (10 jiM). This putative
value was used in the computer curve fitting to determine a hypothetical
EC50 value.
Table 3.2 Effects of H7, staurosporine and Ro 31-8220 on
PDBu-evoked PKC activity partially purified from the cytosolic
fraction of midbrain, anterior pituitary and COS 7 cells.
Tissue
IC50 (|iM)




28 ±5 0.12 ±0.01 0.18 ±0.03
Ca2+-
dependent




145 ±38 0.10 ±0.04 0.34 ±0.07
Ca2+-
dependent




36 ±11 0.17 ±0.03 0.26 ± 0.05
Phosphatidylserine-dependent histone HIS thiophosphorylation was
evoked by 1 pM PDBu at various concentrations of H7 (1-300 pM),
staurosporine (0.01-1 pM) and Ro 31-8220 (0.01-30 pM) in the absence (<3
nM) or presence (100 pM free) of Ca2+. The IC50 value determined by non¬
linear curve fitting (P. Fit) as descibed in Section 2.6. Values are means ±
S.E.M. (4<n<6). There was no detectable Ca2+-independent activity in
COS 7 cells.
Table 3.3 Effect of H7 on PDBu-evoked PKC activity partially purified







pituitary 145 ±38 25 ±4
sheep pituitary 128 ±13 N.D.
lung 87 ±37 39 ±6
midbrain 28 ±5 22 ±1
thalamus 43 ±7 23 ±4
cerebellum 38 ±15 34 ±9
spleen 19 ± 3 25 ±3
intestine 23 ±4 N.D.
liver 15 ± 11 N.D.
COS 7 cells N.D. 36 ±11
Phosphatidylserine-dependent histone HIS thiophosphorylation was evoked
by 1 pM PDBu at six concentrations of H7 (0.01-300 |iM) in the absence (<3
nM) or presence (100 (iM free) of Ca2+. The IC50 values were determined by
non-linear curve fitting (P. Fit) as descibed in Section 2.6. Values are means
± S.E.M. (4<n<6). N.D. not detectable.
Table 3.4 Effect of H7 on mezerein-evoked PKC activity partially







pituitary 148 ±21 N.D.
lung 75 ±10 3 ± 1
midbrain 28 ±4 6 ± 1
thalamus 37 ±8 6 ± 1
spleen 31 ±5 7 ± 1
Phosphatidylserine-dependent histone IMS thiophosphorylation was evoked
by 1 p.M mezerein at six concentrations of H7 (0.01-300 pM) in the absence
(<3 nM) or presence (100 |iM free) of Ca2+. The IC50 value determined by
non-linear curve fitting (P. Fit) as descibed in Section 2.6. Values are means
± S.E.M. (4<n<6). N.D. not detectable.
Table 3.5 Effect of H7 on PDBu-evoked PKC activity using myelin







pituitary 34 ±7 33 ±4
midbrain 43 ±6 40 ±3
intestine 36 ± 1 N.D.
thalamus 37 ±2 6 ± 5
spleen 27 ±2 31 ±8
skin 150 ±30 N.D.
Phosphatidylserine-dependent MBP thiophosphorylation was evoked by 1
pM PDBu at six concentrations of H7 (0.01-300 pM) in the absence (<3 nM)
or presence (100 pM free) of Ca2+. The IC50 value determined by non-linear
curve fitting (P. Fit) as descibed in Section 2.6. Values are means ± S.E.M.
(4<n<6). N.D. not detectable.
Table 3.6 Effect of H7 on PKC activity in partially-purified cytosol






Histone IMS 28 ±5 22 ± 1
Myelin Basic Protein
(MBP) 43 ±6 40 ±3
AcMBP(4_i4) peptide 12 ± 5 25 ±7
a peptide 28 ±9 26 ±9
e peptide 34 ±1 17 ± 0.3
GS peptide
13 ± 2 4 ±0.5
Phosphatidylserine-dependent thiophosphorylation was evoked by 1 pM
PDBu at six concentrations of H7 (0.01-300 pM) in the absence (<3 nM) or
presence (100 pM free) of Ca2+. The IC50 value determined by non-linear
curve fitting (P. Fit) as descibed in Section 2.6. Values are means ± S.E.M.
(4<n<6). N.D. not detectable. Substrate concentrations: proteins, 1.25
mg/ml; e pseudosubstrate peptide, 20 pM; AcMBP(4_i4) peptide, 50 pM; GS
peptide, 100 pM.
Table 3.7 Effects of H7 on PDBu-evoked anterior pituitary PKC
activity with various substrates
Substrate IC50 value (pM)




a peptide 32 ±3
e peptide
40 ±5
£ peptide 22 ±8
GS peptide 4 ± 1 45%*
84 ± 18 55%
Phosphatidylserine-dependent thiophosphorylation was evoked by 1 pM
PDBu at six concentrations of H7 (0.01-300 pM) in the absence (<3 nM) or
presence (100 pM free) of Ca2+. The IC50 value determined by non-linear
curve fitting (P. Fit) as descibed in Section 2.6. Values are means ± S.E.M.
(4<n<6). N.D. not detectable. Substrate concentrations: proteins, 1.25
mg/ml; e pseudosubstrate peptide, 20 pM; AcMBP(4--|4) peptide, 50 pM; GS
peptide, 100 pM.
* When GS peptide was used as the substrate, Ca2+-independent PDBu-
evoked activity was inhibited in a biphasic manner with the majority of the
activity (55%) being relatively insensitive to H7, the other 45% being potently
inhibited by H7.
Figure 3.1 Activation by PDBu of partially-purified cytosolic
PKC activity from rat anterior pituitary.
Histone MIS thiophosphorylation was measured at various concentrations
of 4 (3-PDBu (0.3-10 pM) both in the presence and absence of Ca2+ (100
pM and <3 nM free Ca2+ respectively). All points are means ± S.E.M.
(4<n<6). Baseline activity with PS alone was subtracted from activator
curves and the PDBu-evoked activity was normalised to the activity
obtained with the maximally effective dose (10 pM, in the presence of 100
pM Ca2+). Curve fitting was then conducted as described in the Section
3.2 and the EC50 values obtained were 637 ±311 nM and 380 ± 117 nM in
the absence and presence of Ca2+ respectively. The specificity of the
reaction was tested by replacing 4-(3 PDBu with the essentially inactive
stereoisomer, 4-a PDBu. (•) 4-(3 PDBu in the presence of Ca2+, (■) 4-p
PDBu in the absence of Ca2+, (A) 4-a PDBu in the presence of Ca2+.
Figure 3.1
PDBu concentration (jiM)
Figure 3.2 Comparison of PDBu-evoked thiophosphorylation
of various protein and peptide substrates.
Phorbol dibutyrate-evoked thiophosphorylation of protein and peptide
substrates was compared in both the absence and presence of Ca2+ (<3
nM and 100 p.M respectively). Activity was normalised to the amount of
histone IMS thiophosphorylation measured in the presence of Ca2+. The
sequences of the peptide substrates used are as follows: a peptide
(RFARKGSLRQKNV), £ peptide (ERMRPRKRQGSVRRRV), GS peptide
(PLSRTLSVAAKK), MBP(4-14) peptide (AcQKRPSQRSKYL) and histone H1






























































Figure 3.3 Inhibition by H7 of PKC activity in rat midbrain
with different activators.
Histone MIS thiophosphorylation evoked by (a) PDBu (1 pM) or (b)
mezerein (1 |iM) was measured at various concentrations of H7 in the
presence or absence of Ca2+ (<3 nM or 100|iM respectively). All points are
mean ± S.E.M. (4<n<6). IC50 values for Ca2+-independent activity evoked
by PDBu and mezerein were 28 + 5 and 28 ± 4 pM respectively. Ca2+-
independent activity was subtracted from the activity in the presence of
Ca2+ as described in Section 2.6 and the IC50 values obtained for PDBu
and mezerein-evoked activity were 22 ± 1 and 6 ± 1 respectively. All
activity was sensitive to inhibition by Ro 31-8220 with IC50 values for PDBu
of 180 ± 30 and 190 ± 10 nM and for mezerein of 210 ± 30 and 120 ± 10
nM for Ca2+-independent and -dependent activity respectively. (•) Ca2+-







Figure 3.4 Inhibition by H7 of PKC activity from rat midbrain.
Phorbol 12, 13-dibutyrate (1 jiM)-evoked PKC activity partially-purified from
the cytosolic fraction of rat midbrain was measured using GS peptide (100
p.M) as the substrate. The effect of various concentrations of H7 was
determined in both the presence and absence of Ca2+ (100 (iM and <3 nM
free Ca2+ respectively). The IC50 values were determined by non-linear
curve fitting (P. Fit) as descibed in Section 2.6. All points are means ±
S.E.M. (4<n<6). IC50 values were 13 + 2 and 4 ± 0.5 pM for Ca2+-
independent and Ca2+-dependent activity respectively. (•) Ca2+-
independent, (■) Ca2+-dependent activity.
PDBu-inducedKCactivity(%ofcontrol) rôo>o
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Figure 3.5 Inhibition by H7 of PKC a and (3 purifed from rat
brain by hydroxyapatite chromatography.
Phorbol 12, 13-dibutyrate (1 pM)-evoked PKC activity was measured using
GS peptide (100 pM) as the substrate. The effect of various concentrations
of H7 was determined both in the presence and absence of Ca2+ (100 pM
and <3 nM free Ca2+ respectively) and Ca2+-independent activity was
subtracted from the activity in the presence of Ca2+ to obtain Ca2+-
dependent activity, as described in Section 2.6 . IC50 values for Ca2+-
dependent activity were 31 ± 9 and 3 ± 1 pM for PKC a and [3 respectively.
All points are means ± S.E.M. (4<n<6). (•) PKC a, (■) PKC p.
PDBu-inducedKCactivity (%ofcontrol) IOCD00o
Figure 3.6 Inhibition by H7 of anterior pituitary PKC activity
evoked by different activators.
Histone IIIS thiophosphorylation evoked by (a) PDBu (1 jiM), (b) mezerein
(1 (iM) or (c) DOG (1mM) was measured at various concentrations of H7 in
the presence or absence of Ca2+ (<3 nM or "IOOjiM respectively). All points
are mean + S.E.M. (4<n<6). IC50 values for Ca2+-independent activity
evoked by PDBu, mezerein or DOG were 145 ± 38, 148 + 21 and 118 ± 42
jlxM respectively. Ca2+-independent activity was subtracted from the activity
in the presence of Ca2+ as described in Section 2.6 and the IC50 values
obtained for PDBu or DOG -evoked activity were 25 ± 4 and 21 ± 10 fiM
respectively. Mezerein evoked no additional activity in the presence of
Ca2+. (•) Ca2+-independent, (■) Ca2+-dependent activity.






the H7-resistant PKC from
anterior pituitary
4.1 INTRODUCTION
The identification of PKC as a Ca2+-dependent protein kinase
requiring phospholipid as a cofactor (Takai et al., 1979a), and reports of
the widespread distribution of this kinase in various tissues and animal
species (Kuo et al., 1980), soon lead to investigations into the
biochemical properties of this enzyme. Initial characterisation of PKC
activity was conducted on enzyme purified from a number of tissues
sources, including brain, spleen and heart (Kikkawa et al., 1982;
Schatzman et al., 1983; Wise et al., 1982). However, while purification of
up to 15 000 fold was reported (Wise et al., 1982), in each case the
procedure required several steps, the yield was low and the resulting
enzyme preparation was highly unstable. A simplified procedure was
developed by Uchida et al, which produced a yield of 30-50% while
achieving up to 7700 fold purification, and PKC was purified by this
method from renal cortex (Uchida and Filburn, 1984). This procedure
involved DEAE cellulose chromatography followed by PS affinity
chromatography, and this was the first report to suggest that other Ca2+-
and phospholipid-dependent protein kinases might be present in the
resulting enzyme preparation. However, it was only with the introduction
of hydroxyapatite (HAP) chromatography into the purification process that
PKC was separated into different isoforms (Huang et al., 1986b). In this
study, PKC from rat brain was purified using DEAE cellulose, followed
phenyl sepharose, Sephacryl S-200 and polylysine agarose, but the
different isoforms were found to copurify from all of these procedures,
suggesting that they shared similar charge, size and affinity
characteristics. Subsequent elution from a HAP column resulted in the
now well-documented three peaks of Ca2+-dependent PKC activity which
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were designated as type I, II and III, and were later found to correspond to
the isoforms encoded by the y, p and a genes respectively (Kikkawa et
al., 1987).
Since this initial report of the separation of isoforms from rat brain,
additional members of the PKC family have been identified (Bacher et al.,
1991; Baier et al., 1993; Ono et al., 1988; Pfizenmaier et al., 1993; Selbie
et al., 1993). Some of these Ca2+-independent PKCs have also been
detected in brain (Selbie et al., 1993; Wetsel et al., 1992), so must be
present within the three fractions originally called PKC types l-lll. Indeed
when extracts from rat retina were purified by HAP chromatography, PKC
8, e and £ immunoreactivity was detected within main three peaks of PKC
activity (Fujisawa et al., 1992). Purification of individual PKC isoforms to
homogeneity has been reported by a number of groups (Koide et al.,
1992; Leibersperger et al., 1990; Nakanishi and Exton, 1992; Saido et al.,
1992), each using multiple step procedures that are specifically designed
to remove the other isoforms present in the tissues extract at particular
stages.
The cloning of cDNAs corresponding to various PKC isoforms and
subsequent expression of these cDNA, using either baculovirus
expression systems or mammalian cell lines, has lead to the production
of recombinant PKC isoforms. However this has not superseded the
need to study native PKC purified from tissue sources. While in many
cases the purified enzyme shows similar properties to the recombinant
protein (Olivier et al., 1992), there are some exceptions. Protein kinase C
8, for example, when purified from porcine spleen showed reasonable
activity when activity was measured with histone IIIS (-300
U/mg)(Leibersperger et al., 1990) while the recombinant enzyme was
found to be a poor histone kinase (activity of 70 U/mg)(Olivier and Parker,
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1991). Furthermore results obtained in this laboratory have shown
differences in the potency of PKC activators on purified PKC isoforms
(Johnson et al., 1994) that were not detected with recombinant PKC
isoforms from a baculovirus expression system (Kazanietz et al., 1993).
Indeed PKCs produced in such systems have been found to show
reduced catalytic activity depending on the promoter used (Rankl et al.,
1994). Such differences may reflect post-translational modifications such
as phosphorylation (Connor and Clegg, 1993; Pears et al., 1992) and
comparisons of native and expressed isoforms may provide important
information about the regulation of these isoforms in vivo, in mammalian
cells.
The results presented in Chapter 3 show that a form of PKC is
present in anterior pituitary cytosol that may be distinguished by its
relative resistance to the PKC inhibitor H7 (Table 3.1), and this PKC
shows a tissue distribution that is distinct from that reported for any of the
well-characterised PKC isoforms (Table 3.4). In order to further
characterise the properties of this H7-resistant PKC, and to investigate
whether it is a modified form one of the previously identified PKCs or
whether it may represent a novel isoform of PKC, it was necessary to
biochemically separate this PKC from other pituitary PKCs. Following
initial studies using DEAE cellulose, fractionation of pituitary PKC activity
was carried out using HAP chromatography, this method, as previously
mentioned, being capable of partially resolving the individual PKC
isoforms. In this Chapter, the elution profile of the H7-resistant PKC is
compared with that of the other PKC isoforms present in the anterior
pituitary, and evidence is presented to suggest that the H7-resistant




Anterior pituitaries from 20 male Wistar rats were homogenised
and centrifuged as described in Section 2.4. The resulting cytosolic
preparation was applied to a DEAE cellulose column at 4°C, the matrix
was washed with 6 column volumes of homogenisation buffer, as
described in Section 2.4 and the partially-purified PKC was eluted with 3
column volumes of buffers containing 50, 100, 150 and 200 mM NaCI
sequentially. The Ca2+-independent PKC activity in each eluate was
then assayed and the effect of H7 determined.
Purification by hydroxyapatite chromatography
PKC isoforms were resolved by HAP chromatography as
described in Section 2.5. Midbrain, lung or anterior pituitary tissue, from
6, 4 or 50 male Wistar rats respectively, was homogenised and PKCs
were partially purified on DEAE cellulose before application to the HAP
column. aT3-1 cells were grown in DMEM containing Na-pyruvate (0.11
g/l), penicillin/streptomycin (100 U/ml each) and 10% foetal calf serum.
Confluent at3-1 cells were then washed and harvested before
homogenisation and DEAE cellulose chromatography. Proteins were
eluted in a linear potassium phosphate gradient (5-300 mM; total volume
150 ml, fraction volume 2.5 ml) and the PKC activity was assayed. The
resulting profile was assessed and, in most cases, fractions were pooled
as appropriate for dialysis against 50% glycerol, 10 mM Tris HCI, 0.5 mM
EDTA, 0.5 mM EGTA, 25 mM 2-mercaptoethanol (pH 7.5). Pooled
fractions were stored at -20 °C. Alternatively, for the consensus PKC
immunoblot on unpooled anterior pituitary fractions, 0.5 ml of every
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second fraction was combined with 0.5 ml of the subsequent fraction for
subsequent concentration and immunoblotting.
Mixed micelle PKC activity assay
Protein kinase C activity in partially purified from cytosol or in the
more extensively purified HAP eluate was determined as the PDBu-
evoked thiophosphorylation of GS peptide ([PLSRTLSVAAKK], modified
from the sequence of residues 1-12 of glycogen synthase (House and
Kemp, 1987)), measured in the presence of PS. The method used is
described in detail in Section 2.4. Reactions were started by the addition
of enzyme, incubated at 30°C for 15 min and stopped by addition of 20 jil
TCA (6.8% w/v final). After incubation on ice for 15 min, TCA-precipitable
material was removed by centrifugation and the supernatant was spotted
onto 2x2 cm pieces of P-81 cellulose phosphate ion-exchange
chromatography paper (Whatman International Ltd, Maidstone, Kent, UK),
which were washed extensively in 75 mM H3PO4, dried and counted by
liquid scintillation.
Immunoblotting with antibodies to PKC isoforms
Immunoblots were carried out as described in Section 2.7. Protein
kinase C isoforms were identified with rabbit polyclonal antisera raised to
isoform-specific peptide sequences in PKC a, 5, e and £ (2 p.g/ml)(Gibco
BRL, Paisley, Renfrew, UK) and Pi (2.5 fold dilution)(Marais and Parker,
1989). The specificity of staining with these antisera was confirmed in
each case using antibody blocked by preincubation with the relevant
antigenic peptide (1 (ig/ml). Protein kinase C 0 was detected using a
mouse monoclonal antibody (1 (ig/ml; Transduction Labs, Lexington, KY,
USA). Midbrain, pituitary and lung HAP fractions were also
immunoblotted with a rabbit polyclonal consensus antibody, raised to a
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sequence in the C4 domain conserved between all the PKC isoforms
(PKC a:[Ac 543-550-Cys]) (Calbiochem). Unpooled pituitary HAP
fractions combined in pairs were precipitated with TCA (final
concentration 5% (w/v)) and deoxycholate was added to a final
concentration of 0.0125% (w/v). Samples were then centrifuged (5 min,
4°C) and resulting pellet washed with cold acetone/water (9:1) before
dissolving in SDS-PAGE buffer and electrophoresis and immunoblotting
with the PKC concensus antibody as described in Section 2.7.
4.3 Results
Protein kinase C activity in pituitary DEAE-cellulose eluates
Ca2+-independent PKC activity from anterior pituitary tissue,
measured with GS peptide as the substrate, was shown in Chapter 3 to
be composed of 2 components which varied in their sensitivity to H7
(Table 3.6). To investigate the possibility of biochemically separating the
H7-resistant PKC from other nPKCs, anterior pituitary cytosol was
fractionated on a DEAE-cellulose column, by elution using buffers
containing 50 mM, 100 mM, 150 mM and 200 mM NaCI sequentially. The
Ca2+-independent PDBu-evoked PKC activity in each fraction was
measured and the majority (50%) was detected in the 50-100 mM
fraction. The 0-50 and 100-150 mM fractions contained 33% and 12% of
the total Ca2+-independent PKC activity respectively, while the 150-200
mM fraction contained only 5% of the activity. The effect of H7 on the
three fractions containing the most PDBu-evoked activity was measured
and the IC50 values determined. Activity that was relatively resistant to
H7 was detected only in the 100-150 mM NaCI fraction (IC50 77 ± 11 pM);
PKC activity in the other fractions was sensitive to this inhibitor (Table
4.1).
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Hydroxyapatite fractionation of PKC activity from a variety of
tissues and ceil lines.
Figure 4.1 shows typical elution profiles of PKC activity from a)
midbrain b) anterior pituitary and c) COS 7 cells when fractionated by
HAP chromatography. Midbrain was selected as a control tissue for
comparison with anterior pituitary as midbrain contains all of the well-
characterised PKC isoforms (Scott-Young, 1989), but does not contain
detectable quantities of the H7-resistant PKC (Figure 3.4). COS 7 cells
were also compared as these cells also show no evidence of containing
PDBu-evoked H7-resistant kinase activity (Table 3.1) and they are
reported to contain only PKC a and perhaps C, (Kosaka et al., 1988; Ways
et al., 1992). Fractionation of midbrain extracts by HAP chromatography
resulted in three main peaks of PKC activity as previously described for
whole brain tissue (Huang et al., 1986b)(Figure 4.1a). A substantial
proportion of the activity in the smallest, initial peak was phospholipid-
independent and may represent cleaved catalytic subunits of PKC. The
other two peaks of PKC activity were both of similar height, though the
first of these eluted over more fractions than the second.
Hydroxyapatite chromatography of anterior pituitary extracts also
revealed two main peaks of PS-dependent PKC activity (Figure 4.1b)
although, in this case, the first one was much greater in magnitude than
the second. However there was also a small peak of activity following the
second main peak (fraction V) that was not present in midbrain or COS 7
cells (Figure 4.1a and c). Furthermore this was not seen in HAP profiles
from most other tissues examined, for example cerebellum (R A Clegg, A
J Ison and R Mitchell; unpublished work), spleen, and mammary gland
(Connor and Clegg, 1993). Samples were pooled and five fractions were
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collected from both pituitary and midbrain for further investigation, as
shown in Figure 4.1.
The HAP elution profiles were also investigated for rat lung and the
aT3-1 gonadotroph cell line, as both these sources are thought to contain
the H7-resistant PKC (Table 3.3 and R Mitchell, R A Clegg and M S
Johnson; unpublished data). As shown in Figure 4.2, HAP fractionation
of extracts from both rat lung and aT3-1 cells resulted in profiles similar to
that seen for anterior pituitary extracts, with some PKC activity eluting
after the second main peak, although in both these cases a smaller
proportion of the total activity was contained in the first main peak.
Fractions of HAP column eluate from both lung and aT3-1 cells were also
collected for further analysis.
The effect of H7 on PKC activity in pooled HAP fractions
The effect of H7 was examined on PDBu-evoked PKC activity in
five pooled fractions of pituitary HAP eluate, selected to represent the
main features of the HAP elution profile (Fractions l-V as shown in Figure
4.1). Fraction V was found to contain Ca2+-independent activity that was
relatively insensitive to this inhibitor (IC50 85 ± 10 pM; Figure 4.3). Ca2+-
independent activity in fractions l-lll was sensitive to H7 (IC50 values in
the range 9-18 pM), while an intermediate IC50 value (45 ± 19 pM) was
obtained for fraction IV (Table 4.2). Ca2+-dependent activity was not
detected in fraction II but was present in all other fractions and in each
case it was H7-sensitive (IC50 values in the range 10-23 pM)(Table 4.2).
All PDBu-evoked activity was sensitive to inhibition by the selective PKC
inhibitor Ro 31-8220, with IC50 values for all the Ca2+-independent
activity in fractions l-V in the range 103-169 nM. The Ca2+-independent
PKC activity in the corresponding fractions from midbrain was also
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examined and the effect of H7 determined. As seen in Table 4.3, all
fractions were sensitive to this inhibitor with IC50 values varying between
17 and 35 (iM.
Protein kinase C activity was measured in HAP fractions from lung
corresponding to the second main peak (equivalent to fractions III and IV
from pituitary) and the activity eluting after this (fraction V) and the
potency of H7 determined. The Ca2+-independent PKC activity in fraction
V was relatively resistant to H7 (IC50 value 92 ± 26 pM) while the Ca2+-
dependent activity in this fraction was sensitive to H7 (IC50 values 9 ± 2
jiM)(Figure 4.4). All activity in fraction lll/IV (combined) was sensitive to
H7 (IC50 values of 10 ± 3 pM and 11 ± 5 (iM for Ca2+-dependent and
Ca2+-independent activity respectively).
Two fractions from aT3-1 cells were also analysed. These
corresponded to the two main peaks of PKC activity (fractions 1 and 2
respectively). As shown in Table 4.5, both Ca2+-dependent and Ca2+-
independent PDBu-evoked activity in fraction 1 was sensitive to H7 (IC50
values 21 ± 8 (iM and 21 ± 7 |iM respectively). However, fraction 2
contained Ca2+-independent activity that was relatively insensitive to H7
(IC50 value 122 ± 32 jiM). This activity was, however, highly sensitive to
the selective PKC inhibitor Ro 31-8220 (IC50 value 78 ± 32 nM)
Cofactor dependence of H7 resistant activity
The cofactor dependence of PKC activity in the fraction from aT3-1
cells containing H7-resistant PKC activity was investigated. Activity was
measured in the presence of either PC or PS and the effect of PDBu alone,
Ca2+ alone and PDBu and Ca2+ together were compared with basal
activity, as shown in Figure 4.5. Basal activity was similar in the presence of
either PC or PS, and there was no increase when PDBu or Ca2+ was added
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either alone or together, in the presence of PC. When PC was replaced by
PS, however, both Ca2+ and PDBu alone resulted in increased GS peptide
phosphorylation, and there was a further increase when both these
cofactors were added together.
Immunoblotting of anterior pituitary hydroxyapatite fractions
with isoform-specific antibodies
Pituitary HAP fractions l-V were immunoblotted using antisera for
specific PKC isoforms to allow comparison of the distribution of the H7-
resistant activity with the elution pattern for each isoform. Figure 4.6
shows immunoblots for PKCs a, Pi, 8, e, £ and 0, the isoforms reported to
be present in anterior pituitary tissue ((MacEwan, 1993) and D J
MacEwan (unpublished data)). Protein kinase C a, (3i, 8, e and 0 were all
seen as bands in the 80-94 kDa range. Protein kinase C a
immunoreactivity was present in fractions lll-V, while fraction I contained
the major immunoreactivity for PKCs (3-|, 8 and e. PKC £ immunoreactivity,
seen as bands of 81 and 88 kDa, was present in all fractions, the 81 kDa
band being strongest in fraction I while the 88 kDa band was
predominant in fraction III. The monoclonal anti-PKC 0 antibody
recognised a 80 kDa band in fraction III similar to that obtained in a Jurkat
cell positive control (Baier et al., 1993). This band was also just visible in
fraction IV, while in fraction I there was immunoreactivity at approximately
56, 68 and 73 kDa in I, (results not shown) which may represent PKC
breakdown products or other cross-reacting proteins. Immunoblots were
not performed for either PKC y or PKC r\ as no immunoreactivity has been
detected for these isoforms in anterior pituitary (Naor et al.,
1988)(MacEwan, D. J., Johnson, M. S., Ohno, S. and Mitchell, R;
unpublished work).
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Autophosphorylation of hydroxyapatite fractions
Hydroxyapatite fractions from both midbrain and pituitary were
allowed to autophosphorylate with ATP-y[32P] in the presence of PS and
Ca2+, and the resulting radiolabeled proteins were visualised by
autoradiography. In both cases, a number of proteins were labelled in
fractions l-IV (Figure 4.7). Prominent bands included, in fraction I, one of
88 kDa and, in fractions III and IV, one of approximately 95 kDa. These
may well represent autophosphorylation of PKC (3i and a respectively. In
fraction V from pituitary there was one predominant labelled protein,
f
which had a molecular mass (when phosphorylated) of approximately
140 kDa. This protein was also present in pituitary fraction IV but was not
seen in any of the midbrain fractions.
Immunoblotting of hydroxyapatite fractions with PKC
consensus antibody
Hydroxyapatite fractions from both pituitary and midbrain were
immunoblotted with an antiserum raised to a sequence in the C4 domain
that is conserved between all the PKC isoforms (PKC a:[Ac 543-550-
Cys]). This was to test whether the phosphorylation signal at 140 kDa
represented autophosphorylation of a PKC distinct from the known
species recognised by our isoform-specific antisera or whether it might be
due to phosphorylation of a PKC substrate that coelutes from HAP with
the H7-resistant PKC activity. Although a number of other proteins were
labelled by this antiserum, in both anterior pituitary and midbrain HAP
fractions, the strongest staining of these was a protein of approximately
130 kDa in anterior pituitary fractions IV and V (Figure 4.8). This
immunoreactivity was also present to a lesser degree in fraction III but
was not seen in the other pituitary HAP fractions, or in any fractions from
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midbrain. This protein may represent the non-autophosphorylated form
of the 140 kDa protein which was detected in the autophosphorylation
experiments.
The HAP fractions from lung, corresponding to fractions lll-V in
anterior pituitary, was also immunoblotted with the PKC consensus
antibody, as fraction V from this tissue contains H7-resistant PKC activity
(Figure 4.4). While a number of proteins were stained in all fractions,
there was a distinct band of approximately 130 kDa in fraction V, which
was not present in fractions III and IV (Figure 4.9). This band was also
present in a fraction eluting immediately after fraction V (data not shown),
which contained little other immunoreactivity with this antibody.
Immunoblots to determine the elution pattern of the 130 kDa
PKC immunoreactive protein from anterior pituitary
Anterior pituitary extracts were fractionated on a HAP column and
samples from each individual fraction (before fractions were pooled) were
collected. These were combined in pairs and then immunoblotted with
the PKC consensus antibody, to determine the pattern of elution from
hydroxyapatite of the 130 kDa protein previously detected in fractions IV
and V. As shown in Figure 4.10, immunoreactivity with a molecular mass
of 130 kDa first appeared in fraction 32. This corresponded to the
beginning of the second main peak of PKC activity (elution volume 105
ml in Figure 4.1b). This immunoreactivity increased throughout the
following fractions to reach a peak in fractions 40-42 (corresponding to
pooled fraction V) before decreasing to a low level in fraction 56 (elution
volume 150 ml in Figure 4.1b). Thus the highest levels of PKC
immunoreactivity of approximately 130 kDa corresponded to the pooled
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fraction in which H7-resistant PKC activity was most prominent (Table
4.2).
4.4 Discussion
Ca2+-independent PDBu-evoked PKC activity from anterior
pituitary tissue was shown in Chapter 3 to contain two components, one
of which is relatively resistant to H7, when activity was measured with GS
peptide as the substrate. These experiments have shown that this Ca2+-
independent activity can be biochemically separated into fractions with
different sensitivities to the PKC inhibitor H7. Both preliminary
experiments, using DEAE-cellulose chromatography, and more extensive
studies using HAP chromatography showed that it was possible to
separate the H7-resistant PKC activity from other Ca2+-independent PKC
activity (Table 4.1 and 4.2). Hydroxyapatite fractionation of pituitary tissue
extracts showed that some PKC activity eluted after the main peak of PKC
a (fraction V)(Figure 4.1b), in a position where little PKC activity was
detected in midbrain (Figure 4.1a), COS 7 cells (Figure 4.1c) or a number
of other tissues (Connor and Clegg, 1993). Hydroxyapatite fractionation
of extracts from lung and aT3-1 cells also resulted in some PKC activity
eluting in a similar late position to that in pituitary (Figure 4.2). The aT3-1
cell line is derived from anterior pituitary gonadotrophs, the cell type
which is responsible for secretion of LH. As LHRH-induced priming of LH
secretion and a component of PDBu-evoked LH secretion have been
shown to be relatively resistant to H7 (Johnson et al., 1992b, Thomson et
al., 1993b), a gonadotroph-derived cell line may represent a good source
of the H7-resistant PKC-like kinase. While we were unable to clearly
detect H7-resistant PDBu-evoked activity in partially purified cytosolic
extracts from these cells (IC50 value 38 ±18; (Johnson et al., 1993)),
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evidence from studies on activation of PLD and MAP kinase in aT3-1
cells (Fennell et al., 1994; Sim and Mitchell, 1994) suggested that these
cells do contain the H7-resistant PKC. This was supported by preliminary
studies on DEAE cellulose fractionation of aT3-1 cell PKC activity (M S
Johnson and A J Ison; unpublished data). Lung was also selected for
investigation as Ca2+-independent PKC activity in this tissue was shown
in Chapter 3 to be relatively resistant to H7. Characterisation of the PKC
activity showed that the Ca2+-independent activity in the last-eluting
fraction of interest (fraction V) from anterior pituitary and lung (Figures 4.3
and 4.4 respectively) but not midbrain (Table 4.3) was relatively resistant
to H7. One previous report has also described PKC activity eluting in this
position from rat retinal extracts, although its properties were not
assessed in detail (Fujisawa et al., 1992). However we have found no
evidence of H7-resistant PKC activity in DEAE cellulose eluates from rat
retina (IC50 value 18 ± 6 pM)(A J Ison, M. S. Johnson, and R. Mitchell;
unpublished data). Ca2+-independent PKC activity in the fourth fraction
from pituitary, eluting immediately prior to the H7-resistant fraction, was
inhibited by H7 with an intermediate IC50 value, probably reflecting the
presence of small amounts of the H7-insensitive form of PKC in this
fraction. All fractions except fraction II contained Ca2+-dependent activity
that was sensitive to H7, which is consistent with a previous report that all
the cPKCs are sensitive to this inhibitor (Pelosin et al., 1990). As fraction
II contained only immunoreactivity for nPKCs but not cPKCs (Figure 4.6),
the absence of Ca2+-dependent activity in this fraction was expected.
The Ca2+-dependent activity in fraction V is likely to reflect PKC a, as
small amounts of this isoform were detected on immunoblots, although
the majority of PKC a was found in fractions III and IV. Of the nPKCs, both
PKC 5 and e eluted predominantly in fraction I, while PKC 6 eluted mainly
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in fraction III. This elution position for PKC 8 is consistent with a report of
its co-elution with PKC (3 (Mischak et al., 1991). Immuno reactivity for PKC
£ was generally seen as a doublet of approximately 81 and 88 kDa and
was present in all fractions, although only the 88 kDa band was found in
fraction V. While the apparent molecular mass of 81 kDa for PKC £ on
SDS-PAGE is consistent with previous reports (Gschwendt et al., 1992;
Liyanage et al., 1992), there is some evidence that the 88 kDa band may
be due to cross reaction of this antiserum with another PKC isoform
(Tsutumi et al., 1993). It is therefore clear that, of PKCs a-0, only
immunoreactivity for PKC a and £ was present in fraction V, the fraction
containing the majority of the H7-resistant activity (Figure 4.6). The Ca2+-
dependent activity detected in this fraction is likely to be due to PKC a but
the identity of the PKC responsible for the H7-resistant, Ca2+-
independent activity is not known. While PKC a may be activated by
phorbol esters in the absence of Ca2+, we have shown that PDBu-evoked
activity of PKC a purified by HAP chromatography from rat brain,
measured in the absence of Ca2+, was inhibited by H7 with normal
potency (IC50 value 35 ± 16 pM; (Ison et al., 1993)). Since the activity
measured in the PKC assay is evoked by PDBu, it is unlikely that the
activity of PKC £ would be detected because phorbol esters are reported
to be inactive on this isoform (McGlynn et al., 1992; Nakanishi and Exton,
1992). Furthermore we have evidence that PKC £ is detected in our
assay as basal (not PDBu-evoked) activity and GS peptide, the substrate
used in this study, is not a good substrate for this isoform (Johnson et al.,
1993). The possibility remains, however, that modified states of PKC a-0
could be present, as modification in the region recognised by the
antibody may prevent antigen recognition. Furthermore it is possible that
PKCs 1 (X) and p may be present in this fraction. Protein kinase C 1
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shows 72% sequence homology with PKC £ and it has been reported that
this isoform is also recognised by PKC £ antisera. It is therefore possible
that the PKC £ immunoreactivity detected is, at least in part, due to cross
reactivity with PKC i(k). Preliminary immunoblots with a PKC p-specific
antiserum showed no evidence of immunoreactivity for this isoform in any
of the anterior HAP fractions (R Mitchell and J Pfeilschifter; unpublished
data). However these isoforms are unlikely to be responsible for the H7-
resistant activity as both PKC i (A,) and p are aPKCs (Johannes et al.,
1994; Selbie et al., 1993) and are reported to be unable to bind PDBu
(Akimoto et al., 1994; Johannes et al., 1994).
In aT3-1 cells Ca2+-independent PDBu-evoked PKC activity in one
fraction was also found to be H7-resistant. However this fraction was
collected from the second main peak of PKC activity. While this is slightly
earlier than H7-resistant activity was detected on elution of pituitary
PKCs, there is some evidence to suggest that the precise elution pattern
of PKC isoforms may vary depending on the tissue source. For example,
PKC e from rabbit brain was found to elute in earlier fractions than PKC
(3I/II (Saido et al., 1992), while the main peak of PKC (3 immunoreactivity
from rat retina preceded the main peak of PKC £ immunoreactivity
(Fujisawa et al., 1992). Elution of PKC 5 from HAP showed
immunoreactivity for this isoform from rat brain eluted as a broader peak
than recombinant PKC 5 expressed in COS 7 cells, even though in both
cases the enzyme was detected as a doublet on immunoblots (Ogita,
1992). Further fractionation of aT3-1 cell PKCs into smaller fractions
could be conducted to compare the elution profile of the H7-resistant PKC
with that of the other PKCs present, for example PKC a. Indeed,
immunoblots on unpooled pituitary HAP fractions, using a PKC
consensus antibody, showed that the 130 kDa protein thought to
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represent the H7-resistant kinase (see later in discussion) was present
throughout the second main peak of PKC activity (Figure 4.10). Thus
detection of H7-resistant PKC activity in fractions corresponding to this
peak is likely to dependent on the quantity of this kinase that is present
and the nature of the other PKCs that are also present in the same
fraction.
The possibility that the kinase responsible for the H7-resistant
activity is not a PKC had to be considered, as both histone IIIS and GS
peptide are not PKC-specific substrates, although this seems unlikely as
the activity measured is PDBu-evoked. Ca2+-independent activity in the
H7-resistant fraction from both pituitary and aT3-1 cells was sensitive to
inhibition by the specific PKC inhibitor Ro31-8220 (IC50 values 78-130
nM). When the cofactor dependence of this fraction from aT3-1 cells was
investigated, there was no PDBu-evoked activity when PC replaced PS.
Phosphatidylcholine is unable to act as a cofactor in PKC activation
(Nishizuka, 1984b) so from the PS dependence, PDBu activation and Ro
31-8220 inhibition of this kinase activity it seems likely that the H7-
resistant kinase is a form of PKC.
In order to detect proteins that may be responsible for the H7-
resistant activity, autophosphorylation of HAP fractions was undertaken
and the resulting labelled proteins were visualised by autoradiography
(Figure 4.7). In fractions l-lll, a number of proteins were detected but clear
bands were present at molecular masses appropriate for
autophosphorylated PKC a and (3 (95 and 88 kDa respectively). In
fraction V from anterior pituitary, there was only one clear band, at
approximately 140 kDa. This was also present, though less prominent, in
fraction IV but was not seen in the comparable fractions from midbrain. It
is therefore possible that this 140 kDa band represents the H7-resistant
90
kinase, as its distribution between the pituitary HAP fractions correlates
with that of the H7-resistant activity. Furthermore, this
autophosphorylation signal was also detected in the corresponding HAP
fractions from lung (McCulloch et al., 1994), which also contain H7-
resistant PKC activity (Figure 4.4). Immunoblotting of midbrain, lung and
pituitary fractions lll-IV with a consensus antibody designed to recognise
all PKC isoforms showed strong staining of an approximately 130 kDa
protein in fractions IV and V from pituitary and fraction V from lung. Other
pituitary and lung fractions and all midbrain fractions failed to show this
band. This is consistent with the idea that the 140 kDa phosphorylated
protein may represent the H7-resistant PKC itself rather than a coeluting
substrate. Furthermore, detailed immunoblot analysis to investigate the
HAP elution profile of the 130 kDa band showed that, while it was present
in small amounts throughout the second main peak of PKC activity, it
increased to reach maximum intensity at a position corresponding to
fraction V, (where H7-resistant activity was most prominent), and
decreased in subsequent fractions (Figure 4.10). While this molecular
mass of 130 kDa is somewhat larger than that of the well characterised
PKC isoforms (PKC a-0) as well as for PKC i (X)(Selbie et al., 1993),
reports are now emerging of PKCs that are larger in size. A novel,
membrane-bound isoform, PKC p has been reported in human placenta
and several carcinoma cell lines and this isoform is a 117 kDa protein
(Johannes et al., 1994). Furthermore, a 160 kDa form of PKC apparently
related to the C, isoform has been detected in hippocampus by
immunoblotting (Sacktor et al., 1993). Some studies have also detected,
in both hippocampus and platelets, a form of PKC t|, designated rj', which
has a higher molecular mass than the standard PKC t\ detected in lung
and skin (97 kDa rather than 82 kDa)(Sublette et al., 1993a, Wang et al.,
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1993). Experiments have been carried out to clarify whether this 130 kDa
protein may be responsible for the H7-resistant activity, by fractionating
partially-purified pituitary cytosol using centrifugal molecular mass cut-off
filters. This showed that PDBu-evoked Ca2+-independent activity with
molecular mass greater than 100 kDa contained an H7-resistant
component (McCulloch et al., 1994) that was sensitive to the selective
PKC inhibitors Ro 31-8220 and GF109203X (D A McCulloch and R
Mitchell, ; unpublished data). Furthermore size fractionation of pituitary
PKCs using a gel filtration column detected H7-resistant PKC activity in
fractions containing protein of molecular mass 120-150 kDa.
In summary, the H7-resistant kinase detected in anterior pituitary
tissue in Chapter 3, can be partially separated from other pituitary PKCs
by HAP chromatography. This elution profile of H7-resistant PKC activity
did not correlate with strong immunoreactivity for PKC a-0, although it
was coincident with an autophosphorylation signal of approximately 140
kDa and PKC immunoreactivity of approximately 130 kDa. This 130 kDa
PKC immunoreactivity, like the H7 resistant PKC activity, was present in
pituitary and lung but not midbrain. Thus the H7-resistant PKC in anterior
pituitary can be distinguished from the well characterised PKCs by both
size and biochemical properties and may represent a novel PKC isoform.
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Table 4.1. Effect of H7 on Ca2+-independent PKC activity in pituitary
DEAE-cellulose eluates.
NaCI concentration
(mM) IC50 value (jiM)
0-50 13 ± 7
50-100 16 ± 3
100-150 77 ± 11
150-200 N.D.
Phosphatidylserine-dependent thiophosphorylation of GS peptide was
evoked by 1 pM PDBu at six concentrations of H7 (0.01-300 jiM) in the
absence (<3 nM) of Ca2+ and the IC50 value determined by non-linear curve
fitting (P. Fit) as descibed in Section 2.6. Values are means ± S.E.M.
(4<n<6). N.D., not determined.
Table 4.2. Effect of H7 on PDBu-evoked PKC activity in







I 9 ± 2 10 ± 1
II 18 ± 6 N.D.
III 15 ± 8 18 ± 6
IV 45 ± 19 23 ±5
V 85+10 15 ± 8
Phosphatidylserine-dependent phosphorylation of GS peptide (200 pM) was
evoked by 1 pM PDBu at six concentrations of H7 (0.01-300 pM) in the
presence (100 pM free) or absence (<3 nM) of Ca2+ and the IC50 value
determined by non-linear curve fitting (P. Fit) as descibed in Section 2.6.
Values are means ± S.E.M. (4<n<6). N.D.,not detectable.
Table 4.3 Effect of H7 on PDBu-evoked PKC activity in
hydroxyapatite fractions from midbrain
HAP fractions IC50 value (jiM)
I 35 ±5
II 25 ±7
III 17 ± 4
IV 23 ±5
V 33 ±8
Phosphatidylserine-deperidentthiophosphorylation of GS peptide (200 |iM)
was evoked by 1 jiM PDBu at five concentrations of H7 (0.03-300 pM) in the
absence (<3 nM) of Ca2+ and the IC50 value determined by non-iinear curve
fitting (P. Fit) as described in Section 2.6. Values are means ± S.E.M.
(4<n<6).
Table 4.4. Effect of H7 on PDBu-evoked PKC activity in HAP







lll/IV 11 ±5 10 ± 3
V 92 ±26 9 ± 2
Phosphatidylserine-dependent thiophosphorylation of GS peptide (200 (iM)
was evoked by 1 pM PDBu at six concentrations of H7 (0.01-300 |iM) in the
presence (100 (J.M free) or absence (<3 nM) of Ca2+ and the IC50 value
determined by non-linear curve fitting (P. Fit) as descibed in Section 2.6.
Values are means ± S.E.M. (4<n<6).
Table 4.5. Effect of H7 on PDBu-evoked PKC activity in HAP







1 21 ±8 21 ±7
2 122 ±32 48 ±5
Phosphatidylserine-dependentthiophosphorylation of GS peptide (200 pM)
was evoked by 1 pM PDBu at various concentrations of H7 in the presence
(100 pM free) or absence (<3 nM) of Ca2+ and the IC50 value determined by
non-linear curve fitting (P. Fit) as descibed in Section 2.6. Values are means
± S.E.M. (4<n<6).
Figure 4.1 Elution profiles of PKC activity from
hydroxyapatite column
Tissue extracts were prepared from (a) rat midbrain, (b) rat anterior pituitary
and (c) COS 7 cells and fractionated by HAP chromatography as described
in the Section 2.5. Protein kinase C activity was measured as the amount
of GS peptide (150 pM) phosphorylation in the presence of PS and Ca2+
that could be inhibited by PKC (X19-31 (pseudosubstrate inhibitor peptide;
final concentration 420 |ig/ml). Fractions l-V were collected from pituitary
and midbrain fractionation as indicated by the bars. Typical values for the
highest peak of activity were 18 x103 dpm per assay from midbrain and
12.5 x 103 dpm per assay from anterior pituitary (with approximately 2 fold
greater specific activity of label). The profiles are representative of those


































Figure 4.2 Eiution profiles of PKC activity from
hydroxyapatite column
Tissue extracts were prepared from (a) the aT3-1 gonadotroph cell line and
(b) rat lung and fractionated by HAP chromatography as described in the
Section 2.5. Protein kinase C activity was measured as the amount of
phosphorylation of GS peptide (150 jiM) in the presence of PS and Ca2+
that could be inhibited by PKC a-19-31 (pseudosubstrate inhibitor peptide;
final concentration 420 pg/ml). Typical values for the highest peak of
activity were 6.1 x 103 dpm per assay from aT3 ceils and 20 x 103 dpm per
assay from lung (both with approximately 2 fold greater specific activity of
label than midbrain (Figure 4.1)). The profiles are representative of those





Figure 4.3 Inhibition by H7 of PKC activity from anterior
pituitary hydroxyapatite fraction V.
Phorbol 12, 13-dibutyrate (1 pM)-evoked PKC activity was measured at
various concentrations of H7 both in the presence and absence of Ca2+
(100 pM and <3 nM free Ca2+ respectively). All points are means ± S.E.M.
(4<n<6). Ca2+-independent activity was subtracted from the activity in the
presence of Ca2+ to obtain Ca2+-dependent activity,as described in
Section 2.6. (•) Ca2+-independent, (■) Ca2+-dependent activity
Figure 4.3
Figure 4.4 Inhibition by H7 of PKC activity from lung eluting
from hydroxyapatite in a position equivalent to pituitary
fraction V.
Phorbol 12, 13-dibutyrate (1 ]iM)-evoked PKC activity was measured at
various concentrations of H7, both in the presence and absence of Ca2+
(100 pM and <3 nM free Ca2+ respectively). All points are means ± S.E.M.
(4<n<6). Ca2+-independent activity was subtracted from the activity in the
presence of Ca2+ to obtain Ca2+-dependent activity as described in





Figure 4.5 Cofactor dependence of H7-resistant PKC activity
PKC activity in the HAP fraction from aT3-1 cells which contained the H7-
resistant activity (see Table 4.5) was measured in the presence of either
phosphatidylcholine (PC) or phosphatidylserine (PS)(200 (ig/ml). The
effect of PDBu (1 pM) and Ca2+ (100 (iM free Ca2+) either alone or in
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Figure 4.6 Immunoblots of anterior pituitary hydroxyapatite
fractions for PKC isoforms
Anterior pituitary HAP fractions were immunoblotted with antisera specific
for PKC a, Pi, 8, e, 0 and £ as described in the Section 4.2. The relative
amounts of protein that were loaded onto SDS-PAGE gels for
immunoblotting (the product of sample volume loaded and sample












Figure 4.7 Autophosphorylation autoradiographs of
hydroxyapatite fractions lll-V from midbrain and anterior
pituitary
Autophosphorylation of HAP fractions lll-V from midbrain and anterior
pituitary was carried out in the presence of PS and Ca2+ (5.6 pM), the
labelled products being visualised by autoradiography. Phorbol esters
were not required to activate PKC under these conditions as there was no
detergent present (Hannun and Bell, 1986). In pituitary but not midbrain, a
strong band was visible at approximately 140 kDa, mainly in fraction V
(large arrow). In pituitary fractions III and V and midbrain fraction III, the




Figure 4.8 Immunoblots of hydroxyapatite fractions from
anterior pituitary and midbrain with a PKC consensus
antibody.
Hydroxyapatite fractions l-V from pituitary and midbrain were
immunoblotted with a polyclonal antiserum raised to a PKC consensus
sequence in the catalytic domain, PKC a:[Ac 543-550-Cys]. Fractions IV
and V from pituitary contained an immunoreactive protein of 130 kDa that
was not seen in midbrain or the other pituitary fractions (large arrow). A
number of other bands were also apparent in both midbrain and pituitary,
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Figure 4.9 Immunoblots of hydroxyapatite fractions from lung
with a PKC consensus antibody.
Hydroxyapatite fractions l-V from lung were immunoblotted with a
polyclonal antiserum raised to a PKC consensus sequence in the catalytic
domain, PKC a:[Ac 543-550-Cys]- Fraction V from lung contained-an
immunoreactive protein of 130 kDa that was not seen fractions l-IV (large
arrow). A number of other bands were also apparent in both midbrain and
pituitary, including several in the region of 90 kDa.
Figure 4.9
Figure 4.10 Immunoblots of unpooled hydroxyapatite
fractions from anterior pituitary with a PKC consensus
antibody.
Hydroxyapatite fractions from anterior pituitary were collected throughout
elution with a 5-300 mM potassium phosphate gradient. 0.5 ml of every
second fraction was combined with 0.5 ml of the subsequent fraction and
then concentrated as described in Section 2.7 before immunoblotting with
a polyclonal antiserum raised to a PKC consensus sequence in the
catalytic domain, PKC a:[Ac 543-550-Cys]- An immunoreactive protein of 130
kDa first appeared at fraction 32, reaching a peak at fraction 40-42 and
decreasing by fraction 52 (large arrow). A number of other bands were







Investigation of PKC ^-related
PKCS in anterior pituitary
5.1 Introduction
Although PKC £ was first identified in 1988; (Ono et al., 1988), it is
only more recently that it has been classified separately from the other
Ca2+-independent PKC isoforms, as a member of the atypical group of
PKCs (Nishizuka, 1992). Protein kinase C £ was the first PKC isoform to
be identified that had only one cysteine-rich region in the C1 domain
(Ono et al., 1988), and there has been much research conducted to
determine how this isoform is regulated (Zhou et al., 1994). Initial
transfection experiments, using COS cells, found that PKC £ was unable
to bind phorbol esters (Ono et al., 1989b) and this was supported by
evidence from recombinant PKC produced using a baculovirus
expression system (Goodnight et al., 1992), which was also found to be
active in the absence of phospholipid (Liyanage et al., 1992; McGlynn et
al., 1992). When native PKC £ was purified from both bovine kidney
(Nakanishi and Exton, 1992) and mouse epidermis (Gschwendt et al.,
1992), phorbol esters and DAG were once again found to have no effect
on the activity of this isoform, although, in both these cases, it was
stimulated by phospholipid. Thus it appears that in vitro this isoform
shows no dependence on phorbol esters for activation.
Phorbol esters and DAG bind to the C1 domain of PKC in a
phospholipid-dependent manner (Burns and Bell, 1991). This domain
contains cysteine-rich sequences which resemble the zinc finger motif
found in DNA binding proteins but, in PKC, they are thought to comprise
the phorbol binding site (Burns and Bell, 1991). In all the cPKCs (a-y)
and nPKCs (S-rj), there is a tandem repeat of two cysteine-rich regions
while in PKC £ only the first cysteine motif is present. Deletion mutants of
PKC y have shown that either the first or second cysteine region alone is
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capable of binding phorbol esters, although binding was attenuated 10-
20 fold when compared to native PKC y (Burns and Bell, 1991). On the
basis of sequence alignment of PKCs and the other PDBu-receptors, a
consensus sequence of 15 amino acids required for phorbol binding has
been proposed (Ahmed et al., 1991). Analysis of the C1 domain of PKC C,
shows that this region varies by only one amino acid residue (glycine
instead of proline) from the consensus sequence. Protein kinase C 5 and
0 also differ from this sequence by one amino acid, although this is a
conservative substitution (isoleucine instead of valine), unlike in PKC £,
and these isoforms are capable of binding phorbol esters with high
affinity. Site-directed mutagenesis of PKC £ to restore the proline residue
and so generate the full consensus sequence did not, however, result in
phorbol binding, suggesting that other sequences may be required in
addition to this minimal consensus sequence to generate the appropriate
conformation for ligand binding (Kazanietz et al., 1994). Another atypical
PKC isoform, PKC p, has recently been cloned that has two cysteine-rich
regions which are separated by a 79 amino acid intervening sequence.
Both these regions differ from the consensus sequence by one amino
acid, and this isoform is reported to be unable to bind phorbol esters
(Johannes et al., 1994). Thus the precise requirement for PDBu binding
are not yet clearly defined.
While PKC £ is unable to bind phorbol esters in vitro (Nakanishi
and Exton, 1992; Ono et al., 1989b), there is controversy surrounding the
effects of these compound in vivo. Activation of isoforms in vivo is often
assessed by measuring translocation and down-regulation in response to
a stimulus. Several studies have found no evidence of PKC £
translocation or down-regulation in response to phorbol esters in a
variety of different cell types (Gschwendt et al., 1992; Huwiler et al., 1992;
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Ways et al., 1992). However, PKC £ has been found to translocate from
the cytosol to the membrane in response to phorbol esters in a variety of
cell types including R6 fibroblast ceils (Borner et al., 1992b), human
platelets (Crabos et al., 1992), neutrophils (Dang et al., 1994) and smooth
muscle cells (Mochly-Rosen et al., 1991a). These reports must be treated
with caution as there is evidence that PKC ^-specific antibodies cross-
react with cPKCs, either PKC a (Tsutumi et al., 1993; Zhou et al., 1994) or
another cPKC distinct from PKC a or p (Batlle et al., 1994). However it
would appear that cross-reactivity alone is unable to totally explain all
these reports of PKC £ translocation. In R6 fibroblasts, the presence of
PKC C, was confirmed by both Northern blot analysis and immunoblotting
(Borner et al., 1992b). Protein kinase C £ immunoreactivity was detected
at approximately 72 kDa and weak cross reactivity with PKC a was
detected at 81 kDa. In response to TPA, the 72 kDa PKC £
immunoreactivity, in addition to the 81 kDa PKC a, underwent rapid
translocation from the cytosol to the membrane fraction. Furthermore,
chronic TPA stimulation resulted in total down-regulation of the 72 kDa
PKC £ immunoreactivity. In another study, TPA-stimulated translocation
of PKC £ was detected in human platelets, using an antibody that showed
no cross-reactivity with recombinant PKC a (Crabos et al., 1992). Thus
response in vivo of PKC £ to phorbol esters cannot be totally dismissed.
Factors other than the ability of PKC £ to bind phorbol esters may
also influence response of this isoform to these compounds in vivo.
Overexpression of PKC pi has been shown in rat fibroblasts to influence
the down-regulation of PKC 5 and e, but not a or in response to phorbol
esters (Borner et al., 1992b), so it is possible that other endogenous
isoforms may also effect responses in a particular cell type. In addition it
has been reported that expression of either ras or src may interfere with
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the ability of phorbol esters to induce down-regulation of PKC (Lacal et
al., 1990; Thompson et al., 1988). The activity of other kinases in vivo
may also affect the ability of PKCs to respond to phorbol esters, as it has
been reported that PKC a requires phosphorylation by an as yet
unidentified kinase before it may be activated in a cofactor-dependent
manner (Pears et al., 1992). There is also evidence that PKC 5 activity
may be modulated by tyrosine phosphorylation, although the effect of
phosphorylation may vary with different tyrosine kinases, as src was
found to stimulate PKC 8 more efficiently than fyn (Gschwendt et al.,
1994). Thus a variety of factors may affect the ability of PKC in vivo to
respond to phorbol esters.
There has also been controversy surrounding the molecular mass
of PKC £. Predictions from the open reading frame of 592 amino acids
suggest a molecular mass of 67 kDa but expression of rat PKC £ in COS
7 cells (Ono et al., 1989b) or in insect cells (McGlynn et al., 1992) resulted
in expression of a protein with an apparent molecular mass of 64 and 76
kDa respectively. The major in vitro translation product also has an
apparent molecular mass of 76 kDa and immunoreactivity of 72-82 kDa
has been detected in with anti-PKC £ antibodies in a variety of cell types
(Crabos et al., 1991; Wetsel et al., 1992). The recently cloned human
atypical PKC i shares 72 % identity with human PKC £ (Selbie et al.,
1993) and this isoform cross reacts with anti-PKC £ antisera (Zhou et al.,
1994). This cross reaction may in part be responsible for a number of
reports which detect PKC £ immunoreactivity as a doublet as PKC i has
an apparent molecular mass of 65 kDa (Selbie et al., 1993).
Alternatively, PA, unlike other phospholipids, has been shown not only to
activate PKC £ but also to strongly to bind to this PKC (Limatola et al.,
1994). This interaction was sufficiently strong to withstand SDS treatment
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and result in a electrophoretic mobility shift, from 78 kDa to 80-82 kDa.
Thus the presence or absence of PA may be another factor affecting the
apparent molecular mass of PKC C, from a variety of cell types.
Some of the discrepancies concerning the properties of PKC £
may be a result of the existence of multiple forms of this isoform. It was
originally reported that two major RNA transcripts of 2.2 and 4.2 kilobases
were present in some rat brain, kidney and lung (Ono et al., 1988), which
suggested that this isoform may be alternatively spliced. A recent report
has confirmed this and the novel portion has been cloned and
sequenced (Powell et al., 1994). In studies of LTP in the hippocampus,
immunoblots have also shown the presence of three PKC ^-related
proteins, PKM £, native PKC £ and a high molecular mass form (160
kDa)(Sacktor et al., 1993). Both PKM £ and the 160 kDa form were
significantly increased during maintenance of LTP (Sublette et al.,
1993b).
In view of the controversy surrounding the effects of phorbol esters
on PKC £, the possible existence of multiple forms of this isoform and the
reported cross-reactivity of PKC £ antibodies, it was decided to
investigate the presence of aPKCs in the anterior pituitary and the aT3-1
gonadotroph cell line, using a PCR-based strategy. In particular, the
possibility of extended forms of aPKCs that may be capable of binding
phorbol esters was explored, as such kinases may potentially be
responsible for the H7-resistant activity discussed in Chapters 3 and 4.
5.2 Specific Methodology
PCR Methods
The pituitary cDNA library was synthesised by Clontech
Laboratories Inc. (Palo Alto, CA, USA) in AZapll. RNA was prepared as
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described in Section 2.9. PCR was carried out as described in Section
2.10 using oligonucleotide primers designed as described in Section 5.3.
Conditions for PCR amplification using the primers Z1 and Z2 were as
follows: Step 1, denaturation at 94°C for 1 min; Step 2, annealing at 50°C
for 1 min. This cycle was repeated 35 times, followed by a final cycle;
Step 1, denaturation at 94°C for 1 min; Step 2, annealing/extension at
50°C for 8 min, to ensure complete extension of all products. Using
primers Z3 and Z4 PCR conditions were as follows: Step 1, denaturation
at 94°C for 1 min; Step 2, annealing at 65°C for 1 min. This cycle was
repeated 35 times followed by a final cycle; Step 1, denaturation at 94°C
for 1 min; Step 2, annealing/extension at 65°C for 8 min. Using primers 11
and 12, initial PCR conditions were as follows: denaturation at 94°C for 1
min and annealing/extension at 60°C for 1 min for 5 cycles; denaturation
at 94°C for 1 min and annealing at 63°C for 1 min for 30 cycles and final
cycle with denaturation at 94°C for 1 min and annealing at 63°C for 8 min.
During subsequent experiments using the same pair of primers, the
annealing/extension temperature was decreased to 55°C or 45°C for the
first 5 cycles and 60°C or 55°C for the other 31 cycles. One tenth of the
amplified PCR products were analysed by agarose gel electrophoresis
(Section 2.18.2).
Asymmetric PCR for sequencing PCR products
To enable direct sequencing of a PCR product, asymmetric PCR
was conducted to generate a single-stranded product. This method
involves adding one primer to the PCR mixture in vast excess over the
other, resulting in the generation of an excess of one amplified strand
relative to the other. The original PCR product was first purified, using the
Wizard method of DNA purification (Section 2.11.1). The reaction mixture
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was then prepared as previously described for PCR from cDNA libraries
(Section 2.10.2), but one of the primers (Z3) was first diluted either 25 or
50 fold. PCR amplification was then conducted for 30 cycles, using the
same conditions as for the original amplification. Products were extracted
by adding 0.3 ml chloroform to remove the mineral oil and the upper
aqueous layer was removed and retained. The single-stranded product
was then selectively precipitated with 4M ammonium acetate (100 pi) and
isopropanol (200 pi). After vortexing and incubating at room temperature
(10 min), tubes were centrifuged (room temperature, 10 min), and the
pellets were washed with 70 % ethanol (500 pi) and dried under vacuum.
The pellets were resuspended in distilled water and an aliquot analysed
by agarose gel electrophoresis (Section 2.18.2), before the remainder
was used as a template for dideoxy sequencing (Section 2.17), using the
limiting PCR primer (Z3) as a sequencing primer.
5.3 Results
PCR amplification of PKC ^-related fragments from anterior
pituitary
In order to investigate the possibility of a modified form of PKC
containing an extra sequence in the C1 domain, which may be activated by
phorbol esters, a PCR approach was employed. Initially two oligonucleotide
primers were designed to regions flanking the C1 domain which are not
conserved between PKC £ and the cPKCs or nPKCs. Potential primer
sequences were analysed for complementary nucleotide sequences that
might allow dimerisation of the primers or self annealing, the occurrence of
which would decrease the efficiency of amplification of PKC-related
products. The chosen primers sequences, Z1 and Z2 (shown in Table 5.1)
correspond to the amino acid sequences SIYRRGAR (residues 113-120)
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and VQTEKHVFE (residues 297-305) respectively. The sites to which these
primers bind are located in the pseudosubstrate (Z1) and catalytic domains
(Z2)(Figure 5.1), thus the fragment to be amplified would contain a large
proportion of the regulatory domain. PCR amplification from both the rat
pituitary cDNA library and RNA from the gonadotroph aT3-1 cell line
resulted in no products larger than the 577 base pair (bp) fragment
predicted from the sequence published for PKC C (Goodnight et al., 1992),
as shown in Figure 5.2.
PCR amplification using PKC £,• and PKC i-specific primers
Subsequent publication of the sequence of another aPKC, PKC i
(Selbie et al., 1993), which is closely related to PKC £, revealed that the
primers used to detect PKC C, would also amplify PKC i, if present, as shown
in Figure 5.1, and the resulting product would be of a similar size for both
isoforms. In view of this and the cross reactivity of PKC i with anti-PKC £
antisera, it was decided to design specific primers to allow the detection of
these isoforms separately. The PKC ^-specific oligonucleotide sequences,
Z3 and Z4 (shown in Table 5.1) correspond to the amino acid sequences
TSVDAMTT (residues 29-36 in PKC Q and PVIDGVD (residues 235-242 in
PKC 0 respectively. These sequences are located in V1 region upstream
from the pseudosubstrate domain and in the V3 hinge region linking the
regulatory and catalytic domains, as these regions show little homology
between PKC £ and i, as well as with the other PKC isoforms (Figure 5.3).
Degenerate oligonucleotide primers were designed for PKC i as only the
human sequence was published at that time. The sequences of these
primers, 11 and 12 (shown in Table 5.1) are also located in the V1 and V3
regions (Figure 5.3) and correspond to the amino acid sequences
MSHTVAGG (residues 2-8 in PKC i) and MHSDHAQT (residues 199-206 in
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PKC i) respectively. The sequence of PKC X, the mouse homologue of PKC
i, has subsequently been published and the relationship between the
primers 11 and 12 and this mouse sequence is shown in Figure 5.4.
PCR amplification of RNA from the gonadotroph aT3-1 cell line using
the PKC ^-specific primers Z3 and Z4 produced only one fragment of
approximately the expected length (630 bp)(Figure 5.5). In order to confirm
that this product corresponded to PKC £ as previously published (Goodnight
et al., 1992), asymmetric PCR was employed to obtain a single stranded
fragment. This involved using the original product as a template for PCR
using a large excess of one primer (Z4), as described in Section 5.2. The
resulting single-stranded product was sequenced using the limiting primer
(Z3), and found to be identical to mouse PKC t, (Goodnight et al., 1992)(as
shown in Figure 5.6).
Initial PCR amplification of RNA from anterior pituitary and aT3-1 cells
using the PKC i specific primers 11 and 12 resulted in no detectable
products. As it is possible that the initial PCR conditions were unsuitable for
this pair of primers, PCR amplification of cDNA libraries from both rat
pituitary and dorsal root ganglion (DRG) neurones was conducted at various
levels of stringency (annealing temperatures 45-60°C, as described in
Section 5.2). PCR at conditions of low stringency resulted in amplification of
a large number of products, which are likely to be the result of the primers
annealing non-specifically. Under conditions of intermediate stringency,
individual products were amplified but none were of the expected length
(613 bp). These products were, however, ligated into the pGEM-T vector
and transformed into E coli. as described in Sections 2.13-2.15, and DNA
sequencing analysis conducted. The resulting sequences, however,
showed no homology to PKC i, any of the other PKC isoforms or any
sequence in the GenBank™ and EMBL data bases.
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As previously mentioned, primers 11 and 12 were designed using the
human PKC i sequence (Selbie et al., 1993), the only published sequence
available for this isoform at that time. Although redundancies were
incorporated in the primer sequences to accommodate this, it is possible
that these primers are unable to amplify the rat PKC i sequence even if
present in anterior pituitary. To investigate this, PCR amplification was
conducted on RNA from rat kidney, as this tissue has been shown to contain
PKC i (Selbie et al., 1993). As shown in Figure 5.7, amplification using the
PKC £ primers Z3 and Z4 resulted in a fragment of the expected length (632
bp) but there was no product using the PKC i primers, 11 and 12.
Amplification of rat kidney RNA was also conducted at a range of
magnesium concentrations (2-10 mM), as this can affect the ability of the
primers to bind to homologous sequences (Newton and Graham, 1994).
However, there were still no products of the expected length amplified with
these primers.
5.4 Discussion
The presence of PKC £ and ^-related PKCs in anterior pituitary was
investigated as immunoreactivity for this isoform is detected in HAP fractions
that contain H7-resistant activity (Figure 4.6). Protein kinase C £ is resistant
to lipophilic inhibitors, such as a-tocopherol which is known to interfere with
the regulatory domain (Kochs et al., 1993b). There are also some reports
that staurosporine, which is thought to interact with the catalytic domain,
also shows reduced potency for PKC £ compared to other PKC isoforms
(Kochs et al., 1993b, McGlynn et al., 1992), although there is some
conflicting evidence (Gschwendt et al., 1992). While we have evidence to
suggest that PKC £ is detected as baseline activity, in the presence of PS
but no PDBu, we have also found that this activity is relatively resistant to H7
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(Johnson et al., 1993). Therefore it may be possible that if there is an
extended variant of PKC which is activated by phorbol esters, it could also
be relatively insensitive to H7 inhibition. A high molecular mass form of
PKC £ has been detected in hippocampus by immunoblotting (Sacktor et al.,
1993), and while no such immu no reactivity was detectable in anterior
pituitary or aT3-1 cells, this is likely to depend on the antiserum used.
Therefore a PCR approach was selected, which also permits identification of
any interesting products by DNA sequencing analysis. Oligonucleotide
primers were designed from the sequence of PKC £ (Ono et al., 1989b) to
sites flanking the cysteine-rich region of the C1 domain (Figure 5.1), which
should allow amplification of PKC £ but not PKC a-0. However, while PCR
amplification of RNA from both anterior pituitary and aT3-1 cells resulted in
a product of 577 bp, the length predicted from the sequence published for
PKC £, there were no products of a larger size (Figure 5.2). The PCR
primers bind to sites located in the pseudosubstrate domain and in the
catalytic domain downstream from the ATP binding site, regions which are
conserved in the closely related aPKC, PKC i(A,)(Figure 5.1), and the
resulting amplified fragment contains a large portion of the regulatory
domain. Taken together this suggests that there may not be an extended
PKC ^-related kinase present in anterior pituitary.
As previously mentioned, this pair of primers are likely to anneal to
both PKC £ and PKC i(X), as these isoforms share identical amino acid
sequences at these sites (Figure 5.1). While PKC £ has been detected in
anterior pituitary and aT3-1 cells by immunoblotting (Figure 4.6)(Johnson et
al., 1993), PKC £ antibodies are reported to cross react with PKC i (Zhou et
al., 1994). Western blots detected the presence of PKC £ immunoreactivity
in spleen (Wetsel et al., 1992), although Northern blots detected no mRNA
for PKC £ in this tissue (Ono et al., 1988) and later reports suggest that
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spleen lacks PKC £ but abundantly expresses PKC i (Selbie et al., 1993;
Zhou et al., 1994). While Northern blots provided further evidence for the
presence of PKC C in anterior pituitary (A Ison, E Lutz and R Mitchell;
unpublished data), immunoreactivity for this isoform is present in all the HAP
fractions tested and it is possible that this may be partly due to the presence
of PKC i. Therefore, in order to detect PKC £ and i separately, specific pairs
of primers for each isoform were designed. As these isoforms share 72 %
amino acid identity, it was difficult to find regions that were sufficiently
different to be sure of specificity. The catalytic domain is particularly
homologous, so sites were selected in the more divergent V1 and V3
regions of the regulatory domain (Figure 5.3). Amplification of aT3-1 cell
RNA using the PKC ^-specific primers resulted in a single band of the 632
bp predicted from the mouse PKC £ sequence (Figure 5.5). DNA
sequencing analysis confirmed the identity of this product as PKC £. As
there were no products of a larger size, this supports the initial result
suggesting that, in pituitary gonadotrophs, there are no PKC ^-related
kinases which are extended in the C1 region of the regulatory domain. An
alternatively spliced form of PKC £ has recently been identified in a rat
prostatic adenocarcinoma cell line, as well as in rat brain, and the novel
portion has been cloned and sequenced (Powell et al., 1994). This form of
PKC £ is extended at the 5'end of the original sequence published for this
isoform (Ono et al., 1988), so contains an alternative V1 domain to that of
the full length sequence published for PKC £ (Ono et al., 1989b). As the
point of convergence is the pseudosubstrate site at the beginning of the C1
domain, this means that the original pair of primers used to detect PKC £ (Z1
and Z2) will result in amplification of both forms of PKC £, if present in
anterior pituitary cells, although the two forms would be indistinguishable.
However the second pair of primers (Z3 and Z4) will only result in
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amplification of one of these forms, as the recently-identified variant has a
different sequence in the V1 domain, the region to which Z3 is designed to
bind. While differences in the properties of the two forms of PKC £ have yet
to be explored, modification of the V1 domain seems unlikely to affect the
phorbol binding properties of the enzyme.
Amplification using the PKC i-specific primers 11 and 12 did not result
in products encoding PKC i in any of the tissues or cDNA libraries tested.
These primers were tested under a range of PCR conditions including, in
some cases, annealing temperatures as low as 45°C for the first few cycles.
As the melting temperatures (Tm) of the primers 11 and 12 (calculated as
described in Section 2.10) are 69°C and 68°C respectively and the
recommended starting point for optimisation of conditions is 5°C below the
Tm (Newton and Graham, 1994), the failure of these primers to amplify a
product of the expected size (632 bp) is unlikely to be due to inappropriate
conditions for the PCR cycle. The concentration of Mg2+ in the reaction mix
was also varied between 2-10 mM. Mg2+ forms a complex with dNTPs
which is essential for dNTP incorporation and also stimulates the
polymerase activity. The concentration of MgCl2 can influence both the
specificity and yield of PCR, as insufficient Mg2+ yields leads to low yield
while excess Mg2+ leads to non-specific products (Newton and Graham,
1994). However the optimal concentration can vary with the primer
sequences and the template to be amplified. As PCR using 11 and 12 failed
to amplify specific products from kidney RNA, a tissue which has been
reported to contain PKC i (Selbie et al., 1993), while amplification from the
same RNA preparation using the PKC £ specific primers Z3 and Z4 resulted
in a product expected of the expected size (Figure 5.7), it is possible that
these primers are unsuitable for the amplification of rat PKC i. These
primers were designed from the human sequence for PKC i, although
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degeneracies were incorporated to allow for different codon usage.
However subsequent publication of the sequence for PKC X (Akimoto et al.,
1994), the mouse homologue of human PKC i, shows that there are amino
acid substitutions within the sequences to which the primers are designed to
bind as shown in Figure 5.3. Analysis of the nucleotide sequence of PKC X
in the sites to which the primers 11 and 12 are designed to bind showed that
in each case there are three mismatches, none of which are at the 3' end of
the primer sequences (Figure 5.4). During PCR amplification of a DNA
template, dNTPs are added to the 3' end of the oligonucleotide primer,
which is bound to the template sequence. Where mismatches occur in the
primer sequence, it is preferable that they are located towards the 5' end, as
mismatches near the 3' end will not be tolerated and the mismatched primer
will not be extended (Newton and Graham, 1994). As in this case the
mismatches are not near the 3' end, these primers should be capable of
amplifying PKC X. It is, however, not known how closely the rat sequence
resembles that of either the mouse or human homologues, so it is possible,
if there are be variations in rat sequence at the 3' end of these primer
binding sites, that these could prevent amplification from occurring.
Alternatively, it is possible that the failure of these primers to amplify a
sequence encoding PKC i may be due to the 3' end of the 11 primer forming
a secondary structure, as this sequence contains a number of G and C
residues, which may be capable of self-annealing. Therefore to determine
whether PKC i is present in anterior pituitary and aT3-1 cells, it may be
necessary to design further sets of primers specific for this isoform, based on
similarities between the human and mouse sequences, and optimise the
conditions using RNA from a tissue, such as kidney, which expresses high
levels of PKC i.
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Details regarding the specific use of each oligonucleotide are given in
Chapter 2 and Section 5.2. Redundancies were inserted where the only
sequence available was human, to allow for species variation in codon
usage. Nucleotide positions are derived from the cDNA sequence of rat
PKC mouse PKC £ and human PKC i for primers Z1 and Z2, Z3 and Z4,
and 11 and 12 respectively.
Figure 5.1 Comparison of amino acid sequence of PKC
isoforms i and X.
The amino acid sequence of PKC i and X from either mouse (£ and X) or
human (i) are shown. The C1-4 and V1-3 domains are labelled at the start
of each. Individual PKC isoforms are denoted by the appropriate Greek
letter on the left, and the amino acid residues are numbered on the right.
The positions of the oligonucleotides used as primers for PCR amplification
of PKC £ are indicated by the shaded boxes; Eh Z1, ESI Z2. P, Z and A





X MWDTVACGGGGDH SHQVRVKAYYRGDIMITHFEPSISFEGLC SEVRDMC S











i RIWGLGRQGYKCINCKLLVHKKCHKLVTIECGRH. .SLPQE PVMPMDQS S 200













i PEEHARFYSAEISLALNYLHERGIIYRDL KLDNVLLDSEGHIKLTDYGMC 400
X PEEHARFYSAEISLALNYLHERGIIYRDLKLDNVLLDSEGHIKLTDYGMC
t; PEEHARFYAAE ICIALNFLHERG I IYRDLKLDNVLLDADGH IKLTDYGMC




X SPFDIVGSSDNPDQNTEDYLFQVILEKQIRIPRSL SVKAASVLKS FLNKD
? SPFDIIT. .DNPDMNTEDYLFQVILEKPIRIPRFL SVKASHVLKG FLNKD
i PKERLGCHPQTGFADIQGH PFFRNVDWDMMEQKQVVPPFKPNISGEFGLD 550
X PKERLGCHPQTGFADIQGH PFFRNVDWDMMEQKQVVP PFKPNISGEFGLD




Figure 5.2 Agarose gel electrophoresis of the products from
reverse transcriptase PCR amplification using primers Z1 and
Z2.
10 pi of the reaction mixture after PCR amplification with oligonucleotide
primers Z1 and Z2 (Lanes 2 and 3) and control primers (Lane 1) was
analysed by electrophoresis through a 1% agarose gel containing 0.5
mg/ml ethidium bromide. A strong band was visible at approximately 577
bp (as indicated by the arrow), the predicted size for PKC following
amplification of aT3-1 cell and anterior pituitary RNA (Lanes 2 and 3
respectively), but no larger fragments were detected. Lane 1 shows
amplification of aT3-1 cell RNA using control primers which produced the
expected 293 bp fragment. Sizes of the molecular weight markers are
indicated in base pairs.
Figure 5.2
Figure 5.3 Comparison of amino acid sequence of PKC
isoforms i and A, showing PKC £ and PKC i primer locations.
The amino acid sequence of PKC i and A from either mouse (£ and A) or
human (i) are shown. The C1-4 and V1-3 domains are labelled at the start
of each. Individual PKC isoforms are denoted by the appropriate Greek
letter on the left, and the amino acid residues are numbered on the right.
The positions of the oligonucleotides used as primers for PCR amplification
are indicated by the shaded boxes; ^3 Z3, Z4,^ 11, KSSSI |2. P, Z
and A denote the pseudosubstrate, cysteine-rich zinc finger like region and
ATP binding domains respectively. Amino acids which vary between PKC i
and A, are indicated by asterisks.
Figure 5.3
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i TEKHVFEQASNHPFLVGLH SCFQTESRLFFVIEYVNGGDLMFHMQRQRKL 350
X TEKHVFEQASNHPFLVGLHSCFQTESRLFFVIEYVNGGDLMFHMQRQRKL
£ TEKHVFEQAS SNPFLVGLHSCFQTTSRLFLVIEYVNGGDLMFHMQRQRKL






i SPFDIVGSSDNPDQNTEDYLFQVILEKQIRIPRSLSVKAASVLKSF LNKD 500
X SPFDIVGSSDNPDQNTEDYLFQVILEKQIRIPRSLSVKAASVLKSFLNKD
£ SPFDIIT. .DNPDMNTEDYLFQVILEKPIRIPRFL SVKASHVLKGFLNKD
i PKERLGCHPQTGFADIQGH PF FRNVDWDMMEQKQVVPPFKPNISGEFGLD 550
X PKERLGCHPQTGFADIQGHPFFRNVDWDMMEQKQVVPPFKPNISGEFGLD




Figure 5.4 Comparison of nucleotide sequences of PCR
primers 11 and 12 with the sequences from PKC i and X to which
these primers are designed to bind.
The sequence of the oligonucleotide primers 11 and 12, designed to amplify PI—
are shown aligned with the nucleotide sequence for human PKC t and the mo—
homologue PKC X as reported in the GenBank™ data base. Bars indicate
identical nucleotides and alternative nucleotides in brackets represent
redundancies in the primer sequence. The identity of the each sequence is
shown on the left while the nucleotide numbers are shown on the right.
Figure 5.4
a) Oligonucleotide primer 11
pkc X TCGGACACOSICnDGIQCGG
I I 11 I I II 11 I II IMI
11 tcicacacigtcgciggcgg 20
i I I I 11 I I I I 11 I I I I I I I I
pkc i TOXACACX3giCGCAGGCGG 23





I I I I I I I 111! I I I I 111 I I
atgcattctgacca(t/c)gcacagac 1
I I I I I I I I I 11 I I! I I I I I I I I I
ATCCATICIGACCA T GCACAGAC 617
Figure 5.5 Agarose gel electrophoresis of the products from
reverse transcriptase PCR amplification using primers Z3 and
Z4.
10 pi of the reaction mixture after PCR amplification with oligonucleotide
primers Z3 and Z4 of RNA from the aT3-1 pituitary gonadotroph cell line
was analysed by electrophoresis through a 1% agarose gel containing 0.5
mg/ml ethidium bromide. A strong band was visible at approximately 632
bp (as indicated by the arrow), the predicted size for PKC C, but no larger
fragments were detected. Sizes of the molecular weight markers are
indicated in base pairs.
Figure 5.5
Figure 5.6 DNA sequencing analysis of the PCR product from
PCR amplification using primers Z3 and Z4.
The identity of the product from aT3-1 cells of PCR amplification using the
PKC £ specific primers Z3 and Z4 was confirmed by DNA sequencing
analysis. Asymmetric PCR amplification of the original PCR product was
conducted as described in Section 5.2, resulting in a single-stranded
product. This was then used as the template for DNA sequencing by the
dideoxy method, using Z3, the limiting PCR primer as the primer for the
sequencing reaction. The resulting sequence is shown aligned with the
nucleotide sequence for mouse PKC C, as reported in the GenBank™ data
base. The identity of the each sequence is shown on the left while the
nucleotides are numbered on the right. The location of the Z3





I I II I II I I I I I I II I I I I II I
PKCC AAGTGCGAGACATGTGTGGCCTGCACCAGCAGCACCCACTCACCCTCAAG 200
aT3-l tgggtggacagtgaaggtgacccttgtactgtgtcctcacagatggagct 72
IIIIII I I II I I I I I I I II I I I I I I II I I I I I II I II II I II I II I I I I I
PKCC TGGGTGGACAGTGAAGGTGACCCTTGTACTGTGTCCTCACAGATGGAGCT 250
odi3-l ggaggaggccttccgcctggtctgtcagggcagggacgaagtgctcatca 122
I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
PKCC GGAGGAGGCCTTCCGCCTGGTCTGTCAGGGCAGGGACGAAGTGCTCATCA 300
aH3-l ttcatgttttcccaagcatcccagagcagccgggcatgccttgtcctgga 172
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
PKCC TTCATGTTTTCCCAAGCATCCCAGAGCAGCCGGGCATGCCTTGTCCTGGA 350
aT3-l gaagacaagtccatctaccg 192
I I I I I I I I I I I I I I I I I I I I
PKCC GAAGACAAGTCCATCTACCG 370
Figure 5.7 Agarose gel electrophoresis of the products from
reverse transcriptase PCR amplification of rat kidney RNA.
10 jll! of the reaction mixture after PCR amplification with oligonucleotide
primers Z3 and Z4 (Lane 2) and 11 and 12 (Lane 1) was analysed by
electrophoresis through a 1% agarose gel containing 0.5 mg/ml ethidium
bromide. A strong band was visible at approximately 632 bp (as indicated
by the arrow), the predicted size for PKC following amplification using Z3
and Z4 (Lane 2) but there was no product visible from amplification using 11







designed to isolate CDNAS
encoding the H7-resistant PKC
6.1 Introduction
After the initial discovery of PKC and its activation in response to
diacylglycerol and Ca2+, PKC was soon found to play a role in the induction
of cellular responses by a variety of ligand-receptor systems (Berridge and
Irvine, 1984; Nishizuka, 1984a) and in regulation of cellular responsiveness
to external stimuli (Hunter et al., 1985). However, it remained unclear how a
single molecule could mediate and control such a diverse variety of
signaling pathways (Coussens et al., 1986). It was only when PKC was
cloned that evidence emerged for a PKC gene family (Coussens et al.,
1986) and the true extent of the heterogeneity of this family is only now
being revealed.
Protein kinase C was initially cloned following isolation from bovine
brain using a number of protein purification techniques (Parker et al., 1984).
Partial amino acid sequence was obtained from tryptic peptide fragments
and regions of this sequence were selected for use as oligonucleotide
probes to screen a cDNA library, in order to obtain the full length clone and
thus the full cDNA sequence of PKC (Parker et al., 1986). This soon lead to
the identification of other related cDNAs, thus PKC a, p and y had been
cloned (Coussens et al., 1986). A number of groups simultaneously cloned
Ca2+-dependent PKCs (Knopf et al., 1986; Parker et al., 1986) and PKC
became recognised as a gene family of closely related enzymes. This
allowed comparison of the structure of these PKCs and the conserved
regions of the protein could be identified (Coussens et al., 1986). The
occurrence of further heterogeneity, as a result of alternative splicing, also
became evident with the isolation of cDNA clones PKC pi and II, which
differed only in the carboxyl-terminal regions of 50 and 52 amino acid
residues respectively (Ono et al., 1986). As isoforms were cloned from a
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number of different species, it became clear that the sequences of the PKCs
were highly conserved between mammalian species, even in the regions
that varied between isoforms, suggesting that all regions of the primary
structure may be important in the function of the individual PKC isoforms
(Kubo et al., 1987).
Although the existence of a phorbol ester receptor with Ca2+-
independent protein kinase activity had reported earlier (Shoyab and
Boaze, 1984), it was only later that sequences of the Ca2+-independent
PKC isoforms were identified. The method that had successfully isolated
PKC (3 and y was once again employed, using fragments of the known PKC
sequences as hybridisation probes to identify further PKC-related clones
from a cDNA library. The structures of PKC 8, e and C, were discovered in
this way and they were identified as being related to the previously known
PKC family members, though they differed in their regulatory domains (Ono
et al., 1988).
Protein kinase C 0 was the first isoform to be cloned using a different
approach. Three groups independently reported cloning this isoform, one
using the strategy previously successful in isolating 8, e and £ (Osada et al.,
1992), which had also revealed PKC q (Osada et al., 1990), while the other
two groups employed the Polymerase Chain Reaction (PCR) technique
(Baier et al., 1993; Chang et al., 1993). Both groups aimed to identify PKC
family members present in human blood cells and used degenerate
oligonucleotide primers to regions conserved between the PKC isoforms.
This should result in amplification of the region between the two primers,
from all the PKC sequences that are present in these cells. DNA
sequencing of the resulting products allowed identification of a novel PKC-
like sequence, and the corresponding full length cDNA was obtained either
by using the fragment as a probe to screen a cDNA library or by anchored
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PCR amplification of the 3' and 5' ends. The two members of the PKC family
that have since been identified, PKC i and (i, were also cloned using a PCR-
based strategy (Pfizenmaier et al., 1993; Selbie et a!., 1993).
The evidence presented in Chapter 4 suggested that the H7-resistant
PKC detected in anterior pituitary cytosol is a novel PKC isoform, as post-
translational modifications of known isoforms seem unlikely to account for
the apparent molecular mass of 130 kDa, 40-50 kDa larger than the well
characterised isoforms. As the amount of this protein present in the pituitary
is low, it was decided to attempt to clone this PKC, rather than to isolate it by
protein purification techniques. In view of the number of recent successes
using PCR to clone isoforms, this method was selected. Both total RNA
extracted from pituitary tissue and a pituitary cDNA library were used as a
template for amplification. Total RNA from aT3-1 clonal pituitary cell line
that had been treated with oestrogen was also used. These cells have also
been shown to contain the H7-resistant PKC (Chapter 4 and (Simpson et
al., 1994)) and, as this PKC has been shown to be induced in pituitaries by
oestrogen pretreatment (Thomson et al., 1993a), it is possible that these
cells may represent a good source from which to clone this PKC.
6.2 Specific Methodology
Total RNA was prepared as described in Section 2.9 from either eight
rat pituitaries or two 75 cm2 flasks of aT3-1 cells, which had been split to
50% confluency two days prior to treatment for 24 hours with 10 nM
oestrogen. A pituitary cDNA library was constructed by Clontech
Laboratories Inc. (Palo Alto, CA, USA) in the bacteriophage vector XZapll,
from mRNA from male and female anterior pituitaries. PCR was conducted
as described in Sections 2.10.1 (PCR from cDNA libraries) and 2.10.2
(reverse transcriptase PCR), using degenerate oligonucleotide primers
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designed as described in Section 6.3. Initial PCR conditions with the
primers 592K and 593K were as follows:Step 1, denaturation at 94°C for 1
min; Step 2, annealing at 55°C for 1 min; Step 3, extension at 72°C for 1
min. This cycle was repeated 5 times followed by 35 cycles during which
the annealing step was conducted at 60°C, and a final cycle, annealing at
60°C, during which the extension step was continued for 8 min. In
subsequent experiments the annealing temperature for the first five cycles
was varied between 45 and 55°C. Using primers PC3 and 593K, initial PCR
conditions were as follows: Step 1, denaturation at 94°C for 1 min; Step 2,
annealing at 60°C for 1 min; Step 3, extension at 72°C for 1 min. This cycle
was repeated 5 times followed by 35 cycles during which the annealing step
was conducted at 68°C, and a final cycle, annealing at 68°C, during which
the extension step was continued for 8 min. For subsequent experiments
using the same pair of primers, the annealing temperature was decreased
to 55°C or 45°C for the first 5 cycles and 60°C or 55°C for the other 35
cycles. One tenth of the amplified products was analysed by agarose gel
electrophoresis (Section 2.18.2) and DNA fragments were purified using
one of the methods described in Section 2.11. Products were ligated into
the pBluescript, pGEM4z or pGEM-T vectors (Promega) and propagated in
the DH5a strain of E. coli. Mini prep DNA was prepared from colonies as
described in Section 2.15 and an aliquot (approximately one fifth) was
analysed by restriction digestion. Sequencing analysis was conducted as
described in Section 2.17.
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6.3 Results
PCR amplification of 293 base pair fragments of cDNAs
encoding PKC isoforms
In order to identify novel genes potentially related to the PKC gene
family that are expressed in the anterior pituitary and may represent the H7-
resistant kinase, a PCR based strategy was used. Initially two degenerate
oligonucleotide primers were designed to regions in the catalytic domain
which are conserved between the PKC isoforms. Potential primer
sequences were analysed for complementary nucleotide sequences that
might allow dimerisation of the primers or self-annealing, the occurrence of
which would decrease the efficiency of amplification of PKC-related
products. The chosen primers sequences, 592K and 593K (shown in Table
6.1) correspond to the amino acid sequences LFFVMEYVNGGDLMF
(residues 412-426 in PKC a) and TFCGTPDYIAPEI (residues 497-509 in
PKC a) respectively. Their positions in the catalytic domain and the
homology between the known PKCs in these regions are shown in Figure
6.1. PCR amplification of cDNA templates, prepared from pituitary RNA,
resulted in products of the expected 293 bp size (Figure 6.2). The primer
sequences contained restriction sites for the enzymes Taql (592K) and Xhol
(593K), which were initially used to ligate the products into pBluescript.
After transformation into E. coli, DNA was prepared from 10 colonies and
restriction analysis was conducted to investigate the possible identity of the
PCR fragments they contained. DNA samples were digested with the
endonucleases, Ncol and Sail or with these two enzymes as well as Xbal
and the results compared. As shown in Figure 6.3a, Ncol and Sail cut the
plasmid in the polylinker, while Xbal cleaves DNA at a sequence that is
specific to the PCR product resulting from amplification of PKCe. This
113
identified all 10 clones as fragments of PKC e, an example of which is
shown in Figure 6.3c. This was confirmed by sequencing analysis (Figure
6.4).
In view of the initial PCR only resulting in amplification of PKC e, less
stringent conditions were used, with a lower temperature at the annealing
step of the PCR cycle, to allow amplification of other sequences. The
resulting products of the expected size were ligated into the pGEM4z vector
and, following transformation, DNA from sixteen of the resulting colonies
was prepared. Restriction digestion and sequencing analysis was
conducted as previously described. This identified three of the colonies as
containing PCR fragments encoding PKC e, the other 13 corresponding to
three sequences that did not show significant homology to any of the known
PKC sequences, or to any of the sequences in the GenBank™ and EMBL
data bases.
A third PCR amplification using these primers was conducted under
conditions of intermediate stringency in an attempt to reduce the
amplification of unrelated sequences but still allow amplification of PKC-like
sequences, other than PKC e. The resulting PCR fragments were ligated into
the pGEM-T vector and, following transformation, DNA was prepared from
59 colonies. Ten of these were identified as containing fragments encoding
PKC £, by restriction analysis using the endonucleases Rsal, which
linearises the pGEM-T vector, and Hindlll, which cleaves samples at a site
specific to PKC £, as shown in Figure 6.5. This identification was confirmed
by sequencing analysis (Figure 6.6). The sequence of one clone, shown by
restriction analysis to encode neither PKC e or was found to correspond to
PKC a (Figure 6.7). Of the other 48 clones, 32 represented PKC e and the
sequences of the other 16 showed no homology to any of the known PKC
isoforms or any other sequence in the GenBank™ and EMBL data bases.
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PCR amplification of 494 base pair fragments of cDNAs
encoding PKC isoforms
As the sense primer 592K would be unlikely to anneal to PKC 0 (the
sequence of which had been published since the design of this primer) and
therefore may be unable to recognise other PKC-related sequences, a new
sense primer, PC3, was designed. The sequence of this primer (Table 6.1)
corresponds to the amino acids LGKGSFGKV (residues 333-342 in PKC a)
within the ATP binding site, as shown in Figure 6.1. PCR amplification from
the pituitary cDNA library was conducted as described in Sections 2.10.1
and 6.2 using PC3 and 593K, the original antisense primer. This produced
a fragment of the expected size (494 bp)(Figure 6.8). This was ligated into
the pGEM-T vector and, following transformation, DNA prepared from 12
colonies was analysed by restriction digestion. This identified all clones as
PKC e (Figure 6.9) and this was confirmed by sequencing analysis (Figure
6.10). PCR amplification was repeated using these primers under less
stringent cycling conditions and 31 of the resulting clones were analysed as
previously, one of which encoded PKC a and the remaining 30
corresponded to PKC e. Some of the DNA resulting from this amplification
was also digested with the restriction enzyme Xbal, which cleaves
sequences encoding PKC e but not the other PKC isoforms. The uncut
fragments were separated from cut ones by agarose gel electrophoresis
and gel purification, and subsequently ligated into the pGEM-T vector.
However the DNA from five of the colonies resulting from transformation,
when analysed by sequencing were all identified as encoding PKC e.
PCR amplification from oestrogen-treated aT-1 cells
As oestrogen treatment has been shown to induce the H7-resistant
PKC involved in LH secretion from anterior pituitaries (Thomson et al.,
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1993a), it was decided to see if pretreatment may favour PCR amplification
of a novel PKC-like sequence. Therefore aT3-1 cells were pretreated with
oestrogen for 24 hours prior to RNA extraction. The resulting total RNA was
used as the template for reverse transcriptase PCR using primers 592K and
593K. Of the 10 clones analysed by sequencing analysis, 6 were identified
as PKC e and the remaining 4 were found to encode PKC
6.4 Discussion
The original pair of primers, 592K and 593K, correspond to
sequences located in the C3 region of the catalytic domain, which are
shared by PKC isoforms a-i (Figure 6.1) but are not conserved in other
protein kinases. The resulting 293 bp fragments correspond to a region
within which amino acid identity amongst the known PKC sequences is
approximately 63%, while the corresponding homology levels of known
PKC genes with their nearest relative, cAMP-dependent protein kinase type
a (PKA a), is <41%. Thus, although this region is broadly conserved among
members of the PKC gene family, isoforms vary sufficiently to allow
amplified sequences to be identified as potentially novel members of the
PKC family.
Amplification using these primers in each case resulted in products of
the expected size (293 bp) as calculated from the sequences previously
published for the rat PKC isoforms a-i (Selbie et al., 1993). By varying the
annealing temperatures of the PCR cycle, the selection of amplified
products was altered. Initial conditions resulted in the amplification of only
cDNA fragments encoding PKC e, as determined by restriction and
sequencing analysis (Figure 6.3 and 6.4). This suggests that either PKC e
may be the most abundant PKC isoform in the anterior pituitary, or the
primers used favour amplification of this isoform over the other PKCs
116
present in anterior pituitary cells. Therefore the stringency of the PCR
cycling conditions was varied in an attempt to optimise amplification of a
variety of PKC-related sequences, while minimising amplification of
unrelated products. This resulted in amplification of sequences that were
identified as PKC £ in addition to PKC e, as well as one sequence encoding
PKC a. The primer 592K was designed to favour amplification of the Ca2+-
independent PKC isoforms, as the nucleotides at the 3' end of this
oligonucleotide encode phenylalanine, which only occurs in this position of
the sequences encoding the nPKCs and PKC £ and i (Selbie et al., 1993).
Thus this explains the low incidence of PKC a and absence of PKC (3
encoding sequences, both of these isoforms being present in anterior
pituitary (Figure 4.6), in the amplified products.
Initial PCR experiments failed to amplify the other nPKCs that have
been shown to be present in the anterior pituitary (PKC 5 and 0)(Figure 4.6).
This may be due to the primers favouring amplification of PKC e and £. The
upstream primer 592K is unlikely to anneal to PKC 0, in addition to the
Ca2+-dependent PKC isoforms, as this isoform also lacks the phenylalanine
encoded at the 3' end of this primer sequence (Baier et al., 1993; Chang et
al., 1993). As this means that it is possible that this primer may not amplify
other PKC-related sequences, another sense primer, PC3A was designed as
an alternative to 592K for use with the antisense primer 593K. This primer
(P3) corresponds to a sequence at the start of the catalytic domain within the
ATP binding site, which is highly conserved between PKC a-q (Figure 6.1).
PKC £ and i vary slightly from the other PKC isoforms in this region so it is
possible that this primer may not amplify these isoforms. However both PKC
£ and i, unlike the H7-resistant PKC, are not stimulated by phorbol esters
and primers specific for these isoforms had failed to identify in anterior
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pituitary ceils any potentially related PKCs which may be extended in the
phorbol binding domain (Chapter 5).
Amplification using the primers PC3 and 593K resulted in a product
of 494 bp, the size predicted from the sequences published for PKC a-t
(Selbie et al., 1993). Cloning of this product resulted predominantly in
clones containing the sequence encoding PKC e (Figure 6.10), while one
contained a sequence encoding PKC a. The lack of PKC C sequence
suggests that, as previously proposed, the primer PC3 may not be able to
bind to sequences encoding this isoform. Although the conditions of PCR
cycling using this pair of primers were varied, it is possible that they were
still too stringent to allow amplification of other PKC-related sequences.
Alternatively PKC e and £ may be expressed at higher levels in anterior
pituitary cells than the other PKC isoforms that are known to be present
(PKC a, p, 5 and 0) which would mean that the probability of amplifying
fragments encoding these predominant isoforms would be much greater
than that for amplification of the other less abundant isoforms. This is
supported by evidence from Northern blots using oligonucleotide probes
directed against unique sequences in PKC 8-£, which detected PKC e and £
but only small amounts of PKC 5 in anterior pituitary cells (E. Lutz, A. Ison
and R. Mitchell, unpublished observations). In an attempt to eliminate
sequences encoding PKC e, the product of PCR amplification with these
primers was incubated with the restriction endonuclease Xbal prior to
ligation, as this enzyme cleaves a sequence that is present in the amplified
fragment of PKC e but not the other PKC isoforms. However, the sequences
that were obtained from ligating into the pGEM-T vector only the PCR
products that remained uncleaved following digestion were subsequently
identified as PKC e, suggesting that the digestion of the DNA was
incomplete.
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To try to favour amplification of novel PKC-like sequences that might
correspond to the H7-resistant kinase, oestrogen-treated aT3-1 cell RNA
was used as the template for PCR amplification, using primers 592K and
593K. Oestrogen has been shown to induce the H7-resistant PKC that is
involved in LH release from rat pituitaries, so it was hoped that RNA from
this pituitary cell line derived from LH secreting cells treated with oestrogen
may be enriched in this kinase and thereby increase the chances of
amplifying a novel PKC-related sequence. However, oestrogen has also
been shown to increase the total PKC content of all types of pituitary cells
(Drouva et al., 1990), so it is likely to stimulate expression of other PKC
isoforms, in addition to the H7-resistant kinase. This may explain the failure
of this approach to selectively amplify sequences other than those encoding
PKC e and C-
There are still a number of approaches yet to be explored that may
result in amplification of a novel PKC-related sequence. It is possible that
the antisense primer used in these experiments is biased towards
amplification of PKC e rather than other sequences, so an alternative primer
could be designed for PCR with either of the sense primers used previously.
The use of two pairs of nested primers may also be considered, as this was
the strategy that resulted in the cloning of PKC 9 (Chang et al., 1993). Using
this approach, a first round of amplification could be conducted at low
stringency, using one set of primers corresponding to regions that are
conserved between PKC isoforms, and the products could then be used as
the template for a second round of amplification, using different primers.
The second pair of primers bind to conserved sequences that are contained
within the fragment amplified in the initial PCR reaction. This means that
sequences unrelated to PKC that may have been amplified in the first round
of PCR, are unlikely to be amplified in the second round, as they should not
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contain the sites to which the second pair of primers bind. This technique
therefore avoids the problem of amplification of unrelated sequences of
unknown identity, which occurred in these experiments when the stringency
of the PCR conditions was reduced, as only PKC-related sequences would
be amplified on the second round of amplification. The resulting clones
could be screened by colony hybridisation, using a probe that was designed
to hybridise to PKC £, which would enable analysis only of clones thought to
contain sequences other than PKC e.
Evidence presented in Chapter 4 suggested that the H7-resistant
PKC may correspond to a 130 kDa protein. This molecular mass is much
higher that those reported for PKC a-i (65-90 kDa), which suggests that this
PKC could be more closely related to PKC 1p, which has a molecular mass of
115 kDa(Pfizenmaier et al., 1993). PKC p. has been assigned to the PKC
family as it shows significant homologies in both the regulatory and catalytic
domains, though it is more distantly related than the other PKCs. The amino
terminus of PKC p contains a putative signal peptide and transmembrane
domain which is not present in any of the other PKC isoforms. The catalytic
domain of PKC p shows 25-31% amino acid identity with the other Ca2+-
independent PKCs while these isoforms show 45-75% homology in this
region. Analysis of the sequence of PKC p, which has only been recently
published and was not available at the time of designing the PCR primers
used in this study, suggests that this isoform may not be amplified even if
present in anterior pituitary using these primers. Therefore the failure of
these experiments to identify a novel sequence representing the H7-
resistant kinase may conceivably be due to similarity of this kinase to PKC p,
rather than the other PKC isoforms. PKC p, however, is not activated by
phorbol esters, unlike the H7-resistant kinase, although it differs from the
other phorbol unresponsive PKCs as it contains two of the cysteine-rich
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regions thought to be responsible for phorbol binding. Thus, while the H7-
resistant kinase may resemble PKC p., it is unlikely to share high homology
with this isoform in the C1 domain of the regulatory subunit. However
designing primers based on the amino acid residues in the catalytic domain
that are conserved between PKC |x and the other PKCs may increase the
probability of amplifying a novel PKC-related sequence.
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PC3 5'-TIGG IAA(A/G)GG IAG(C/T)TT (C/T)
1242-1267
(sense) GG(C/G)AAGGT-3'
Details regarding the specific use of each oligonucleotide are given in
Sections 2.10 and 6.2. Redundancies were inserted where PKC isoforms
varied in their codon usage or amino acid sequence. Nucleotide positions
are derived from the cDNA sequence of PKC a.
Figure 6.1 Comparison of amino acid sequence of the catalytic
domain of PKC isoforms oc-i.
The amino acid sequence of the C3/C4 regions (catalytic domain) for PKC
a-i, either rat or human are shown and regions that are identical in at least
60% of the aligned sequences are boxed. Individual PKC isoforms are
denoted by the appropriate Greek letter on the left, and the amino acid
residues are numbered on the right. The positions of the oligonucleotides
used as primers for PCR are indicated by the shaded boxes; 592K,
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ED E LF QS i MEHNVA YP
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ek le nre I q ppf k p kvc 6 19
ek le rke I q pp[yk p k ac 622
er le rle i a ppf r p r pc 6 3 6
nl le krkve ppf k p kvk 6 23
ee le rke 1 D F0F r p kvk 656
vl le qkk J k ppf k p rik 690
aq 4nhrq 1 e ppf r p rik 63 5
dl lekkqal ppf q p2it 540
DM qkqvv ppf k p mis 53 5
a GKGA-E NFC KF FT RGQ P V
P GRNA-E NFC RF FT RHP p V
Y GRSG-E NFC KF FT RA a P a
8 SPSDYS NFC PE F LN e K P Q
0 S PF dc £ NFD KE F LN e K F A
E TKRDVF NFD QE ftJr e e P V
SREDVS NFD PD FF K E e e V
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Figure 6.2 Agarose gel electrophoresis of the products from
PCR amplification of reverse transcribed RNA encoding PKC
isoforms expressed in rat anterior pituitary gland.
10 pi of the reaction mixture after PCR amplification with oligonucleotide
primers 592K and 593K was analysed by electrophoresis through a 1%
agarose gel containing 0.5 mg/ml ethidium bromide. A band was visible at
approximately 300 bp (as indicated by the arrow), the predicted size for
PKC isoforms a-i. Sizes of the molecular weight markers are indicated in
base pairs.
Figure 6.2
Figure 6.3 Identification of sequences encoding PKC e by
restriction analysis.
Products of PCR amplification were ligated into a plasmid vector and
transformed into E coli. An aliquot of the DNA prepared from each colony
selected was analysed by digestion with the restriction endonucleases,
Ncol, Sail and Xbal in the One-for-AII restriction enzyme buffer
(1.5x)(Promega). a) shows the location of restriction sites for these
enzymes in a construct containing PCR fragment encoding PKC e.
Numbers refer to positions in the cloning vector, or in the amplified PCR
product (in italics), b) shows the expected size of the fragments obtained
from cleavage of a clone containing the sequence encoding PKC e. c)
Agarose gel electrophoresis of typical restriction digests showing a PKC e-
containing plasmid (lane 2) and plasmid containing a PCR product with a
different sequence (lane 1). The top arrow indicates the fragment
corresponding to the cloning vector and the other arrows show the insert
either encoding PKC e (bottom) or a different sequence (middle). Sizes of













Figure 6.4 DNA sequencing analysis of a clone containing a
PCR product encoding PKC e.
The identity of some of the colonies indicated by restriction analysis as
containing fragments encoding PKC e was confirmed by DNA sequencing
analysis using the dideoxy method. One such sequence, 4r is shown
aligned with the nucleotide sequence for rat PKC e as reported in the
GenBank™ data base. Bars indicate identical nucleotides and the site of
cleavage by Xbal, the endonuclease used in restriction analysis, is shown
by the arrow. The identity of the each sequence is shown on the left while
the nucleotides are numbered on the right. Sequences representing the




4r TIGGTCAAGGAGTTTGTCAACG. . GGGGACCTCATGTTCCAGATTCAGCGG 236
II II I I III I III I I I I II I I I I I I II I I I I I I I I I I II I II I
PKC e TTCGTCATGGAATATGTAAACGGTGGAGACCTCATGTTCCAGATTCAGCGG 1692
4r TCCCGAAAATTCGATGAGCCTCGTTCCCGGTTCTATGCTGCCGAGGTCACA 185
I I II I I I I II I II I I I I I I I I I I I I II I I I I I I I I I II II I I I I I I I II I
PKC e TCCCGAAAATTCGATGAGCCTCGTTCCGGGTTCTATGCTGCCGAGGTCACA 1743
4r TCTGCTCTCATGTTTCTCCACCAACATGGAGTGATCTACAGGGATTT.AAA 135
I I I I I I I I I I I I I II I I II I II II I I II I I I I II I I I I II I I I II I I III
PKC e TCTGCTCTCATGTTTCTCCACCAACATGGAGTGATCTACAGGGATTTGAAA 1794
I
4r CTGGACAACATCCTTCTAGATGCAGAAGGTCACTGCAAGCTGGCTGACTTT 84
I I I I I I I II I I I II II II I I I II I I I I I I I II I I I II I I I I I I I I I I II I
PKC e CTGGACAACATCCTTCTAGATGCAGAAGGTCACTCCAAGCTGGCTCACTTT 1845
cvwww
4r GGGATGTGCAAGGAAGGGATTCTGAATGGCGTGACAACTA. CACCTTCTGT 34
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
PKC e GGGATGTGCAAGGAAGGGATTCTGAATGGCGTGACAACTACCACCTTCTGT 1896
593K
4r GGCACCCCGAACTACATCGCCCCCGAGATCCTG 1
I I I I I II I I I I I I I II II I II I I I I II
PKC e GGGACTCCTGACTACATAGCTCCAGAGATCCTG 1929
Figure 6.5 Identification of sequences encoding PKC £ by
restriction analysis.
Products of PCR amplification were ligated into the pGemT vector and
transformed into E coli. An aliquot of the DNA prepared from each clone
was analysed by digestion with the restriction endonucleases, Hindi 11 and
Rsal in the One-for-AII restriction enzyme buffer (1.5x)(Promega). a) shows
the location of restriction sites for these enzymes in a construct containing a
PCR fragment encoding PKC £. Numbers refer to positions in the cloning
vector, or in the amplified PCR product (in italics), b) shows the expected
size of the fragments obtained from cleavage of a plasmid containing the
sequence encoding PKC £. c) Agarose gel electrophoresis of typical
restriction digests showing a PKC £ containing plasmid (photo ii) and a
plasmid containing a PCR product with a different sequence (photo i).
Photo (i) shows the fragment corresponding to the linearised construct,
while photo (ii) shows the two fragments obtained from plasmid with an
insert encoding PKC Sizes of the DNA molecular weight markers are






















Figure 6.6 DNA sequencing analysis of a clone containing a
PCR product encoding PKC
The identity of some of the plasmids indicated by restriction analysis as
containing fragments encoding PKC £ was confirmed by DNA sequencing
analysis using the dideoxy method. The sequence of one such plasmid, 4n
is shown aligned with the nucleotide sequence for rat PKC C, as reported in
the GenBank™ data base. Bars indicate identical nucleotides and the site
of cleavage by Hindlll, the endonuclease used in restriction analysis, is
shown by the arrow. The identity of the each sequence is shown on the left
while the nucleotide numbers are shown on the right. Sequences






I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I




I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I
PKC C AGAGGAAGCTTCCAGAGGAACACGCCAGGTTCTATGCTGCTGAGATCTGT 1230
4n atcgctctcaacttcctacatgagagagggatcatctaccgggacctaaa 150
I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I
PKC C ATCGCTCTCAACTTCCTACATGAGAGAGGGATCATCTACCGGGACCTAAA 1280
4n actggacaacg.cttcctcgatgccgatggacacattaagctgacggact 199
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I
PKC C ACTGGACAACGTCCTCCTCGATGCCGATGGACACATTAAGCTGACGGACT 1330
4n acggcatgtgcaaggaaggcctagg.cccggcgacaca 236
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
PKC C ACGGCATGTGCAAGGAAGGCCTAGGCCCCGGCGACACAACAAGCACTTTT 1380
K\V\VM
593K
Figure 6.7 DNA sequencing analysis of a clone containing a
PCR product encoding PKC a.
Plasmids indicated by restriction analysis as containing fragments of the
expected size but identified as encoding neither PKC e or £ were
sequencing analysis using the dideoxy method. The sequence of one such
plasmid, P1, which was found to encode PKC a is shown aligned with the
nucleotide sequence for rat PKC a as reported in the GenBank™ data
base. Bars indicate identical nucleotides and the sequence representing
the PCR primers 593K is indicated by the shaded box . The identity of




I I I I I I I I I II I I I I I I II I I I I II II I I II I I I I I II I I I II I I I I I I I
PRC a AAAATTTAAGGAGCCACAAGCAGTATTCTATGCAGCCGAGATCTCCATCG 1567
EL gactgttctttcttcacaaaagaggaatcatttaca.ggatctgaagctg 133
I I I I I II I I II I I I II II II I I I II I II I I I I I I II I I I I I I I I I I I I I
PRC a GACTGTTCTTTCTTCACAAAAGAGGAATCATTTACAGGGATCTGAAGCTG 1617
EI gacaacgtcatgctggactcagaagggcatatcaaaatcgccgacttcgg 83
II I I I I I I II I I I I I I I I I I II I I I I I II I II I I II I I I I I I I II I I I I I
PRC a GACAACGTCATGCTGGACTCAGAAGGGCATATCAAAATCGCCGACTTCGG 1667
EI gatgtgcaaggaacacatgatggacggggtcacgaccaggaccttctgtg 33
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I II I I I I I I I I I I
PRC a GATGTGCAAGGAACACATGATGGACGGGGTCACACCAGGACCTTCTGTGG 1717
593K
EI gcaccccgaactatatcgcccccgagatcctg. 1
PRC a GGACTCCGGATTACATTGCCCCAGAGATAATC 1749
Figure 6.8 Agarose gel electrophoresis of products from PCR
amplification of cDNA encoding PKC isoforms expressed in rat
anterior pituitary gland.
10 |il of the reaction mixture after PCR amplification with PC3 and 593K
was analysed by electrophoresis through a 1% agarose gel containing 0.5
mg/ml ethidium bromide. A strong band was visible at approximately 500
bp (as indicated by the arrow), the predicted size for PKC isoforms a-i.
Sizes of the molecular weight markers are indicated in base pairs.
Figure 6.8
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Figure 6.9 Identification of sequences encoding PKC e by
restriction analysis.
Products of PCR amplification using PC3 and 593K as primers were cloned
and an aliquot of the DNA prepared from each clone was analysed by
digestion with the restriction endonucleases, Xbal and Sacl in the One-for-
All restriction enzyme buffer (1,5x)(Promega). a) shows the location of
restriction sites for these enzymes in a construct containing a clone
encoding PKC e. Numbers refer to positions in the cloning vector, or in the
amplified PCR product (in italics), b) shows the expected size of the
fragments obtained from cleavage of a clone containing the sequence
encoding PKC e. c) Agarose gel electrophoresis of typical restriction
digests showing a clone of a PCR product of unknown sequence (i) and a



















Figure 6.10 DNA sequencing analysis of a clone containing a
PCR product encoding PKC e.
The identity of some of the clones indicated by restriction analysis as
containing fragments encoding PKC e was confirmed by DNA sequencing
analysis using the dideoxy method. The sequence of one such clone, 4X12
is shown aligned with the nucleotide sequence for rat PKC e as reported in
the GenBank™ data base. The identity of the each sequence is shown on
the left while the nucleotides are numbered on the right. The sequence





II I I I I I I I I I I I I I I II I I I I II I I I I I I I I I I I I I I I I I I I I I I I
PRC e CAGCTTTGGCAAGGTCATGCTGGCCGAGCTCAAGGGTAAGGATGAAGTCT 1491
4X12 atcctgtgaaggtcttaaagaaggacgtcatcctgcaggatggcaccgtg 100
II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
PRC e ATGCTGTGAAGGTCTTAAAGAAGGACGTCATCCTGCAGGATGACGACGTG 1541
4X12 gactgcacgatgacagagaagaggattttggctctggagcagccaaacac 150
I II MINIMI II I MINI
PRC e GACTGCACGATGACAGAGAAGAGGATTTTGGCTCTGGCGCGG. .AAACAC 1591
4X12 ccttatctaacccaactctattgctgcttccagaccaaggaccggctctt 200
I I I III I I I II I II I I I IIIIII II I I II I I II II I II II I II I II I II I
PRC e CCTTATCTAACCCAACTCTATTGCTGCTTCCAGACCAAGGACCGGCTCTT 1641
4X12 cttcgtcatggaatatgtaaacggtg 226
IIIIII I II I I II II I I I II II I I I I
PRC e CTTCGTCATGGAATATGTAAACGGTG 1667
Chapter 7
Overview
This present study has shown that the H7-resistant form of PKC
which is involved in a number of anterior pituitary cell responses (MacEwan
et al., 1992; Thomson et al., 1993b) can be detected in vitro in a mixed
micelle thiophosphorylation assay using extracts of cytosol from anterior
pituitary. As illustrated in Chapter 3, this H7-resistant PKC activity is PS-
dependent but Ca2+-independent and is stimulated by the tumour
promoters PDBu and mezerein and also by the synthetic diglyceride DOG.
H7-resistant PKC activity is detected when histone IMS and glycogen
synthase peptide are the substrate for thiophosphorylation but not with the a
or e pseudosubstrate peptides as the substrate, as these peptides are
particularly efficiently phosphorylated by PKC e (Koide et al., 1992), one of
the predominant nPKCs present in anterior pituitary cytosol. H7-resistant
PKC-like kinase activity was present in anterior pituitary tissue and to a
lesser extent lung but not in midbrain, spleen, COS 7 cells or a range of
other tissues tested. This tissue distribution is distinct from that of the well
characterised PKCs a-C, (Wetsel et al., 1992), the majority of which have
been reported to be sensitive to H7 (Pelosin et al., 1990). Further
purification by HAP chromatography showed that anterior pituitary is
unusual in containing PKC activity which elutes after the major peak of PKC
a immunoreactivity, in a position where little activity is detected on HAP
separation of PKCs from the majority of the other tissues investigated.
Activity was also found to elute in this position on HAP fractionation of
extracts from lung and from the pituitary-derived aT3-1 cell line, both
thought to contain the H7 resistant PKC (Chapter 3)(Fennell et al., 1994;
Sim and Mitchell, 1994).
Pharmacological analysis of the enzymatic activity in HAP fractions
from pituitary, aT3-1 cells and lung showed that the PKC eluting in this
position, but not in earlier fractions, was relatively resistant to H7 . There is
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only one previous report of activity eluting from HAP columns in this
position, in an extract from rat retina (Fujisawa et al., 1992). This PKC
activity has yet to be characterised but our analysis of PKC activity partially
purified from rat retina found no evidence of H7-resistant activity in this
tissue.
Immunoblotting of pituitary HAP fractions showed that only
immunoreactivity for PKC a and C, was detected in the HAP fractions
containing H7-resistant activity. Protein kinase C a is dependent on Ca2+
for activation (Nishizuka, 1992) and has been reported to be sensitive to H7
(Pelosin et al., 1990). Protein kinase C t, activity in vitro has been shown to
be independent of phorbol ester stimulation (Gschwendt et al., 1992;
Nakanishi and Exton, 1992) and this isoform, unlike the H7-resistant PKC is
reported to be less sensitive to inhibition by staurosporine and other related
bisindolylmaleimides (Kochs et al., 1993b, Martiny-Baron et al., 1993;
McGlynn et al., 1992). Immunoreactivity for PKC C, is visible as a doublet of
79 and 88 kDa in pituitary HAP fractions. There are reports to suggest that
the high molecular weight band of these may be a result of cross reaction
with another PKC isoform, possibly PKC a, (Batlle et al., 1994; Tsutumi et
al., 1993) as this band is translocated and downregulated in response to
phorbol esters. In order to investigate the possibility of an extended form of
PKC £ that is responsive to phorbol esters being present in anterior pituitary
cells, PCR was conducted using zeta-specific primers (Chapter 5) but this
approach found no evidence for such a hypothetical PKC ^-related kinase
in anterior pituitary or aT3-1 cells.
To determine the possible identity of the H7-insensitive kinase, HAP
fractions were allowed to autophosphorylate and subsequent SDS-PAGE
revealed a 140 kDa protein present only in the fractions containing H7-
resistant PKC activity. A corresponding 130 kDa protein was detectable in
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the same fractions after immunoblotting with an anti-PKC antibody raised to
a consensus sequence conserved between PKC isoforms. Both the 140
kDa autophosphorylation signal and the corresponding PKC-like
immunoreactivity were also present in the H7-resistant HAP fractions from
lung (Chapter 4 and (McCulloch et al., 1994)) but not in the corresponding
HAP fractions from midbrain, a tissue which does not contain H7-resistant
PKC activity. Therefore the elution profile from HAP chromatography and
the tissue distribution of this high molecular mass autophosphorylation
signal correlates with the H7-resistant PKC activity, and the reactivity with
the PKC consensus antibody suggests it may be the H7-resistant PKC itself
rather than a co-eluting substrate protein. This is further supported by
preliminary studies conducted in this laboratory which have shown that the
H7-resistant PKC activity can be separated from some of the other pituitary
PKCs using 100 kDa molecular mass cut-off filters, and by subsequent gel
filtration studies which detected H7-resistant PKC activity in fractions
corresponding to a molecular mass of 120-150 kDa (D McCulloch and R
Mitchell; unpublished data).
Thus the H7-resistant PKC appears to correspond to a protein with a
molecular mass of approximately 130 kDa. This size is larger than that of
the well characterised PKC isoforms (PKC a-i), which vary between 65-90
kDa (Nishizuka, 1992), and this protein is not detected by isoform-specific
antisera for PKC a, p, 5, 0, e and C, (Chapter 4). While the lack of
immunoreactivity for these isoforms does not rule out the possibility of the
H7-resistant kinase being a modified form of one of these isoforms (for
example a phosphorylated form), as it is conceivable that such
modifications could disrupt antigenicity, the particularly high molecular
mass makes this possibility unlikely. This is not the only report of a PKC
with a higher molecular mass than 90 kDa. Recently, immunoreactivity for
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high molecular mass forms of PKC r\ (97 kDa)(Sublette et al., 1993a) and
PKC t, (160 kDa)(Sacktor et al., 1993) has been detected in the CA1 region
of the hippocampus and these forms have been proposed to be involved in
the maintenance of long term potentiation (Sublette et al., 1993b). A 95 kDa
PKC which is detected using an anti-PKC r| antibody has also been
detected in platelets and is involved in the signal transduction stimulated by
platelet activating factor (Wang et al., 1993). Furthermore a novel
membrane bound isoform, PKC p, that has a molecular mass of 117 kDa has
recently been cloned. Thus on the basis of its high molecular mass of 130
kDa, distinct elution profile from HAP chromatography, tissue distribution
and characteristic resistance to H7 but not other PKC inhibitors it seems
likely that this kinase represents a novel isoform of PKC.
Future Directions
To identify and further characterise this novel form of PKC, it will be
necessary to obtain a partial sequence which can be used to clone it. There
are two obvious approaches which may be used to obtain this:
Homology cloning could be conducted using degenerate PCR
primers to consensus PKC sequences as this approach has been
successfully used to clone and identify PKC 0, i and p,. Initial attempts at
this approach as outlined in Chapter 6 succeeded in cloning PCR fragments
encoding PKC e, C and a but no novel PKC related sequences were
obtained. If the H7-resistant PKC is a novel isoform, it should be possible to
amplify a fragment by PCR, provided it is homologous to the other PKC
isoforms in the regions to which the PCR primers are designed. It would
therefore be necessary to design alternative primers to those used in
Chapter 6, especially since those would have been unable to amplify PKC p.
if present and so potentially other PKC-related kinases may also have
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remained undetected. A rapid method, for example colony hybridisation,
would also be needed for analysis of the resulting clones containing PCR
fragments, as the majority of such clones are likely to encode the PKC
isoforms most abundantly expressed in anterior pituitary. This would
enable further analysis to be conducted only on those colonies containing
the less abundant PKCs.
An alternative approach for obtaining a partial sequence is by protein
purification. The extensive purification procedures that have been used
previously for isolating PKC isoforms would not be viable for the H7-
resistant PKC as they require large quantities of protein. However, as this
PKC can be recognised by its unique autophosphorylation signal, 2D SDS
PAGE could be used to purify this protein. Preliminary experiments using
this method have identified the H7-resistant PKC on 2D gels following
autophosphorylation of the relevant HAP fraction using 32P labelled ATP (J
Simpson and R Mitchell; unpublished results). By this method the kinase
could be separated from the other proteins present in the same HAP fraction
and extracted for microsequencing. This would however require more
protein than is currently obtained from HAP fractionation of 50 male rat
pituitaries. It may therefore be necessary to obtain the H7-resistant kinase
from an alternative tissue source. Potential candidates are rat lung, aT3-1
cells (which may be grown in large quantities) or sheep pituitary, as this
species was also found to contain this form of PKC (Chapter 3). This
method would result in a short amino acid sequence from the H7-resistant
PKC which could then be used to design degenerate primers for PCR in
conjunction with a PKC consensus sequence, in order to generate a larger
fragment.
Both these possible strategies would result in the generation of a
portion of the sequence encoding the H7-resistant kinase. At this stage
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there are once again two possible approaches which may be adopted to
obtain the full length clone of this PKC. The fragment obtained could be
radiolabeled and used as a probe for screening a pituitary cDNA library
under conditions of high stringency to obtain clones which may be
sequenced to reveal the primary structure of this protein. Alternatively, an
anchored PCR procedure, RACE (rapid amplification of cDNA ends) could
be employed. This approach uses gene specific primers and either the
natural poly (A) tail of the mRNA (3'-RACE) or a poly (A) tail added to
specific first strand cDNA ends by terminal deoxynucleotidyl transferase as
PCR priming sites to result in amplification of fragment encoding the full
length open reading frame.
Cloning and sequencing of the H7-resistant PKC would enable
further investigation into the role of this kinase in cellular signalling
pathways. Its distribution could be determined by Northern and in situ
analysis, as, although it appears to be predominantly expressed in anterior
pituitary, it may be present at lower levels in other tissues. Furthermore its
subcellular distribution is as yet unknown. The consequences of
overexpression of this isoform in host cells and its deletion in normal cells
by either the expression of dominant negative mutants or the use of
antisense oligonucleotides could provide further information on the role of
this kinase in cellular responses.
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Abstract
A number of cellular responses mediated by protein kinase C (PKC) in the
anterior pituitary gland involve a form of PKC that is unusually resistant to the
PKC inhibitor H7. We have previously shown that a component of the Ca2+-
independent phorbol 12, 13-dibutyrate (PDBu)-induced PKC enzymic activity
from this tissue has a corresponding resistance to H7 and that the PKC species
responsible is detected predominantly in the anterior pituitary gland. The present
study showed initially that DEAE-cellulose chromatography can separate Ca2+-
independent PKC activity from anterior pituitary tissue into fractions with different
sensitivities to H7. Furthermore fractionation by hydroxyapatite (HAP)
chromatography of both anterior pituitary and midbrain extracts resulted in three
main peaks of PKC activity with only anterior pituitary containing significant
PDBu-induced PKC activity which eluted after the third main peak. Ca2+-
independent activity in this fraction was sensitive to the PKC inhibitor Ro 31-8220
but relatively resistant to H7. Immunoblotting with antisera specific for PKC a,
Pi, 5, s, £ and 0 showed that this fraction did not contain the major
immunoreactivity for any of these isoforms. Phosphatidylserine-dependent
autophosphorylation of HAP fractions from anterior pituitary revealed the
presence of a 140 kDa protein which was not seen in midbrain and whose
distribution between the fractions correlated with the H7-resistant PKC activity.
Similarly, immunoblotting with an antiserum raised to a PKC consensus
sequence (in the catalytic domain) showed a prominent immunoreactive species
at approximately 130 kDa which was present solely in those anterior pituitary
HAP fractions displaying H7-resistant activity. Size fractionation using 100 kDa
cut-off filters showed that, in cytosol from anterior pituitary but not midbrain, there
was H7-resistant PDBu-induced activity in the fraction containing proteins of
molecular mass greater than 100 kDa. This 130 kDa protein may well represent




The protein kinase C (PKC) family of phospholipid-dependent
serine/threonine kinases has been implicated in a wide variety of cellular
processes, including growth, differentiation, control of gene expression and
secretion of hormones and neurotransmitters [1, 2, 3]. There are now known to
be at least eleven different isoforms, the product of ten genes, each isoform
varying in its structure and biochemical properties [4], They may be divided into
subgroups on the basis of their activation characteristics. The classical cPKCs
(a, Pi, P2 and y) are dependent on Ca2+ for activation while the novel nPKCs (5,
e, r| and 0) and atypical aPKCs (£, 1 and (i) are all Ca2+-independent and lack the
proposed Ca2+ binding region, the C2 domain [5]. The cPKCs and nPKCs are
activated by diglycerides and the tumour-promoting phorbol esters, but the
aPKCs have modifications in the C1 domain containing the cysteine-rich regions
thought to compose the diglyceride/phorbol ester binding site [6, 7, 8] and are
reported to be unaffected by these compounds [9, 10]. The eleven isoforms
have been shown to differ widely in their substrate specificity [11] and
phospholipid dependence [12] as well as in their tissue and cellular localisation
[13, 14].
A number of studies have found that PKC activators and inhibitors vary in
their ability to influence different PKC-mediated responses, possibly due to the
differential sensitivity of certain isoforms to these pharmacological agents [15, 16,
17, 18]. We have previously shown in the anterior pituitary that a number of
physiological processes are mediated by a form of PKC which, although sensitive
to the PKC inhibitors staurosporine and Ro 31-8220, is unusually resistant to
another PKC inhibitor H7 [19, 20, 21, 22]. This kinase, detectable in anterior
pituitary cytosol using a mixed-micelle PKC activity assay, is activated by phorbol
esters in the absence of Ca2+ but does not appear to correspond to any of the
well-characterised PKC isoforms [23]. In this study we show that this H7-
resistant PKC can be biochemically separated from other pituitary PKCs by
3
DEAE cellulose and hydroxyapatite (HAP) chromatography, and present
evidence to suggest that it may represent a novel form of PKC.
Experimental
DEAE cellulose separation
Anterior pituitaries from 20 male Wistar rats were homogenised in 2
volumes of 20 mM Tris HCI (pH 7.5) containing 50 mM 2-mercaptoethanol, 2
mM EDTA, 1 mM phenylmethylsulphonyl fluoride (PMSF; Sigma Chemical
Company, Poole, Dorset, UK), 0.01% (w/v) leupeptin (Sigma) and 20 |iM
trans-epoxysuccinyl-l-leucylamido (4-guanidino) butane (E64; Sigma), using a
Ystral polytron homogenizer (Scientific International Industries Ltd,
Loughborough, Leics, UK). The homogenate was centrifuged (16 000 g, 20
min, 4°C); the supernatant was collected and recentrifuged for 5 min. The
second supernatant was taken to represent cytosol and the PKCs present
were partially purified on DEAE cellulose (DE52; Whatman International Ltd,
Maidstone, Kent, UK)(0.5 ml) in a Bio-Rad Poly-Prep chromatography column
(Bio-Rad Laboratories, Richmond, California, USA) at 4°C. After sample
loading, the matrix was then washed with 6 column volumes of
homogenisation buffer before the partially-purified PKC was eluted with 3
column volumes of buffers containing 50, 100, 150 and 200 mM NaCI
sequentially. The PKC activity in each eluate was then assessed.
Purification by hydroxyapatite chromatography
PKC isoforms were resolved by HAP chromatography (Biogel HT, Bio-
Rad Laboratories, Watford, Herts, UK) using a procedure based on that
published in [24, 25] and similar to that described in [26] . Midbrain or anterior
pituitary tissue from male Wistar rats was homogenised in 6 volumes of ice-cold
buffer (25 mM Tris/HCI, 250 mM sucrose, 2 mM EDTA, 10 mM EGTA, 50 mM 2-
mercaptoethanol) containing 1 mM PMSF, 1 mM benzamidine, 2 pg/ml soya
bean trypsin inhibitor and 25 pg/ml leupeptin and centrifuged (10 min, 6000 g,
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4°C). The resulting supernatant was strained through glass wool and Triton X-
100 was added (final concentration 1% (v/v)) before further centrifugation (60
min, 105 000 g, 4°C). The PKCs in the supernatant were partially purified on
DEAE cellulose columns as described above but the elution buffer contained 300
mM NaCI. This fraction was dialysed into 5 mM potassium phosphate buffer (pH
7.5) containing 10% (v/v) glycerol, 0.5 mM EDTA, 0.5 mM EGTA, 1 mM
dithiothreitol and loaded onto a HAP column equilibrated in the same buffer,
which was also used to wash the column (4 volumes). Proteins were eluted in a
linear potassium phosphate gradient (5-300 mM; fraction volume 2.5 ml) and the
PKC activity was assayed. Fractions were pooled as appropriate, and dialysed
against 50% glycerol, 10 mM Tris HCI, 0.5 mM EDTA, 0.5 mM EGTA, 25 mM 2-
mercaptoethanol (pH 7.5) for storage at -20 °C.
Mixed micelle PKC activity assay
The PKC activity partially-purified from cytosol or in the more extensively
purified HAP eluate was determined as the phorbol 12, 13-dibutyrate (PDBu)-
induced thiophosphorylation of GS peptide ([Pro, Leu, Ser, Arg, Thr, Leu, Ser,
Val, Ala, Ala, Lys, Lys], modified from the sequence of residues 1-12 of glycogen
synthase [27]), measured in the presence of phosphatidylserine (PS). All of the
activity measured was PS-dependent as substitution with phosphatidylcholine,
which is unable to act as a cofactor in PKC activation [28], abolished it. A mixed-
micelle assay was used in this study to enable the Ca2+-dependent and
-independent activity to be analysed separately, as PKC activation is obligatorily
dependent on phorbol/diglyceride activators under these conditions [29]. The
methods used were modified from those in references [30, 31] and are similar to
those described in [23]. Protein kinase C activity was measured in an assay
mixture (total volume 50 pi) containing, unless otherwise stated, (final
concentrations): 10 mM MgCl2, 200 pg/ml PS (sodium salt) (Lipid Products,
Nutfield, Surrey, UK), 0.04% Nonidet P-40 (Calbiochem, Novabiochem,
Nottingham, UK), 200 pM GS peptide (Bachem Ltd, Saffron Walden, Essex, UK),
50 pM ATP-y-[35S] (NEN, DuPont, Dreiech, Germany)(0.6 pCi/tube), 1pM PDBu
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(LC Laboratories, Calbiochem) and 10 pi cytosol or HAP eluate. Assay tubes
also contained either 600 pM CaCl2 (100 pM free Ca2+) or 5 mM EGTA (less
than 3 nM free Ca2+) and inhibitors at various concentrations. (H7, Ro 31-8220
and GF109203X were from LC Laboratories, Roche Products Ltd, Welwyn,
Herts, UK and Calbiochem respectively). All assay components and drugs were
dissolved in 20 mM Tris HCI (pH 7.5) with 0.5 mM EGTA. Reactions were
started by the addition of enzyme, incubated at 30°C for 15 min and stopped by
addition of 20 pi TCA (6.8% w/v final). After incubation on ice for 15 min, TCA-
precipitable material was removed by centrifugation and the supernatant was
spotted onto 2x2 cm pieces of P-81 cellulose phosphate ion-exchange
chromatography paper (Whatman International Ltd, Maidstone, Kent, UK), which
were washed extensively in 75 mM H3PO4, dried and counted by liquid
scintillation.
Data Analysis
Basal activity with PS alone (at appropriate inhibitor concentrations) was
subtracted from the inhibitor curves in the absence/presence of Ca2+. A
normalised asymmetric sigmoid Hill curve was fitted to the Ca2+-independent
PDBu-induced activity and subtracted from the evoked activity values obtained in
the presence of Ca2+. A normalised curve was then similarly fitted to the
resulting values for Ca2+-dependent activity. Curve fitting was carried out using
the iterative error-weighted curve fitting program, P.fit (Elsevier Biosoft,
Cambridge, UK).
Immunoblotting with antibodies to PKC isoforms
Pituitary HAP fractions were diluted 1:1 (v/v) with 50 mM Tris/HCI (pH
7.2), or, for immunostaining of PKC a, (3-|, ^ and 0, concentrated 5 fold and
resuspended in the same buffer using a Centricon-30 ultrafiltration device
(Amicon, Stonehouse, Gloucs, UK) then heated at 100°C for 5 min in the
presence of 2% (w/v) SDS and 5% (v/v) 2-mercaptoethanol. Four pi or, for
immunostaining of PKC 8, 1 pi aliquots were applied to 7.5% homogenous
microgels and SDS-PAGE and electroblotting were performed using a
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PhastSystem apparatus (Pharmacia Biotech, Milton Keynes, Bucks, UK). PKC
isoforms were identified with rabbit polyclonal antisera raised to isoform-specific
peptide sequences in a, 5, e and £ (2 jig/ml)(Gibco BRL, Paisley, Renfrew, UK)
and (3i (2.5 fold dilution [32]. The specificity of staining with these antisera was
confirmed in each case by use of antibody blocked by preincubation with the
relevant antigenic peptide (1 |ig/ml). PKC 0 was detected using a mouse
monoclonal antibody (1 jig/ml; Transduction Labs, Lexington, KY, USA). Both
the midbrain and pituitary HAP fractions were also immunoblotted with a rabbit
polyclonal consensus antibody raised to a sequence in the C4 domain conserved
between all the PKC isoforms (PKC a:[Ac 543-550-Cys]) (Calbiochem). In each
case the antibody reaction was visualised with horseradish peroxidase-labelled
anti-IgG (Scottish Antibody Production Unit, Carluke, Lanarks, UK) followed by
an enhanced chemiluminescence detection system (ECL; Amersham, Aylesbury,
Bucks, UK).
Autophosphorylation of hydroxyapatite fractions
Midbrain and pituitary HAP fractions were incubated at 30°C in a
mixture containing 13.3 mM Mops/KOH, 10.7 mM magnesium acetate, 66.7
jiM [y-32P] ATP (approximately 106 cpm), 6.7 mM dithiothreitol, 4.2 mM 2-
mercaptoethanol, 83 (iM EDTA, 1 mM EGTA, 1 mM CaCl2, 50 fig/ml PS, 3.3
mM Tris/HCI, 2 pg of BSA and 1 |ig/ml protein kinase A peptide inhibitor [26].
After 30 min, reaction mixtures were disaggregated for SDS/PAGE and
electrophoresed on 15 cm homogenous 8% gels. Phosphoproteins were
located by autoradiography after gels had been fixed, stained with Coomassie
Blue and destained.
Size fractionation of cytosolic PKC activity
Cytosol from midbrain and pituitary was prepared by DEAE cellulose
separation as described above then diluted 12-fold in the homogenisation buffer
before application to Centriprep-100 Filters (Amicon). After centrifugation twice
(500 g, 4°C, 15 min), the filtrate and similarly diluted retentate were
reconcentrated by applying to DEAE cellulose columns as before.
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Results
Protein kinase C activity of pituitary DEAE-cellulose eluates
To investigate the possibility of biochemically separating the H7-resistant
PKC from other nPKCs, anterior pituitary cytosol was fractionated on a DEAE-
cellulose column, using sequentially buffers containing 50 mM, 100 mM, 150 mM
and 200 mM NaCI. The Ca2+-independent PDBu-induced PKC activity in each
fraction was measured and the majority (50%) was detected in the 50-100 mM
fraction. The 0-50 and 100-150 mM fractions contained 33% and 12% of the
total Ca2+-independent PKC activity respectively while the 150-200 mM fraction
contained only 5% of the activity. The effect of H7 on the three fractions
containing the most PDBu-induced activity was assayed and the IC50 values
determined. H7-resistant activity was detected only in the 100-150 mM NaCI
fraction (IC50 77 ± 11 jiM); PKC activity in the other fractions was sensitive to
this inhibitor (Table 1).
Hydroxyapatite fractionation of PKC from anterior pituitary and midbrain
Figure 1 shows typical elution profiles of PKC activity from midbrain and
anterior pituitary when fractionated by HAP chromatography. Midbrain was
selected as a control tissue for comparison with anterior pituitary as midbrain
contains all of the well-characterised PKC isoforms [33] but does not contain
significant levels of the H7-resistant PKC [23]. Fractionation of midbrain
extracts by HAP chromatography resulted in three main peaks of PKC activity as
previously described for brain tissue [24], (Figure 1a). A substantial proportion of
the activity in the smallest, initial peak was phospholipid-independent and may
represent cleaved catalytic subunits of PKC. The other two peaks of PKC
activity were both of similar height, though the first of these two eluted over more
fractions than the second.
Hydroxyapatite chromatography of anterior pituitary extracts also revealed
two main peaks of PS-dependent PKC activity (Figure 1b) although, in this case,
the first one was much greater in magnitude than the second. However, unlike in
midbrain, there was a small peak of activity after the second main peak (fraction
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V) that was not seen in HAP profiles from other tissues examined, for example
spleen, cerebellum, mammary gland and the COS 7 fibroblast cell line [26].
Samples were pooled and five fractions were collected from both pituitary and
midbrain for further investigation, as shown in Figure 1.
The effect of H7 was examined on PDBu-induced PKC activity in pituitary
HAP fractions l-V and fraction V was found to contain Ca2+-independent activity
that was relatively insensitive to this inhibitor (IC50 85+10 pM; Figure 2). Ca2+-
independent activity in fractions l-lll was sensitive to H7 (IC50 values in the range
9-18 pM) while an intermediate IC50 value (45 ± 19 pM) was obtained for fraction
IV (Table 2). Ca2+-dependent activity was not detected in fraction II but was
present in all other fractions and in each case it was H7-sensitive (IC50 values in
the range 10-23 pM). All PDBu-induced activity was sensitive to inhibition by the
selective PKC inhibitor Ro 31-8220 with IC50 values for all the Ca2+-independent
activity in fractions l-V in the range 103-169 nM. The Ca2+-independent PKC
activity in the corresponding fractions from midbrain was also examined and the
effect of H7 determined. As seen in Table 3, all fractions were sensitive to this
inhibitor with IC50 values varying between 17 and 35 pM.
Immunoblotting of anterior pituitary hydroxyapatite fractions with isoform-
specific antibodies
Pituitary HAP fractions l-V were immunoblotted using antisera for specific
PKC isoforms to allow comparison of the distribution of the H7-resistant activity
with the elution pattern for each isoform. Figure 3 shows immunoblots for PKCs
a, Pi, 5, e, £, and 9, the isoforms reported to be present in anterior pituitary tissue
([34] and D J MacEwan (unpublished data)). Protein kinase C a, Pi, 8, e and 0
were all seen as bands in the 80-94 kDa range. Protein kinase C a
immunoreactivity was present in fractions lll-V, while fraction I contained the
major immunoreactivity for PKCs pi, 8 and e. PKC C, immunoreactivity, seen as
bands of 81 and 88 kDa, was present in all fractions, the 81 kDa band being
strongest in fraction I while the 88 kDa band was predominant in fraction III. The
monoclonal anti-PKC 0 antibody recognised a 80 kDa band in fraction III similar
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to that obtained in a Jurkat cell positive control [35]. This band was also just
visible in fraction IV while in fraction I there was immunoreactivity at
approximately 56, 68 and 73 kDa in I, (results not shown) which may represent
PKC breakdown products or other cross reacting proteins. Immunoblots were
not performed for either PKC y or PKC r\ as no immunoreactivity has been
detected for these isoforms in anterior pituitary [36][MacEwan, D. J., Johnson, M.
S., Ohno, S. and Mitchell, R.; unpublished work].
Autophosphorylation of hydroxyapatite fractions
Hydroxyapatite fractions from both midbrain and pituitary were allowed to
autophosphorylate in the presence of PS and Ca2+, with ATP-y [32P] and the
resulting labelled proteins were visualised by autoradiography. In both cases, a
number of proteins were labelled in fractions l-IV. Prominent bands included, in
fraction I, one of 88 kDa and, in fractions III and IV, one of approximately 95 kDa.
These may well represent autophosphoryiation of PKC Pi and a respectively. In
fraction V from pituitary there was one predominant labelled protein which had a
molecular mass (when phosphorylated) of approximately 140 kDa (Figure 4).
This protein was also present in pituitary fraction IV but was not seen in any of
the midbrain fractions.
Immunoblotting of hydroxyapatite fractions with PKC consensus antibody
Hydroxyapatite fractions from both pituitary and midbrain were
immunoblotted with an antiserum raised to a sequence in the C4 domain
conserved between all the PKC isoforms (PKC a:[Ac 543-550-Cys]). This was to
test whether the phosphorylation signal at 140 kDa represented
autophosphorylation of a PKC distinct from the known species recognised by our
isoform-specific antisera or whether it might be due to phosphorylation of a PKC
substrate that coelutes from HAP with the H7-resistant PKC. Although a number
of other proteins were labelled by this antiserum in both anterior pituitary and
midbrain HAP fractions, the strongest staining was of a protein of approximately
130 kDa in anterior pituitary fractions IV and V (Figure 5). This immunoreactivity
was also present to a lesser degree in fraction III but was not seen in the other
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pituitary HAP fractions or any of those from midbrain. This protein may represent
the unphosphorylated form of the 140 kDa autophosphorylation product.
Fractionation of cytosolic PKC activity by molecular mass
As shown in Figure 6a, when the DEAE eluate of the cytosol from
midbrain was passed through a 100 kDa centrifugal filter, Ca2+-independent
PDBu-induced PKC activity in both the retentate and filtrate was sensitive to H7,
with IC50 values of 5.8 ± 2.8 jiM and 9.0 ± 1.7 pM respectively. However, in
cytosol from anterior pituitary, a component of the Ca2+-independent PKC activity
in the filter retentate was markedly resistant to H7 and computer analysis for the
inhibition curve for this data showed that a 2 site rather that a 1 site model gave a
better fit (IC50 values 3.4 ± 1.4 pM (40.7 % of binding sites) and 260 ± 89 p.M
(59.3 % of sites)). In contrast the PKCs in the corresponding filtrate were H7
sensitive (IC50 value 8.2 ± 1.6 jiM)(Fig 6b). The sensitivity of the H7-resistant
PKC to other PKC inhibitors was examined by assaying the retentate activity in
the presence of 30 jiM H7 (sufficient to almost completely block the H7-sensitive
component of the activity; Figure 6b). The selective PKC inhibitors Ro 31-8220
and GF 109203X gave corresponding IC50 values of 285 and 170 nM
respectively on this H7-resistant activity, providing further evidence of its identity
as a PKC-like enzyme.
Discussion
In this study we have shown that PDBu-induced PKC activity from anterior
pituitary tissue may be biochemically separated into fractions with different
sensitivities to the PKC inhibitor H7. This is consistent with previous reports that
some but not all PKC-mediated responses in anterior pituitary cells are unusually
resistant to this inhibitor [19, 20], and that relatively H7-insensitive PKC activity
may be detected in cytosolic extracts from anterior pituitary tissue [23]. Both
preliminary experiments using DEAE-cellulose and more extensive studies using
HAP chromatography showed that it was possible to separate the H7-resistant
activity from other PKCs (Table 1 and 2). Hydroxyapatite fractionation of pituitary
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tissue extracts showed that some PKC activity eluted after the main peak of PKC
a, at concentrations of potassium phosphate where little PKC activity was
detected in midbrain (fraction V)(Figure 1 b) or a number of other tissues [26].
Characterisation of the PKC activity showed that the Ca2+-independent activity in
this fraction was resistant to H7. One previous report has also described activity
eluting in this position from rat retinal extracts [37]. However we have found no
evidence of H7-resistant PKC activity in DEAE cellulose eluates from rat retina
(IC50 value 18 ± 6 jiM)(lson, A. J., Johnson, M. S. and Mitchell, R.; unpublished
work). Ca2+-independent activity in the fourth fraction, eluting immediately prior
to the H7-resistant fraction, was inhibited by H7 with an intermediate IC50 value,
probably reflecting the presence of small amounts of the H7-insensitive form of
PKC in this fraction. All fractions except fraction II contained Ca2+-dependent
activity that was sensitive to H7, which is consistent with a previous report that all
the cPKCs are sensitive to this inhibitor [38]. As fraction II contained only
immunoreactivity for nPKCs but not cPKCs (Figure 3), the absence of Ca2+-
dependent activity in this fraction was expected. The Ca2+-dependent activity in
fraction V is likely to reflect PKC a, as small amounts of this isoform were
detected on immunoblots, although the majority of PKC a was found in fractions
III and IV. Of the nPKCs, both 5 and e eluted predominantly in fraction I while 0
eluted mainly in fraction III. This elution position for PKC 8 is consistent with a
report of its co-elution with PKC (3 [39]. Immunoreactivity for PKC ^ was seen as
a doublet of approximately 81 and 88 kDa and was present in all fractions,
although only the 88 kDa band was found in fraction V. While the apparent
molecular mass of 81 kDa for PKC C, on SDS-PAGE is consistent with previous
reports [40, 41], there is some evidence that the 88 kDa band may be due to
cross reaction of this antiserum with another PKC isoform [42]. It is therefore
clear that, of PKCs a-0, only immunoreactivity for PKC a and £ was present in
fraction V, the fraction containing the majority of the H7-resistant activity (Figure
3). The Ca2+-dependent activity detected in this fraction is likely to be due to
PKC a but the identity of the kinase responsible for the H7-resistant, Ca2+-
independent activity is not known. Since the activity measured in the PKC assay
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is evoked by PDBu, it is unlikely that the activity of PKC C, would be detected
because phorbol esters are reported to be inactive on this isoform [9, 10].
Furthermore we have evidence that PKC t, is detected in our assay as basal (not
PDBu-induced) activity and GS peptide, the substrate used in this study, is not a
good substrate for this isoform [43]. The possibility remains however that
modified states of PKC a-0 could be present, as modification in the region
recognised by the antibody may prevent antigen recognition. Furthermore it is
possible that PKCs i (A) and p may be present in this fraction although PKC i (A)
and p, being aPKCs [7, 8], are unlikely to display activation in the presence of
PDBu [4].
In order to detect proteins that may be responsible for the H7-resistant
activity, autophosphorylation of HAP fractions was undertaken and the resulting
labelled proteins were visualised by autoradiography (Figure 4). In fractions l-lll
a number of proteins were detected but clear bands were present at molecular
masses appropriate for autophosphorylated PKC a and (3 (95 and 88 kDa
respectively). In fraction V from anterior pituitary there was only one clear band,
at approximately 140 kDa. This was also present though less prominent in
fraction IV but was not seen in the comparable fractions from midbrain. It is
therefore possible that this 140 kDa band represents the H7-resistant kinase as
its distribution between the pituitary HAP fractions correlates with that of the H7-
resistant activity, and this autophosphorylation signal was also detected in the
corresponding HAP fractions from lung (unpublished data), another tissue in
which a component of the PKC activity is H7-resistant [23], Immunoblotting of
midbrain and pituitary fractions lll-IV with a consensus antibody designed to
recognise all PKC isoforms showed strong staining of an approximately 130 kDa
protein in fractions IV and V from pituitary. Other pituitary fractions and all
midbrain fractions failed to show this band. This is consistent with the idea that
the 140 kDa phosphorylated protein may represent the H7-resistant PKC itself
rather than a coeluting substrate. While this molecular mass is somewhat larger
than that of the well characterised PKC isoforms (PKC a-0) as well as for PKC i
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(A.)[7], reports are now emerging of PKCs that are larger in size. A novel,
membrane-bound PKC, PKC p. has been reported in human placenta and
several carcinoma ceil lines and this isoform is a 117 kDa protein [8].
Furthermore, a 160 kDa form of PKC apparently related to the C, isoform has
been detected in hippocampus by immunoblotting [44]. Some studies have also
detected in both hippocampus and platelets, a form of PKC rj, designated rj',
which has a higher molecular mass than the standard PKC r| detected in lung
and skin (97 kDa rather than 82 kDa)[45, 46]. To verify that this 130 kDa protein
may be responsible for the H7-resistant activity, DEAE cellulose eluates of
cytosol were fractionated into proteins of molecular mass less than or greater
than 100 kDa using centrifugal molecular mass cut-off filters. The PDBu-induced
Ca2+-independent PKC activity in the retentate containing proteins with
molecular mass greater than 100 kDa was found to contain two components with
varying sensitivities to H7. The H7-sensitive activity in this retenate may reflect
PKC e, some of which is likely to be retained by these filters as this isoform has a
molecular mass of 94-96 kDa (Figure 3)[47]. The H7-resistant component was
inhibited with high potency by the selective PKC inhibitors Ro 31-8220 and
GF109203X, providing further evidence that the H7-reistant species is a member
of the PKC family with an unusually high molecular mass.
In summary, the H7-resistant kinase previously detected in anterior
pituitary tissue can be partially separated from other pituitary PKCs by HAP
chromatography. It elutes after the two main peaks of PS-dependent activity,
where no activity was detected in other tissues, including midbrain, cerebellum,
spleen, mammary gland and COS 7 cells. This elution profile of H7-resistant
PKC activity did not correlate with strong immunoreactivity for PKC a-9 though it
is conceivable that a modified state of one of these isoforms may not be
recognised by the antibodies used. However autophosphorylation revealed a
phosphoprotein of approximately 140 kDa which was coincident with and may be
responsible for the H7-resistant activity, and a protein of 130 kDa sharing a
similar distribution between the fractions was recognised by a PKC consensus
antibody. Furthermore ultrafiltration using 100 kDa cut-off filters revealed the H7-
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resistant PKC activity to be of a higher molecular mass than other H7-sensitive
PKC species (probably greater than 100 kDa). Thus the H7-resistant PKC in
anterior pituitary can be distinguished by both size and biochemical properties
from the well characterised PKC species and may represent a novel PKC
isoform.
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Table 1. Effect of H7 on Ca2+-independent PKC activity in pituitary DEAE-
ceiluiose eluates.
NaCI concentration
(mM) IC50 value (pM)
0-50 13 ± 7
50-100 16 + 3
100-150 77+11
150-200 N.D.
Phosphatidylserine-dependent GS peptide phosphorylation was evoked by 1 pM
PDBu at various concentrations of H7 in the absence (<3 nM) of Ca2+ and the IC50
value determined. Values are means ± S.E.M. (4<n<6). N.D., not detectable.




Ca2+-independent activity Ca2+-dependent activity
I 9 + 2 10 ± 1
II 18 ± 6 N.D.
III 15 ± 8 18 ± 6
IV 45 ± 19 23 + 5
V 85 ± 10 15 + 8
Phosphatidylserine-dependent GS peptide phosphorylation was evoked by 1 jiM
PDBu at various concentrations of H7 in the presence (100 jiM free) or absence (<3
nM) of Ca2+ and the IC50 value determined. Values are means ± S.E.M. (4<n<6).
N.D.,not detectable.
Table 3 Effect of H7 on PKC activity in hydroxyapatite fractions from
midbrain
HAP fractions IC50 value (pM)
I 35 ±5
II 25 + 7
III 17 + 4
IV 23 ±5
V 33 + 8
Phosphatidylserine-dependent GS peptide phosphorylation was evoked by 1 pM
PDBu at various concentrations of H7 in the absence (<3 nM) of Ca2+ and the IC50
value determined. Values are means ± S.E.M. (4<n<6).
Figure 1 Elution profiles of PKC activity from hydroxyapatite
column
Tissue extracts were prepared from (a) rat midbrain and (b) rat anterior
pituitary and fractionated by HAP chromatography as described in the
experimental section. Protein kinase C activity was measured as the
amount of phosphorylation of GS peptide (150 pM) phosphorylation in the
presence of PS and Ca2+ that could be inhibited by PKC a19-31
(pseudosubstrate inhibitor peptide; final concentration 420 |ig/ml). Fractions
l-V were collected from pituitary fractionation as indicated by the bars and
comparable fractions from midbrain were also collected. Typical values for
the highest peak of activity were 18 x103 dpm per assay from midbrain and
12.5 x 103 dpm per assay from anterior pituitary (with approximately 2 fold
greater specific activity of label). The profiles are representative of those
from at least 3 separate experiments in each case.
Figure 2 Inhibition by H7 of PKC activity from anterior pituitary
hydroxyapatite fraction V.
Phorbol 12, 13-dibutyrate (1 pM)-induced PKC activity was measured at
various concentrations of H7 both in the presence and absence of Ca2+
(100 pM and <3 nM free Ca2+ respectively). All points are means ± S.E.M.
(4<n<6). Activity in the presence of Ca2+ was stripped of Ca2+-independent
activity as described in the Experimental section, to obtain Ca2+-dependent
activity. (■) Ca2+-independent, (•) Ca2+-dependent activity
Figure 3 Immunoblots of anterior pituitary hydroxyapatite fractions
for PKC isoforms
Anterior pituitary HAP fractions were immunoblotted with antisera specific
for PKC a, Pi, 8, e, 0 and £ as described in the Experimental section. The
relative amounts of protein that were loaded onto SDS-PAGE gels for
immunoblotting (the product of sample volume loaded and sample
dilution/concentration) were 40:40:1:4:40:40 for anti-PKC a:pi:5:e:^:0.
Figure 4 Autophosphorylation autoradiographs of hydroxyapatite
fractions Ill-V from midbrain and anterior pituitary
Autophosphorylation of HAP fractions lll-V from midbrain and anterior
pituitary was carried out in the presence of PS and Ca2+ (5.6 pM), the
labelled products being visualised by autoradiography. Phorbol esters were
not required to activate PKC under these conditions as there was no
detergent present [29]. In pituitary but not midbrain, a strong band was
visible at approximately 140 kDa, mainly in fraction V (large arrow). In
pituitary fractions III and V and midbrain fraction III, the presumed
autophosphorylation of PKC a was visible at about 95 kDa (small arrow).
Figure 5 Immunoblots of hydroxyapatite fractions from anterior
pituitary and midbrain with a PKC consensus antibody.
Hydroxyapatite fractions l-V from pituitary and midbrain were immunoblotted
with a polyclonal antiserum raised to a PKC consensus sequence in the
catalytic domain, PKC a:[Ac 543-550-Cys], Fractions IV and V from
pituitary contained an immunoreactive protein of 130 kDa that was not seen
in midbrain or the other pituitary fractions (large arrow). A number of other
bands were also apparent in both midbrain and pituitary, including several in
the region of 90 kDa (small arrow).
Figure 6 Inhibition by H7 of cytosolic PKC activity separated
using 100 kDa molecular mass cut-off filters.
Partially purified cytosolic PKCs from midbrain (a) and anterior pituitary (b)
were passed through 100 kDa molecular mass cut off filters and the H7
inhibition of the filtrate, containing proteins less than 100 kDa, and the
retentate, containing proteins greater than 100 kDa, were compared.
Activity induced by PDBu (1jiM) was measured in the absence of Ca2+ (<3
nM free Ca2+). All values are means ± S.E.M. (4<n<6). Typical values for
PDBu-induced activity in the retentate and filtrate from midbrain in absence
of inhibitor were 8.3 x 103 and 10 x103 dpm per assay respectively.
Corresponding values from anterior pituitary (with 2 fold greater specific
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PROPERTIES' AND ACTIONS OF A PHORBOL ESTER-
STIMULATED BUT H7-RESISTANT HISTONE KINASE IN
PITUITARY TISSUE
R. Mitchell", M.S. Johnson, F.J. Thomson, A. Ison, E. Lutz,
J. Simpson and M. Fenneil, MRC Brain Metabolism Unit,
1 George Square, Edinburgh EH8 9JZ
We have described a number of cellular responses in
anterior pituitary which appear to be mediated by a distinct
PKC-like kinase, distinguished by its resistance to
isoquinoline but not indolocarbazole or bisindolylmaleimide
PKC inhibitors. This kinase appears to be involved in
facilitation of 'L'-type Ca2+ channel function, secretion of
growth hormone, activation of phospholipase A2 and the self-
priming effect of LHRH. Compared to other phorbol-induced
responses in similar modeis, this kinase shows a 6-20 fold
reduced potency towards H7 but not staurosporine or Ro31-
8220.
A number of putative substrates for this kinase have been
identified in [32P] phosphorylation, 2D PAGE experiments,
notably 69 kDa, pi 6.1, 36 kDa, pi 6.9 and 16 kDa, pi 6.7.
A mixed micelle kinase assay showed a component of
phorbol ester-stimulated. PS-dependent histone lll-s kinase
activity in pituitary cytosol, which was highly resistant to H7
but not staurosporine. This activity was Ca2+-independent,
was eluted from DEAE-cellulose between 0-150 mM NaCI
and showed a novel distribution; detected only in anterior
pituitary and lung. Northern blots using 3' tailed
oligonucleotide probes indicated that mRNA for e, £ and
perhaps 5 PKC are present in pituitary. However, regions
rich in 5 (thalamus), ^ (PVN), q (skin), a (COS7), (5 (spleen,
cerebral cortex), y (hippocampus, cerebellum) showed no
evidence of H7-resistant activity. It has been reported that a,
[3, y and e are highly H7-sensitive, that y is absent from
anterior pituitary and that of the B senes isoforms, e at least
has very low histone kinase activity. This PKC-like kinase
may therefore represent a form distinct from the so-far
characterised isoforms.
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Evidence for a distinct H7-resistant form of protein kinase C in rat
anterior pituitary gland
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Inhibition of phorbol 12.13-dibutvrate-induced protein kinase C (PKC) activity from rat midbrain, anterior pituitary and a number of other tissues,
as well as COS 7 cells, was studied in vitro. In anterior pituitary, Ca:~-indepenaent activity was notably resistant to H7 but sensitive to staurosporine
and Ro 31-8220. All Ca-~-dependent activity was sensitive to these three inhibitors. Mezerein and 1.2-dioctanoyl-jn-glycerol also activated this
H7-insensitive PKC from anterior pituitary. The distribution of this activity, prominently expressed in pituitary and perhaps also lung, and its
characteristic resistance to H7 but not other inhibitors, does not obviously correlate with that of any of the well-characterised PK.Cs. and may reflect
either a novel or a modified isoform.
Protein kinase C: Pituitary gland: Calcium dependence
1. INTRODUCTION
Protein kinase C (PKC) was originally defined as a
phospholipid- and calcium-dependent serine/threonine
protein kinase that could be activated by diglvcerides
and tumour-promoting phorbol esters [1.2]. It is now
known that at least 10 structurally different isoforms of
PKC exist, which may be subdivided into three groups
[3], The cPKCs (a. pi. pil and y) all require Ca:+ for
activation, while the nPKCs (5. e. r\. 9) and the aPKCs
(C and A) all lack the proposed Cz2' binding domain and
are active in the absence of Ca2+ [3]. Each isoform has
been shown to exhibit a unique tissue distribution [4.5];
some (for example 5) being widespread [6]. while others,
like 6, are highly tissue specific [7], suggesting that each
isoform may play a different physiological role. This is
supported by studies showing that PKC isoforms vary
in their biochemical properties, such as activation by
diglvcerides and phorbol esters [8], phospholipid de¬
pendence [9] and substrate specificity [10]. PKC £", for
example, is reported not to be activated by phorbol
esters and diglycerides [11.12], as this isoform (like X)
lacks one of the cvsteine-rich regions that are thought
to constitute the high-affinity phorbol binding domain
[13], It is therefore possible that particular PKC
isoforms may be activated in response to different cellu-
Corrcspondence address: R. Mitchell. MRC Brain Metabolism Unit.
University Department of Pharmacology. 1 George Square.
Edinburgh. EH8 9JZ. UK. Fax: (44) (31) 662 0240.
lar stimuli and may phosphorylate distinct target pro¬
teins.
In this study, the effect of the inhibitors, stauro¬
sporine [14], H7 [15] and Ro31-8220 [16]. on cvtosolic
PKCs partially purified from rat midbrain, anterior pi¬
tuitary gland and a variety of other tissues, was investi¬
gated. The anterior pituitary was assessed because our
studies there on the role of PKC in stimulus-secretion
coupling revealed participation of a form of PKC that
is unusually resistant to H7 but not other PKC inhib¬
itors [17.18], Midbrain is reported to contain all of the
well-characterised PKC isoforms [19], while the other
tissues were investigated because of their reported en¬
richment in particular isoforms. PKC activity evoked
by the diterpenes phorbol 12.13-dibutyrate (PDBu) and
mezerein, and by the synthetic diglyceride. 1.2-dioc-
tanoyl-s/7-giycerol (DOG), was studied in cytosol from
anterior pituitary and midbrain since certain PKC ac¬
tivators have been shown to differ in their ability to
activate individual PKC isoforms in vitro [8] and vari¬
ous PKC-mediated processes in vivo [20-22],
2. MATERIALS AND METHODS
2.1. Cytosolic PKC activity assay
Partially purified cytosolic PKC activity was determined as the
PDBu-induced histone II1-S thiophosphorylation in the presence of
phosphatidylsenne (PS). All of the activity measured was PS depend¬
ent. as it was absent when PS was replaced by phosphatidylcholine
which is unable to act as a cofactor in PKC activation [2]. A mixed
micelle assay was used in this study to enable the Ca;"-dependcnt and
-independent activity to be analysed separately, as PKC activation is
Published by Elsevier Science Publishers B. V. 199
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obligatorily dependent on phorbol/diglyceride activators under these
conditions [23], The methods used were modified from those in [24.25]
and have been briefly described previously [18]. Tissue from male
Wistar rats (230-350 g) was homogenised in 2 vols. ol"20 mM Tris-HCl
(pH 7.5) containing 50 mM 2-mercaptoethanol. 2 mM EDTA. 1 mM
phenylmeihvlsulphonyl fluoride (Sigma). 0.01% (w/v) leupeptin
(Sigma) and 20 grM rruns-epoxysuccinyi-i-leucvlamido (4-guanidino)
butane (E64) (Sigma). Alternatively. COS 7 cells (cultured at 37°C in
DMEM with 10% normal calf serum under 5% CO-) were washed in
Ca27Mg;*-free Hank's salt solution and then harvested from tissue
culture flasks by scraping into ice-cold homogenization buffer. The
suspension was then homogenized using a Ystral polvtron homoge-
mzer (Scientific International Industries Ltd.. Loughborough. Leics..
UK). The homogenate was centrifuged (16.000 x g. 20 min. 4°C) and
the supernatant was collected and recentrifuged (16.000 x g. 5 min.
4°C). The supernatant from the second spin was taken to represent
cytosol and was partially purified by loading onto 0.5 ml (cells and
pituiiaries) or 1.5 ml (tissues) diethylaminoethyl cellulose (DE52:
Whatman International Ltd.. Maidstone. Kent. UK) in a Bio-Rad
Polv-Prep chromatography column (Bio-Rad Laboratories.
Richmond. CA, USA) at 4°C. The matrix was then washed with 6
column vols, of homogenization buffer before the partially purified
PKC was eluted with 3 column vols, of buffer containing 150 mM
NaCl. Cvtosolic PKC activity was then measured in an assay mixture
(total volume 100 /rl) containing, unless otherwise stated, (final con¬
centrations): 10 mM MgCL. 200 itg/ml PS (sodium salt) (Lipid Prod¬
ucts. Nutfield. Surrey. UK). 0.04% Nonidet P-40 (Calbiocnem. Nova-
biochem. Nottingham. UK), 1.25 mg/'ml histone III-S (Sigma). 50 /rM
y-[3iS)ATP (NEN) (0.1S //Ci/tube). 1 /rM PDBu (LC Services Corp..
Scientific Marketing Associates. Barnet. UK) and 25 u\ cytosol. PS
vesicles were prepared by drying the lipid from chloroform/methanol
under a stream of N:. The subsequent film of PS was scraped into 20
mM Tris-HCl (pH 7.5) with 0.5 mM EGTA. sonicated, then 0.16%
Nonidet P-40 was added. The mixture was vortexed before use. Assay-
tubes also contained either 600 gM CaCK (100 /rM free Ca2*) or 5 mM
EGTA (less than 3 nM free Ca2U and inhibitors at various concentra¬
tions. All assay components and drugs were dissolved in 20 mM
Tns-HCl (pH 7.5) with 0.5 mM EGTA except the substrate, histone
III-S. which was dissolved in the MgCl- solution. Reactions were
started by the addition of enzyme, incubated at 30°C for 15 min and
stopped by quenching with 20/d 0.1 M ATP in 0.1 MEDTAipH 7.0).
50 u\ of the quenched reaction mixture was spotted onto a 4 cm: piece
of P-81 cellulose phosphate ion-exchange chromatography paper
(Whatman International Ltd.) then washed (3x10 ml. 2 min. room
temperature) in 75 mM H,POj, dned and counted by liquid scintilla¬
tion.
2.2. PKC activators and inhibitors
PDBu. mezerein (LC Services Corp.). DOG (Sigma), staurosporine
(Calbiochem) and Ro31-8220 (Roche Products Ltd. Weiwvn Garden
City. UK) were made up as 1-10 mM stock solutions in dimethvlfor-
mamide (DMF). With the exception of DOG (freshly prepared), all
of these reagents were used from stocks maintained at -20°C. H7 (LC
Services Corp.) was dissolved in distilled water (10 mM) and used from
aiiquots maintained at -20°C.
2.3. Purification of PKC a and
PKC a and f were more extensively purified from rat brain by
hydroxvlapatite (Biogel HT. Bio-Rad Laboratories) chromatography
following DEAE-cellulose treatment of tissue extracts as described in
[26], Following PAGE the presence of specific immunoreactivitv for
a and f PKC. respectively, in these preparations was confirmed with
specific antipeptide antisera for these isoforms [27], The specific activ¬
ities of the preparations used were 17.S mU/ml and 36.6 mU/ml for
PKC a and fi. respectively.
2.4. Data analysis
Basal activity with PS alone (at appropriate inhibitor concentra¬
tions) was subtracted from the inhibitor curves in the absence/presence
of Ca2*. A normalised asymmetric sigmoid Hill curve was fitted to the
Ca2*-independenl evoked activity and subtracted from the evoked
activity values obtained in the presence of Ca2*. A normalised curve
was then similarly fitted to the resulting values for Cu;"-dependem
activity. Curve fitting was carried out using the iterative error-
weighted curve fitting program. P.fit (Biosoft. Cambridge. UK).
3. RESULTS
3.1. Effects of different PKC inhibitors
Both Ca'+-independent and -dependent PKC activity
was elicited in midbrain and anterior pituitary cytosol
in a concentration-dependent manner by PDBu (10
nM-3 ,kM). The response to 1 gM PDBu was almost
maximal in each case with typical values for Ca:~-de-
pendent and -independent activity in midbrain of
5.6 ± 0.4 and 12.0 ± 0.3 x 103 dpm per mg tissue equiv¬
alent. The corresponding values for anterior pituitary
were 3.0 ± 1.3 and 3.6 ± 1.9 x 103 dpm per mg tissue
equivalent. The 1 //M PDBu-induced PKC activity from
COS 7 cells was entirely Ca2+-dependent. which is con¬
sistent with reports that PKC a is the only phorbol-
activated isoform present in these cells [28].
Table I shows ICJ0 values (the concentration required
to inhibit 50% of the effect) for inhibition of PKC activ¬
ity from rat midbrain, anterior pituitary and COS 7 cells
by H7. staurosporine and Ro31-8220. In each case, his¬
tone III-S thiophosphorylation was stimulated by
PDBu (1 nM). In midbrain, staurosporine. Ro-31-8220
and H7 all inhibited both Ca3"-dependent and -inde¬
pendent activity with similar IC50 values. The potencies
of all three inhibitors on activity from COS 7 cells were
similar to those obtained in midbrain. This is in contrast
to in anterior pituitary where, although staurosporine
Table I
Effects of H7. staurosporine and Ro31-8220 on PDBu-induced PKC




Midbrain Ca2*- 28 ± 5 0.12 ± 0.01 0.18 +0.03
-mdeoendent
Ca2*- 22 ± 1 0.10 ± 0.04 0.19 ±0.01
-dependent
Pituitary Ca2*- 145 ± 38 0.10 + 0.04 0.34 ± 0.07
-lndependent
Ca2*- 25 + 4 0.12 + 0.05 0.14 + 0.03
-dependent
COS 7 cells Ca2*- 36+11 0.17 + 0.03 0.26 ± 0.05
-dependent
PS-dependent histone III-S phosphorylation was evoked by 1 /rM
PDBu at varying concentrations of inhibitor and the IC<„ value deter¬
mined (means r S.E.M.) (4 s 6). Ca2"-independent activity was
measured in the presence of EGTA (5 mM) while Ca2*-dependent
activity was calculated from the activity in the presence of calcium (100
giM free). There was no detectable Ca2*-indepcndent activity in COS
7 cells.
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and Ro31-S220 inhibited Ca2+-dependent and -inde¬
pendent activity with similar potencies. H7 was consid¬
erably less potent on Ca:"-independent activity (1C5U
values of 148 ± 3S and 25 ± 4uM for Ca:*-independent
and -dependent, respectively).
3.2. Regional differences in the inhibition of PKC
Table II shows the IC50 values for H7 inhibition of
PDBu-induced PKC activity from a variety of tissues
and cell lines. In the majority of the regions studied,
there was no difference in the potency of H7 on the
Ca^-dependent and -independent activity evoked by
PDBu. the IC50 values varying between 10 and 45 i/M.
However, in cvtosol from anterior pituitary, and per¬
haps to a lesser extent lung, the Ca2~-independent. but
not -dependent, activity was relatively insensitive to H7.
3.3. The effect of different PKC activators on H7-resis-
tant activity
The inhibition by H7 of activity evoked by either
PDBu (1 uM). mezerein (1 ,6iM) or DOG (1 mM), in
midbrain and pituitary preparations is shown in Figs.
1 and 2. At these concentrations both Ca2+-dependent
and -independent PKC activity was almost maximal in
anterior pituitary (data not shown). In midbrain. H7
was equipotent on Ca2*-dependent and -independent
activity evoked by PDBu and DOG (IC50 values in the
range 22-33 fiM) (Fig. la and c), although the Ca2~-
dependent activity induced by mezerein was somewhat
more sensitive to H7 (IC50 value 6 ± 1 juM) (Fig. lb).
This is as we have previously reported [29] and is likely
to be due to a form of cPKC that is more potently
inhibited by H7. retaining rigorous Ca2+-dependence
when activated by mezerein. However, in anterior pitu¬
itary. PDBu. mezerein and DOG evoked Ca2+-inde-
pendent activity that was insensitive to H7 (ICj0 values
145 i 38, 148 ± 21 and 118 ± 42 /^M. respectively) (Fig.
2a). The Ca2"-dependent activity induced by PDBu and
DOG in anterior pituitary cvtosol was H7 sensitive
Table II





Midbrain 28 ± 5 22 ± 1
Pitimarv 148 ± 38 25 ± 4
COS 7 cells N.D. 36 ± 11
Cerebellum 38 ± 15 34 ± 9
Luns S7 1 37 39 ± 6
Spleen 19 + 3 25 ± 3
Liver 15+11 N.D.
PS-dependent histonc IIIS phosphorylation was evoked by 1 gM
PDBu at various concentrations of H7 in the presence (100 /rM free)
or absence (< 3 nM| of calcium and the IC50 value determined. Values
arc means i S.E.M. (4 s n e 6). N.D.. not detectable.
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(IC50 values 25 ± 4. 21 ± 10,oM) (Fig. 2b). In anterior
pituitary, maximal activity was evoked by mezerein (1
/iM) even in the absence of Ca2~. and thus no separate
determination of the potency of H7 on Ca2"-dependent
mezerein-evoked activity could be made. The maximal
amount of PKC activity was similar with both PDBu
and mezerein. the only difference being the Ca2+-de-
pendence. which is consistent with previous reports that
some activators, like some substrates, do not display
rigorous Ca2+ dependence [8.9].
3.4. Inhibition by H7 of a and fl isoforms
Since the cPKC isoforms show some activity in the
absence of Ca2+ [8], and there is evidence that auto-
phosphorylation of PKC /? may diminish its Ca:+ de¬
pendence [30]. it was possible that the H7-resistant
Ca:~-independent activity could be due to PKC a or j5
being activated in the absence of Ca2+. The potency of
H7 was therefore determined, in the absence of Ca2*. on
PKC a and /?, more extensively purified from rat brain
by hydroxylapatite (HAP) chromatography. Small
quantities of other isoforms may be present within these
preparations, but it was evident that both the PKC a
and PKC f activities in the absence of Ca2+ were sensi¬
tive to H7. with IC50 values of 35 ± 16 and 40 ± 7 aM.
respectively (Fig. 3).
4. DISCUSSION
In this study, the effects of catalytic domain inhibitors
on PKC activity partially purified from several tissue
and cell line sources have been compared. Stauro-
sporine. H7 and Ro31-8220 are ATP-competitive inhib¬
itors [14-16] but this study has shown differences in
their inhibition properties. There is evidence to suggest
that, although they all bind close to the ATP site, the
precise sites of action appear to be different. H7 has
been shown to compete kineticaliy with ATP [31] but
only partially protects the ATP site against denatura-
tion by covalent chemical reagents [32], and this inhibi¬
tor displaces Ro31-8220-sensitive the binding of
[3H]A)A'-dimethyl staurosporine only at high concentra¬
tions [33]. Staurosporine was equipotent on the Ca2+-
dependent and -independent activity from midbrain, pi¬
tuitary and COS 7 cells. This compound is a potent
PKC inhibitor but lacks selectivity, also inhibiting other
serine/threonine kinases, as well as some tyrosine ki¬
nases [34], The more selective PKC inhibitor, Ro 31-
8220 [16], showed a small variation in potency on PKC
activity from the sources tested, which is consistent with
a recent report [35] that Ro31-S220 shows modest dif¬
ferences in potency between PKC isoforms. The only
marked differences in potency, however, occurred with
H7; the Ca2*-independent activity from anterior pitui¬
tary being particularly insensitive to this inhibitor
(Table II). This is consistent with previous reports from
this laboratory that a number of pituitary cell functions
FEBS LETTERS
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Fig. 1. Inhibition by H7 of (a) PDBu-, (b) mezerein- and (c) DOG- induced PKC activity from midbrain. Histone III-S thiophosphorylation induced
by (a) PDBu (1 /iM), fb) mezerein (1 /^M) or (c) DOG (1 mM) was measured at various concentrations of H7 in the presence of either 100 l/M
or < 3 nM free Ca2*. All points are means ± S.E.M. (4 /7 6). IC50 values for Ca2"-independent activity were 28 ± 5. 28 ± 4 and 33 ± 13 fiM
for PDBu. mezerein and DOG. respectively. Activity in the presence of Ca2~ was stripped for Ca2~-independent activity as described in section
2. and the IC50 values obtained were 22 ± 1, 6 ± 1 and 31 ± 5 for PDBu. mezerein and DOG. respectively. (•) Ca:~-independent activity: (■)
Ca2*-dependent activity.
are mediated by an H7-resistant form of PKC [17,18],
and from other laboratories describing phorbol ester-
induced responses that are inhibited by staurosporine
but not H7 [36.37]. When the ICJ0 values for H7 were
determined for a number of different tissues, there was
little variation in potency on the Ca:+-dependent activ¬
ity from all the tissues tested, including COS 7 cells
where PKC a is the only phorbol—responsive isoform
present [28], spleen (containing some a but predomi¬
nantly /? of the cPKCs) [38], and cerebellum (particu¬
larly rich in cPKC y) [38], This is consistent with previ¬
ous evidence that the cPKCs do not vary in their re¬
sponse to H7 [39]. The IC50 values for Ca:+-independent
activity, however, showed wide variations, with pitui¬
tary and perhaps lung (but not the other sources tested)
containing H7-resistant activity (Table II). Pituitary
cells have been shown by immunobiotting to contain
PKC a. p. S. e and £ but not the y or r\ isoforms [40].
while lung has been reported to contain the nPKCs 5.
C and r\ but not e [5.41]. However. Ca2+-independent
activity from thalamus and spleen, both containing
large amounts of PKC 5 [19.42], showed no evidence of
H7-resistant activity (Table II), and this isoform. puri¬
fied from 3Y1 cells, has been reported to be sensitive to
H7 [43]. PKC £. although present in pituitary, is absent
from lung [5] and has previously been shown to be H7
sensitive [44], Furthermore, there is evidence that PKC
£ is not able to efficiently phosphoryiate histone [44.45].
The other isoform common to both tissues. PKC £. is
reported not to be activated by phorbol esters [11.12]
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H7 concentration (jjMI
Fig. 2. Inhibition by H7 of (a) PDBu-. fb) mezerein- and (c) DOG- induced PKC activity from anterior pituitary. Histone III-S thiophosphorviation
induced by (a) PDBu (1 //M), (b) mezerein (1 //M) or (c) DOG (1 mM) was measured at various concentrations of H7 in both the presence of either
100 //M or < 3 nM free Ca2~. All points are means ± S.E.M. (4 ^ n «£ 6). IC50 values for Ca:*-independent activity were 145 ± 38. 148 ± 1 and
118 ± 42 for PDBu, mezerein and DOG. respectively. Activity in the presence of Ca:~ was stripped for Ca2~-independent activity as described
in section 2. and the IC50 values obtained were 25 ± 4 and 21 ± 10,uM for PDBu and DOG. respectively. Mezerein induced no additional activity
in the presence of Ca2~. (•) Ca2*-independent activity: (■) Ca2*-depenaent activity.
and is also present in COS 7 cells [46] which showed no
PDBu- induced Ca-'-independent activity. Thus the tis¬
sue distribution of this H7-resistant PDBu-induced ac¬
tivity clearly does not correspond to any of these nPKC
or aPKC isoforms.
PKC activators other than PDBu have been shown
to elicit quite different effects on 45Ca:+ influx through
L-type Ca2" channels in the anterior pituitary compared
to the GH, cell line [20.21], and to differ in their ability
to activate individual PKC isoforms in vitro [8]. This
study has shown that both mezerein and DOG were also
able to evoke H7-insensitive Ca2*-independent PKC ac¬
tivity in pituitary cvtosol (Fig. 2). consistent with the
ability of these compounds to selectively activate an
H7-resistant form of PKC which facilitates Ca2* entry
through L channels [23.24], It has been reported that
certain diterpenes are capable of activating cPKCs in
the absence of Ca2~ [8], but there is evidence that DOG
is only able to activate PKC a and possibly /? in the
presence of Ca2+ ([47] and Johnson et al.. unpublished
observations). Thus the ability of DOG to elicit the
H7-resistant kinase activity suggests that this is not due
to Ca2""-independent cPKC activity. This was further
substantiated when the inhibition by H7 of PKC a and
P purified from rat brain by HAP chromatography were
studied in the absence of Ca2* and shown to be of nor¬
mally high potency.
Thus it appears that the H7-insensitive kinase, found
in pituitary and perhaps lung does not correspond to
any of the well-characterised Ca2+-independent iso-
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Fig. 3. Inhibition by H7 of PKC a and /? purified from rat brain by
HAP chromatography. PDBu (1 ,uMi-evoked PKC activity was meas¬
ured in the presence of < 3 nM free Ca-~ with varying concentrations
of H7. AI! points are means ± S.E.M. (n = 4). (•) PKC a: (■) PKC
0. IC50 values for PKC a and /? were 35 ± 16 and 40 + 7 ,uM. respec¬
tively.
forms and is not a cPKC activated in the absence of
Ca"+. This activity may represent one of the incom¬
pletely characterised isoforms. such as PKC 8 or X;
alternatively it may be a modified form of one of the
known PKCs or perhaps a novel PKC isoform.
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D 122 T CHARACTERIZATION OF AN H7-RESISTANT PROTEIN KINASE C FROM
ANTERIOR PITUITARY CELLS. A.J. Ison, E. Lutz, M.S. Johnson, D.J. MacEwan and
R. Mitchell, MRC Brain Metabolism Unit, 1 George Square, Edinburgh, EH8 9JZ, UK.
It has previously been shown that a variety of anterior pituitary cell functions, including LHRH
priming, are mediated by a calcium-independent form of protein kinase C (PKC) that is
unusually resistant to the PKC inhibitor, H7. To further characterize this kinase, a mixed-
micelle assay was used to measure the phosphatidyl serine-dependent kinase activity of
partially-purified cytosol in the absence of calcium. In anterior pituitary, phorbol 12,13-
dibutyrate (PDBu)-induced phosphorylation of histone IIIS was relatively insensitive to H7
(IC50 154 ± 42 pM) but sensitive to staurosporine and Ro 31-8220 (IC50S 117 ± 46 and 295 ±
84 nM, respectively). PDBu-induced activity in many other tissues was sensitive to H7 (eg
midbrain, IC50 27± 9 pM). Mezerein, but not 1,2 dioctanoyl-s/rglycerol, also induced H7-
resistant activity in pituitary (IC50S 177 ± 27 and 23 ± 9 pM, respectively). We investigated the
possible involvement of B-series PKC isoforms. Northern blots showed that anterior pituitary
contains e and £ but provided no evidence for 8. Kinase activity in thalamus and intestine (8-
rich) and PVN of the hypothalamus (£-rich) was sensitive to H7. PKCe is reported to be H7-
sensitive and to efficiently phosphorylate myelin basic protein (MBP) but not histone IIIS.
PDBu-induced MBP phosphorylation in anterior pituitary cells showed no H7 resistance (IC50
46 ± 12 pM). These results suggest that this H7-insensitive kinase is unlikely to be PKC 8, e
or C.
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Biochemical characterisation of an apparently novel
isoform of protein kinase C in pituitary
ANGELA J. ISON, MELANIE S. JOHNSON, DAVID J,
MacEWAN*, JAMES SIMPSON, ROGER A. CLEGG1",
KEVIN CONNOR1" and RORY MITCHELL
MRC Brain Metabolism
Edinburgh, EH8 9JZ, UK
'Department of Biochemistry
Research, Palo Alto, CA 94304, USA
"•"Hannah Research Institute, Ayr, KA6 5HL, UK
Unit, 1 George Square,
Syntex Discovery
The protein kinase C (PKC) family of phospholipid-
dependent serine/threonine protein kinases is now known
to contain at least ten structurally different members [1],
These isoforms may be subdivided into two groups, the
cPKCs (a, pi, pil and y) which are dependent on calcium
for activation and the nPKCs (5, e, £, q, 9, and X) which
are active in the absence of calcium. Each isoform has
been shown to have a unique tissue distribution [2, 3] and
to vary in their biochemical properties such as substrate
specificity [4], phospholipid dependence [5] and activation
by different tumour promoters [6]. It is therefore likely
that they may play different roles in signal transduction.
We have previously shown that a variety of anterior
pituitary cell functions are mediated by a form of PKC that
is unusually resistant to the PKC inhibitor H7 but
sensitive to other inhibitors such as staurosporine and
Ro31-8220 [7, 8, 9, 10], To further characterise this form
of PKC, we used a mixed micelle assay to measure PKC
activity in cytosol from various tissues, partially-purified
on DEAE cellulose columns as described in [8]. Phorbol
12, 13-dibutyrate (PDBu)-induced phosphatidylserine
(PS)-dependent histone IIIS thiophosphorylation was
determined in both the presence and absence of Ca2+.
In cytosol from the anterior pituitary, the Ca2 + -
independent but not Ca2+-dependent activity was
relatively insensitive to H7 (IC50 values 148 ± 40 and 25
± 4 pM respectively). The other tissues investigated,
including midbrain, cerebellum, spleen and liver showed
no evidence of H7-resistant PS-dependent activity (IC50
values ranging from 15-43 pM). When [Ala9'10, Lys11'12]
glycogen synthasei-12 (GS peptide) but not [Ser]25 PKC
aig-31 was the phosphate acceptor, a clear component
of the activity, which was Ca2+-independent, was
resistant to H7 (IC50 value 71 ± 11 pM).
To further purify this species of PKC, DEAE-cellulose
chromotography of pituitary cytosol was followed by
hydroxylapatite (HAP) chromatography as described in
[11], This method has previously been shown to resolve
PKC from brain into 3 separate peaks of activity
containing either PKC a, [3 ory, although these will also
contain the nPKCs. The PS-dependent PKC activity in
pituitary cytosoi was resolved into two main peaks
eluting at 95-135 mM and 165-190 mM potassium
phosphate but there was also PKC activity eluting at a
higher phosphate concentration (200-220 mM) that was
not present in cytosol from other sources including brain,
spleen and COS 7 cells. Fractions were collected as
indicated and immunoblotted for the a, (3, 5, e and £
isoforms of PKC. The numbers in parentheses represent
the apparent molecular weight (kDa) of the predominant
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Inhibition of the PDBu-induced PS-dependent GS peptide
phosphorylation activity of these fractions showed H7
resistant, Ca2+-independent activity in fraction V (IC50
value 83 ± 17 pM) but not in fractions l-lll (IC50 values 9-
18 pM). The IC50 value of the Ca2+-independent activity
in peak IV was intermediate between these values (45 ±
19 pM), probably reflecting a combination of H7-sensitive
and resistant PKCs. All Ca2+-dependent activity was H7-
sensitive (IC50 values 10-23 pM) and all activity in
fractions l-V was inhibited by Ro 31-8220 (IC50 values
103-169 nM).
Thus these studies have shown that it is possible to
partially purify the H7-resistant PKC from other isoforms
present in pituitary. The anterior pituitary has been
shown by immunoblotting to contain the a, (3, 8, e and C,
isoforms of PKC but not PKC y [12, 13]. The H7-
insensitive kinase is unlikely to represent PKC5-£ as it
elutes from HAP columns at a position not coincident with
strong anti 5-£ immunoreactivity. Furthermore, PKC 5
and e have previously been reported to be H7-sensitive
[14, 15] and PKC £ is not thought to be activated by
phorbol esters [16, 17]. The H7-resistant PKC may
represent one of the less-characterised isoforms such as
r|, 0 or X, a modified form of a PKC or possibly a novel
isoform.
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BIOCHEMICAL AND PHARMACOLOGICAL EVIDENCE FOR A
DISTINCT FORM OF PROTEIN KINASE C SELECTIVELY
EXPRESSED IN PITUITARY. A .J. Ison. M.S. Johnson. R.A. Cleaa1". K.
Connor"1". G. Fink* and R. Mitchell. MRC Brain Metabolism Unit, 1
George Square, Edinburgh, EH8 9JZ, U.K. and + Hannah Research
Institute, Ayr, KA6 5HL, U.K.
We have previously shown in a variety of physiological models of
anterior pituitary cell function, including LHRH self priming and
regulation of L-type Ca2+ channels, the involvement of a form of protein
kinase C (PKC) that is unusually resistant to the kinase inhibitor, H7. To
further investigate this in vitro, a mixed micelle assay was used to
measure phorbol 12, 13-dibutyrate (PDBu)-induced, phosphatidyl serine-
dependent kinase activity . In partially-purified cytosol from anterior
pituitary but not midbrain, Ca2+-independent activity was relatively
insensitive to H7 (IC50 values 148 + 40 and 28 ± 5 pM respectively),
though in both cases Ca2+-dependent activity was H7 sensitive (IC50
values 25 ± 4, 22 ± 1 pM respectively). Fractionation by hydroxylapatite
chromatography revealed that cytosol from pituitary but not midbrain
contained PDBu-induced kinase activity eluting after the positions of
PKC a-£, beyond the main peak of PKC a activity. H7 inhibition profiles
showed that the Ca2+-independent activity in this fraction but not in
fractions containing the majority of PKC a activity or in those eluting prior
to this, was H7-resistant (IC50 value 83 ± 17 pM compared to a range of
9-20 pM in the other fractions). All Ca2+-dependent activity was H7
sensitive (IC50 values 10-23 pM). PDBu-induced activity in all fractions
was sensitive to the PKC inhibitor Ro31-8220 (IC50 values < 200 nM).
This H7-insensitive kinase found in the anterior pituitary may represent a
novel isoform of PKC or another PKC-like kinase.
Neuroendocrinology (1994) 60 (SI): S6.2
UNCONVENTIONAL SIGNALLING BY THE LHRH RECEPTOR
R Mitchell, M S Johnson, J Simpson, P J Sim, W B Wolbers, M Fennell and A J Ison
MRC Brain Metabolism Unit, University Department of Pharmacology, 1 George
Square, Edinburgh EH8 9JZ, Scotland
The LHRH receptor is a member of the family of G protein-linked receptors coupled to
hydrolysis of phosphoinositides [1]. The dependence of LHRH-induced gonadotrophin
secretion upon phospholipase C activity has however been questioned [2]. In view of the
unique ability of the LHRH receptor to elicit the phenomenon of self-priming [3], we have
sought to define unconventional signals emanating from this receptor that may not be
generated by other members of the receptor family.
The phenomenon of LHRH self-priming is dependent upon an apparently novel species of
PKC with a pituitary-selective distribution [4] that we have partially purified and
characterised [5]. Amongst the cellular targets of a PKC with these properties are PLA2
and PLD.
Signalling by means of tyrosine kinase and MAP kinase cascades is classically associated
with growth factor receptors. Nevertheless we have shown that each of these is strongly
activated by LHRH both in normal pituitary tissue and in the aT3-1 gonadotroph cell line.
LHRH-induced production of phosphotyrosine-immunoreactive proteins is mimicked in part
by phorbol esters but not by ionomycin and is essential for LHRH-induced PLD activation
and LH secretion [6]. LHRH-induced MAP kinase activation correlates strongly with the
ability of gonadotrophs to demonstrate self-priming and occurs through a PKC-dependent
rather than Ca2+-dependent or tyrosine kinase-dependent mechanism [7], Since MAP
kinase is involved in the regulation of transcriptional, translational and cytoskeletal
organisation, it is a strong candidate for a central role in the self-priming phenomenon
which is reliant on the rapid induction of protein synthesis and cytoskeletal changes.
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A novel high molecular weight form of protein kinase C
in anterior pituitary
ANGELA J. ISON, JAMES SIMPSON, EVE M. LUTZ
ROGER A. CLEGG1", KEVIN CONNOR1" and RORY
MITCHELL.
MRC Brain Metabolism Unit, 1 George Square, Edinburgh
EH8 9JZ, UK
"•"Hannah Research Institute, Ayr, KA6 5HL, UK
The protein kinase C (PKC) family of phospholipid-
dependent serine/threonine kinases has been implicated in
a wide variety of cellular processes, including growth,
differentiation, control of gene expression and secretion of
hormones [1], There are now known to be at least eleven
structurally different isoforms, which may be divided into
subgroups on the basis of their activation characteristics;
the Ca2+-dependent cPKCs (a, Pi, p2 and y), the Ca2+-
independent nPKCs (5, e, q and 0) and atypical aPKCs (£, i
and p), the activity of which, unlike the other two groups is
reported to be unaffected by phorbol esters. The eleven
isoforms have been shown to differ widely in their substrate
specificity and phospholipid dependence [2] as well as in
their tissue and cellular localisation [3, 4],
We have previously shown in the anterior pituitary that a
number of physiological processes are mediated by a form
of PKC which, although sensitive to the PKC inhibitors
staurosporine and Ro 31-8220, is unusually resistant to
another PKC inhibitor H7 [5, 6, 7], This kinase, detectable
in anterior pituitary cytosol using a mixed-micelle PKC
activity assay, is activated by phorbol esters in the absence
of Ca2+ but does not appear to correspond to any of the
well-characterised PKC isoforms [8] and can be
biochemically separated from some of the other pituitary
PKCs by hydroxyapatite (HAP) chromatography [9], On
HAP fractionation of pituitary tissue extracts, the H7-
resistant kinase activity elutes after the main peak of PKC a
in a region where no activity is seen in other tissues. To
detect proteins that may be responsible for this H7-resistant
kinase activity, five HAP fractions from anterior pituitary
were collected and allowed to autophosphorylate in the
presence of phosphatidylserine and Ca2+ with ATP-y[32P].
The resulting phosphorylated proteins were visualised by
autoradiography. The fractions containing H7-resistant
activity (fractions IV and V, both eluting after the main peak
of PKC a) contained one predominant phosphoprotein with
a molecular mass of approximately 140 kDa. This protein
was not detected in fractions l-lll (corresponding to the
main peaks of PKC a and (3, and the region between these
two peaks). Immunoblotting with an antiserum raised to a
sequence conserved between all the PKC isoforms
(PKC a: [Ac 543-550-Cys]) showed corresponding
immunoreactivity of a 130 kDa protein, which was strongly
detected in fractions IV and V. Small amounts of
immunoreactivity was also visible in fraction III but not in
any of the other fractions.
To assess whether the H7-resistant kinase may be a
modified version of one of the well-characterised PKC
isoforms, fractions were immunoblotted with antisera
specific for PKC a-9. This showed that only PKC a and £
were present in fractions IV and V, and no specific
immunoreactivity >100 kDa was detected. Protein kinase C
a is unlikely to be responsible for the H7-resistant activity
detected in these fractions as this isoform is dependent on
Ca2+ for activation while the H7-resistant activity found in
anterior pituitary is Ca2+-independent. Furthermore PKC a
purified from brain was sensitive to H7 in both the presence
or absence of Ca2+ (IC50 values 13 ± 6 and 18 ± 8 pM
respectively). The other isoform detected in fractions IV
and V, PKC is reported to be active in the absence of
phorbol esters [10] and we have evidence that this isoform
is detected in our assay as basal activity [11], unlike the
H7-resistant activity which is PDBu-evoked. Thus the 130
kDa protein may well represent the H7-resistant kinase. To
investigate the possibility of an extended PKC £-like
species which may be able to bind phorbol esters, a PCR
approach was employed. PKC (, and 1 (X), unlike the
phorbol-activated PKC isoforms, contain only one cysteine
rich region in the C1 domain, thought to contain the phorbol
ester binding site, so a modified form containing an extra
sequence in this domain might be phorbol-responsive.
Therefore oligonucleotide primers were designed from the
rat PKC C, sequence corresponding to the regions flanking
C1 domain. However PCR amplification from a rat pituitary
cDNA library resulted in only one product of 577 base pairs,
the size expected for PKC and when the 5 primer was
paired with a primer corresponding to a conserved region in
the protein kinase domain of PKC, only the predicted 933
base pair fragment was amplified.
Thus these studies have shown that the H7-resistant
PKC activity found in anterior pituitary coelutes from HAP
with a 140 kDa phosphoprotein (as detected by
autophosphorylation) and which also appears to be
recognised by a PKC consensus antiserum. While this size
is larger than that of the well-characterised PKC isoforms
(PKC a-0), there are recent reports of larger forms of PKC.
A novel membrane-bound PKC isoform, PKC p has a
molecular mass of 117 kDa [12] and there are also reports
of high molecular mass forms of PKC q and £ in platelets
and hippocampus respectively [13, 14], Since we were
unable to detect an extended form of PKC £ by PCR, or any
high molecular mass immunoreactivity for PKC £ and q,
and PKC p is reported to be unreponsive to phorbol esters,
it would appear that this H7-insensitive kinase may
represent a novel high molecular mass form of PKC.
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